0001144204-11-046835.txt : 20110815 0001144204-11-046835.hdr.sgml : 20110815 20110815130544 ACCESSION NUMBER: 0001144204-11-046835 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110815 DATE AS OF CHANGE: 20110815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN MEDICAL ALERT CORP CENTRAL INDEX KEY: 0000700721 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380] IRS NUMBER: 112571221 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08635 FILM NUMBER: 111034719 BUSINESS ADDRESS: STREET 1: 3265 LAWSON BLVD CITY: OCEANSIDE STATE: NY ZIP: 11572 BUSINESS PHONE: 5165365850 MAIL ADDRESS: STREET 1: 3265 LAWSON BLVD CITY: OCEANSIDE STATE: NY ZIP: 11572 10-Q 1 v230635_10q.htm Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2011.
 
OR
 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ____________ to ____________
 
Commission File Number 001-08635
 
AMERICAN MEDICAL ALERT CORP.
(Exact Name of Registrant as Specified in its Charter)
 
New York
 
11-2571221
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification Number)

36-36 33rd Street, Long Island City, New York 11106
(Address of principal executive offices)
(Zip Code)
 
(212) 879-5700
 (Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
 Yes x  No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the  preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No ¨

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 
Large accelerated filer ¨
 Accelerated filer ¨
 
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
 Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 on the Exchange Act).
Yes ¨   No x
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 9,615,280 shares of $.01 par value common stock as of August 10, 2011.
 
 
 

 

AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
 
INDEX
 
   
PAGE
     
Part I  Financial Information
 
   
 
Report of Independent Registered Public Accounting Firm
1
     
 
Condensed Consolidated Balance Sheets for June 30, 2011 and December 31, 2010
2
     
 
Condensed Consolidated Statements of Income for the Six Months Ended June 30, 2011 and 2010
3
     
 
Condensed Consolidated Statements of Income for the Three Months Ended June 30, 2011 and 2010
4
     
 
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010
5
     
 
Notes to Condensed Consolidated Financial Statements
7
     
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
17
     
 
Quantitative and Qualitative Disclosures About Market Risk
36
     
 
Controls and Procedures
37
     
Part II  Other Information
37
 
 
 

 

Report of Independent Registered Public Accounting Firm

Board of Directors and Shareholders
American Medical Alert Corp. and Subsidiaries
Long Island City, New York

We have reviewed the accompanying condensed consolidated balance sheet of American Medical Alert Corp. and Subsidiaries (the “Company”) as of June 30, 2011 and the related condensed consolidated statements of income for the six-month and three-month periods ended June 30, 2011 and 2010 and cash flows for the six-months ended June 30, 2011 and 2010. These interim financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of American Medical Alert Corp. and Subsidiaries as of December 31, 2010, and the related consolidated statements of income, shareholders’ equity and cash flows for the year then ended (not presented herein), and in our report dated March 31, 2011 we expressed an unqualified opinion on those consolidated financial statements based on our audit and the report of other auditors with respect to the Company’s investment in Lifecomm, LLC.  In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2010 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.
 
/s/ Margolin, Winer & Evens LLP
 
Margolin, Winer & Evens LLP
Garden City, New York
 
August 15, 2011
 
 
1

 

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
 
AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 
   
June 30, 2011
(Unaudited)
   
Dec. 31, 2010
 
ASSETS
           
CURRENT ASSETS
           
Cash
  $ 7,193,332     $ 4,090,528  
Accounts receivable
               
(net of allowance for doubtful accounts of $453,800 and $452,000)
    6,986,432       7,497,367  
Inventory, net of non-current portion
    928,943       1,005,488  
Prepaid income taxes
    467,905       610,479  
Prepaid expenses and other current assets
    339,173       364,747  
Deferred income tax asset
    187,000       219,000  
                 
Total Current Assets
    16,102,785       13,787,609  
                 
FIXED ASSETS
               
(Net of accumulated depreciation and amortization)
    6,623,057       7,195,019  
                 
OTHER ASSETS
               
Intangible assets
               
(net of accumulated amortization of $7,124,593 and $6,864,657)
    1,090,999       1,350,936  
Goodwill
    10,842,352       10,842,352  
Investment in limited liability company
    1,898,298       2,970,210  
Other assets (including inventory of $481,135 and $407,615)
    1,380,647       1,371,359  
      15,212,296       16,534,857  
TOTAL ASSETS
  $ 37,938,138     $ 37,517,485  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
                 
CURRENT LIABILITIES:
               
Current portion of long-term debt
  $ 500,000     $ 660,000  
Accounts payable
    710,985       732,849  
Accrued expense – acquisitions
    98,625       105,807  
Accrued expenses
    1,901,732       2,013,152  
Deferred revenue
    259,153       231,825  
Total Current Liabilities
    3,470,495       3,743,633  
                 
DEFERRED INCOME TAX LIABILITY
    1,196,000       1,228,000  
LONG-TERM DEBT, Net of Current Portion
    1,950,000       2,150,000  
CUSTOMER DEPOSITS
    90,899       101,499  
ACCRUED RENTAL OBLIGATION
    565,814       566,235  
ACCRUED EXPENSE - ACQUISITION
    24,100       72,300  
TOTAL LIABILITIES
    7,297,308       7,861,667  
                 
COMMITMENTS AND CONTINGENT LIABILITIES
    0       0  
                 
SHAREHOLDERS’ EQUITY
               
Preferred stock, $.01 par value – authorized, 1,000,000 shares; none issued and outstanding
               
Common stock, $.01 par value – authorized 20,000,000 shares; issued 9,631,603 shares in 2011 and 9,618,083 shares in 2010
    96,316       96,181  
Additional paid-in capital
    16,721,947       16,606,018  
Retained earnings
    13,959,144       13,090,196  
      30,777,407       29,792,395  
Less treasury stock, at cost (48,573 shares in 2011 and 2010)
    (136,577 )     (136,577 )
Total Shareholders’ Equity
    30,640,830       29,655,818  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
  $ 37,938,138     $ 37,517,485  
 
See accompanying notes to condensed financial statements.
 
 
2

 

AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
   
Six Months Ended June 30,
 
   
2011
   
2010
 
Revenues:
           
Services
  $ 20,574,977     $ 19,264,763  
Product sales
    376,323       358,629  
      20,951,300       19,623,392  
Costs and Expenses (Income):
               
Costs related to services
    9,589,617       8,878,500  
Costs of products sold
    182,744       167,830  
Selling, general and administrative expenses
    8,430,381       7,765,084  
Interest expense
    28,008       26,267  
Equity in net loss from investment in limited liability company
    1,071,912       116,127  
Other income
    (23,310 )     (59,691 )
                 
Income before Provision for Income Taxes
    1,671,948       2,729,275  
                 
Provision for Income Taxes
    803,000       1,119,000  
                 
NET INCOME
  $ 868,948     $ 1,610,275  
                 
Net income per share:
               
Basic
  $ .09     $ .17  
Diluted
  $ .09     $ .16  
                 
Weighted average number of common shares outstanding:
               
Basic
    9,576,622       9,537,894  
                 
Diluted
    9,824,536       9,835,180  
 
See accompanying notes to condensed financial statements.
 
 
3

 
 
AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
 
   
Three Months Ended June 30,
 
   
2011
   
2010
 
Revenues:
           
Services
  $ 10,177,103     $ 9,556,032  
Product sales
    142,464       156,113  
      10,319,567       9,712,145  
Costs and Expenses (Income):
               
Costs related to services
    4,844,008       4,447,545  
Costs of products sold
    66,809       75,346  
Selling, general and administrative expenses
    4,401,965       3,857,251  
Interest expense
    13,348       13,836  
Equity in net loss from investment in limited liability company
    512,030       116,127  
Other income
    (10,962 )     (29,863 )
                 
Income before Provision for Income Taxes
    492,369       1,231,903  
                 
Provision for Income Taxes
    333,000       509,000  
                 
NET INCOME
  $ 159,369     $ 722,903  
                 
Net income per share:
               
Basic
  $ .02     $ .08  
Diluted
  $ .02     $ .07  
                 
Weighted average number of common shares outstanding
               
Basic
    9,580,005       9,549,355  
                 
Diluted
    9,816,209       9,828,473  
 
See accompanying notes to condensed financial statements.
 
 
4

 

AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
 
   
Six Months Ended June 30,
 
   
2011
   
2010
 
Cash Flows From Operating Activities:
           
             
Net income
  $ 868,948     $ 1,610,275  
                 
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
    1,540,028       1,842,231  
Stock compensation charge
    116,064       160,419  
Equity in net loss from investment in limited liability company
    1,071,912       116,127  
Decrease (increase) in:
               
Accounts receivable
    510,935       173,530  
Inventory
    3,025       (226,445 )
Prepaid income taxes
    142,574       (127,069 )
Prepaid expenses and other current assets
    25,574       (206,876 )
Increase (decrease) in:
               
Accounts payable, accrued expenses and other
    (144,304 )     122,566  
Deferred revenue
    27,328       (30,838 )
                 
Net Cash Provided by Operating Activities
    4,162,084       3,433,920  
                 
Cash Flows From Investing Activities:
               
Expenditures for fixed assets
    (695,389 )     (400,624 )
Deposit on equipment
    0       (21,875 )
Payment of Investment in limited liability company
    0       (4,130,731 )
Decrease in other assets
    51,491       5,065  
                 
Net Cash Used In Investing Activities
    (643,898 )     (4,548,165 )
                 
Cash Flows From Financing Activities:
               
Proceeds from long-term debt
    0       2,000,000  
Repayment of long-term debt
    (360,000 )     (1,326,667 )
Payment of accrued expense - acquisitions
    (55,382 )     (73,346 )
Proceeds upon exercise of stock options
    0       43,985  
Payment of loan financing costs
    0       (4,370 )
Dividends paid
    0       (950,364 )
                 
Net Cash Used In Financing Activities
    (415,382 )     (310,762 )
 
See accompanying notes to condensed financial statements.
 
 
5

 

AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
(Unaudited)

   
Six Months Ended June 30,
 
   
2011
   
2010
 
             
Net Increase (Decrease) in Cash
  $ 3,102,804     $ (1,425,007 )
                 
Cash, Beginning of Period
    4,090,528       5,498,448  
                 
Cash, End of Period
  $ 7,193,332     $ 4,073,441  
                 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
               
                 
CASH PAID DURING THE PERIOD FOR INTEREST
  $ 30,495     $ 26,014  
                 
CASH PAID DURING THE PERIOD FOR INCOME TAXES
  $ 675,204     $ 1,274,617  
                 
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES:
               
                 
Accrued expense – acquisitions / additional goodwill
               
- American Mediconnect Inc.
  $ 0     $ 38,298  
                 
Other assets, deposits on product transferred to inventory
  $ 0     $ 89,685  

See accompanying notes to condensed financial statements.
 
 
6

 

AMERICAN MEDICAL ALERT CORP. AND SUBSIDIARIES
 
Notes to Condensed Consolidated Financial Statements
(Unaudited)
 
1.
General:
 
These financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2010 included in the Annual Report on Form 10-K for the year ended December 31, 2010 of American Medical Alert Corp.
 
2.
Results of Operations:
 
The accompanying condensed consolidated financial statements include the accounts of American Medical Alert Corp. and its wholly-owned subsidiaries; together the “Company.”  All material inter-company balances and transactions have been eliminated.
 
In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position as of June 30, 2011 and the results of operations for the six and three  months ended June 30, 2011 and 2010 and cash flows for the six months ended June 30, 2011 and 2010.
 
The accounting policies used in preparing these financial statements are the same as those described in the December 31, 2010 financial statements.
 
The results of operations for the six and three months ended June 30, 2011 are not necessarily indicative of the results to be expected for any other interim period or for the full year.
 
3.
Recent Accounting Pronouncements:
 
In December 2010, the FASB issued Update 2010-29, “Disclosure of Supplementary Pro Forma Information for Business Combinations”. The amendments in Update 2010-29 specify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. Update 2010-29 also expands the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributed to the business combination included in the pro forma financial data. The Company is required to adopt all the provisions of Update 2010-29 for any business combinations for which the acquisition date is on or after January 1, 2011. The impact of the provisions of this guidance on the Company’s consolidated financial statements depends upon the nature, terms and size of the acquisitions it will consummate in the future.

 
7

 

In December 2010, the FASB issued Update 2010-28, “Intangibles - Goodwill and Other (Topic 350)”.  Update 2010-28 modifies the first step of the goodwill impairment test to include reporting units with zero or negative carrying amounts. For these reporting units, the second step of the goodwill impairment test shall be performed to measure the amount of impairment loss, if any; when it is more likely than not that a goodwill impairment exists. Update 2010-28 is effective for fiscal years and interim periods beginning after December 15, 2010.  The adoption of this guidance did not have a material impact on the consolidated financial statements of the Company.
 
4.
Accounting for Stock-Based Compensation:
 
Stock based compensation is recorded in accordance with ASC Topic 718, Compensation – Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payments to employees, including grants of stock and employee stock options, based on estimated fair values.
 
The Company granted options to purchase 10,000 shares of common stock during the six months ended June 30, 2011.  No options were granted during the six months ended June 30, 2010.
 
The following tables summarize stock option activity for the six months ended June 30, 2011 and 2010.
 
2011
 
               
Weighted
       
               
Average
       
         
Weighted
   
Remaining
   
Aggregate
 
   
Number of
   
Average
   
Contractual
   
Intrinsic
 
   
Options
   
Option Price
   
Term (years)
   
Value
 
Balance at January 1
    718,343     $ 3.85              
Granted
    10,000       5.85              
Exercised
    -       -              
Expired/Forfeited
    (25,650 )     6.86              
                             
Balance at June 30
    702,693     $ 3.77       1.49     $ 1,339,659  
                                 
Vested and exercisable
    678,419     $ 3.69       1.42     $ 1,339,659  
 
2010
 
               
Weighted
       
               
Average
       
         
Weighted
   
Remaining
   
Aggregate
 
   
Number of
   
Average
   
Contractual
   
Intrinsic
 
   
Options
   
Option Price
   
Term (years)
   
Value
 
Balance at January 1
    894,785     $ 4.29              
Granted
    -       -              
Exercised
    (10,325 )     4.26              
Expired/Forfeited
    -       -              
                             
Balance at June 30
    884,460     $ 4.29       2.00     $ 1,565,633  
                                 
Vested and exercisable
    851,760     $ 4.23       1.92     $ 1,561,911  

 
8

 

No options were exercised during the six months ended June 30, 2011.  The aggregate intrinsic value of options exercised during the six months ended June 30, 2010 was $24,560.  There were 24,274 and 32,700 nonvested stock options outstanding as of June 30, 2011 and 2010, respectively.

The following table summarizes stock-based compensation expense related to all share-based payments recognized in the condensed consolidated statements of income.

   
Three Months
   
Three Months
 
   
Ended June 30,
   
Ended June 30,
 
   
2011
   
2010
 
Stock options
  $ 7,310     $ -  
Stock grants – other
    16,384       10,882  
Service based awards
    23,599       32,037  
Performance based awards
    -       37,294  
Tax benefit
    (28,341 )     (33,098 )
Stock-based compensation expense, net of tax
  $ 18,952     $ 47,115  

   
Six Months
   
Six Months
 
   
Ended June 30,
   
Ended June 30,
 
   
2011
   
2010
 
Stock options
  $ 36,101     $ -  
Stock grants – other
    32,765       21,759  
Service based awards
    47,198       64,072  
Performance based awards
    -       74,588  
Tax benefit
    (55,743 )     (65,772 )
Stock-based compensation expense, net of tax
  $ 60,321     $ 94,647  

Stock Grants - Other

The non-employee members of the Board of Directors have an option to elect at the beginning of each calendar year to receive either shares of common stock or cash at the end of each quarter as compensation for services provided as members of the Board of Directors and other committees.  Share grants issued vest immediately, but are subject to a one-year restriction on transfer.  In addition, stock grants may be issued to employees at the Board of Directors’ discretion.

 
9

 

Service Based Awards

In January 2006, May 2007, January 2009 and December 2010 the Company granted 50,000, 22,000, 12,000 (net of 9,500 shares waived by an executive) and 46,500 restricted shares, respectively, to certain executives in respect of services rendered but at no monetary cost.  These shares vest over periods ranging from 2 to 5 years, on December 31 of each year.  The Company records the compensation expense on a straight-line basis over the vesting period.  Fair value for restricted stock awards is based on the Company's closing common stock price on the date of grant. There were 84,000 shares and 63,000 shares vested as of June 30, 2011 and 2010, respectively.  The aggregate grant date fair value of restricted stock grants was $830,845.  The vesting period of the January 2006 and May 2007 grants expired on December 31, 2010.  As of June 30, 2011 and 2010, the Company had approximately $236,000 and $68,000, respectively, of total unrecognized compensation costs related to nonvested restricted stock units expected to be recognized over a weighted average period of 2.5 years.

Performance Based Awards

In January 2006 and May 2007, respectively, the Company granted share awards for up to 90,000 shares (up to 18,000 shares per year through December 31, 2010) and 46,000 shares (up to 11,500 shares per year through December 31, 2010) to certain executives.  Vesting of such shares was contingent upon the Company achieving certain specified consolidated gross revenue and Earnings before Interest and Taxes (“EBIT”) objectives in each of the fiscal years ending December 31, 2006 through December 31, 2010.  The fair value of the performance shares (aggregate value of $909,400) was based on the closing trade value of the Company’s stock on the date of grant and assumed that performance goals would be achieved.  The fair value of the shares was expensed over the performance period for those shares that were expected to ultimately vest.  If such objectives were not met, no compensation cost was recognized and any recognized compensation cost was reversed.  All performance based awards were either earned or forfeited as of December 31, 2010.  During 2011, there were no performance shares vesting and there were no unrecognized compensation costs related to performance share awards.  As of June 30, 2010, 57,250 shares were vested and there was approximately $75,000 of total unrecognized compensation costs related to nonvested share awards.
 
5.
Earnings Per Share:
 
Earnings per share data for the six and three months ended June 30, 2011 and 2010 is presented in conformity with ASC Topic 250, Earnings Per Share.

 
10

 

The following table is a reconciliation of the numerators and denominators in computing earnings per share:

   
Income
   
Shares
   
Per-Share
 
   
(Numerator)
   
(Denominator)
   
Amounts
 
Six Months Ended June 30, 2011
                 
                   
Basic EPS - Income available to common stockholders
  $ 868,948       9,576,622     $ .09  
Effect of dilutive securities - Options and warrants
    -       247,914          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 868,948       9,824,536     $ .09  
                         
Three Months Ended June 30, 2011
                       
                         
Basic EPS -Income available to common stockholders
  $ 159,369       9,580,005     $ .02  
Effect of dilutive securities - Options and warrants
    -       236,204          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 159,369       9,816,209     $ .02  
                         
Six Months Ended June 30, 2010
                       
                         
Basic EPS - Income available to common stockholders
  $ 1,610,275       9,537,894     $ .17  
Effect of dilutive securities - Options and warrants
    -       297,286          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 1,610,275       9,835,180     $ .16  
                         
Three Months Ended June 30, 2010
                       
                         
Basic EPS -Income available to common stockholders
  $ 722,903       9,549,355     $ .08  
Effect of dilutive securities - Options and warrants
    -       279,118          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 722,903       9,828,473     $ .07  

 
11

 

6.
Goodwill

Changes in the carrying amount of goodwill, all of which relates to the Company’s TBCS segment, for the six months ended June 30, 2011 and 2010 are as follows:

Six Months Ended June 30, 2011
     
       
Balance as of January 1, 2011
  $ 10,842,352  
Additional Goodwill
    -  
         
Balance as of June 30, 2011
  $ 10,842,352  
         
Six Months Ended June 30, 2010
       
         
Balance as of January 1, 2010
  $ 10,255,983  
Additional Goodwill
    38,298  
         
Balance as of June 30, 2010
  $ 10,294,281  

The addition to goodwill during the six months ended June 30, 2010 related to the additional purchase price of American Mediconnect, Inc. based on the cash receipts from the clinical trials portion of the business.

7.
Acquisition:

On September 29, 2010, the Company acquired substantially all of the assets of Alpha Message Center, Inc. (“Alpha”), a New Jersey based company that provides telephone after-hours answering and pager services.  The purchase price of this acquisition consisted of an initial cash payment of $577,977 and an accrual of $200,000, which represented the estimated fair value (derived using significant unobservable inputs categorized within Level 3 of the fair value hierarchy) of the contingent consideration expected to be paid through September 2012.  The contingent consideration is based on the acquisition agreement that calls for the Company to pay the former owner of Alpha fourteen percent (14%) of the cash expected to be collected by the Company, excluding sales taxes, from certain revenue generated by Alpha through September 2012.  The Company estimated the future contingent consideration expected to be paid based upon Alpha’s historic revenue data.  As of June 30, 2011, $77,275 has been paid to the former owner based on cash receipts.  The Company also incurred finder and professional fees of approximately $57,000, which were included in selling, general and administrative expenses for the year ended December 31, 2010.  The results of operations of Alpha are included in the Telephone Based Communications Services (“TBCS”) segment as of the date of acquisition.

The following table summarizes the estimated fair values of the assets acquired at the date of acquisition.

Accounts receivable
  $ 4,906  
Fixed assets
    25,000  
Non-compete agreement
    15,000  
Customer list
    185,000  
Goodwill
    548,071  
Cost to acquire Alpha
  $ 777,977  

 
12

 

The purchase price of the acquisition exceeded the fair value of the identifiable net assets acquired inasmuch as the acquisition was consummated to enable the Company to strengthen its position in the area where it was already operating.  Furthermore, the acquisition was for the business' future cash flows and net earnings as opposed to solely for the identifiable tangible and intangible assets.

The results of operations for Alpha are included in the condensed consolidated statements of income for the six and three months ended June 30, 2011.  On a pro forma basis, had the Alpha acquisition taken place as of the beginning of 2010, the Company’s results of operations for the six  and three months ended June 30, 2010 would not have been materially affected.

8.
Investment in Limited Liability Company

On May 12, 2010, the Company entered into a limited liability company agreement with Hughes Telematics, Inc. and Qualcomm Incorporated to design, develop, finance and operate a mobile PERS system.  The Company invested $4,000,000 and incurred $150,336 in professional fees to acquire a minority interest (approximately 10%) in the new company, Lifecomm, LLC (“Lifecomm”). As part of this transaction, the Company borrowed $2,000,000 from its bank to partially finance this transaction.  In addition, pursuant to the limited liability company agreement, the Company has agreed to fund its share ($200,000) of a stand-by equity commitment for Lifecomm’s benefit, if required.  As of June 30, 2011, the Company’s exposure to loss is limited to the recorded equity investment balance of $1,898,298 and its share ($200,000) of a stand-by equity commitment, if required.

Hughes Telematics, Inc., parent of Lifecomm and the party who has a controlling financial interest in Lifecomm, has determined that Lifecomm is a variable interest entity and that HTI is the primary beneficiary.

Lifecomm is a development stage company that has yet to generate any revenue, and has generated a pre-tax net loss of $4,312,480 and $2,356,758 during the six and three months ended June 30, 2011 ($7,934,372 during the period from inception, May 12, 2010 to June 30, 2011).  Lifecomm will continue to generate losses until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.
 
In accordance with the limited liability company agreement, profits are generally allocated to members in the amount of and in proportion to their ownership of the outstanding membership units.  Losses are generally allocated to members in the amount of and in proportion to their unreturned capital contributions, which for the purposes of determining the allocation of losses is defined as the aggregate of (i) cash contributions, (ii) the fair value of other contributed assets and (iii) the value of in-kind services contributed by the members through the date of determination, less (iv) the fair value of any assets distributed to the members; provided, however, that any losses generated through May 12, 2012 will be generally allocated to the members first in the amount of and in proportion to the unreturned capital contributions attributable to only the cash contributions and the value of in-kind services contributed by the members through the date of determination and then in the amount of and in proportion to the unreturned capital contributions attributable to the fair value of other contributed assets.

 
13

 

During the six and three months ended June 30, 2011, the Company recorded a pre-tax net loss of $1,071,912 and $512,030, respectively ($2,252,038 during the period from inception, May 12, 2010 to June 30, 2011) for its share of losses from the equity investment in Lifecomm.  The equity loss primarily relates to research and development costs as well as other selling, general and administrative expenses incurred for the development of the next generation mobile PERS.  As the development continues to progress, the Company expects that its share of equity loss will continue throughout 2011 until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.

In connection with the formation of Lifecomm, the Company entered into a Value Added Reseller Agreement (“VAR Agreement”) with Lifecomm.  Under the VAR Agreement, the Company will be a reseller of the Mobile PERS Solution in the United States, as well as a preferred provider of the emergency assistance call center (“EACC”) component of the Mobile PERS Solution provided by Lifecomm to customers.  The Company will be the sole provider of the EACC to the customers to whom it resells the Mobile PERS Solution.  The term of the VAR Agreement is perpetual, subject to termination as set forth therein.  The VAR Agreement contains standard indemnification provisions for agreements of this nature.

9.
Long-term Debt:

The Company had a credit facility arrangement for $4,500,000 which included a revolving credit line which permitted borrowings of $1,500,000 (based on eligible receivables as defined) and a $3,000,000 term loan payable. The term loan was payable in equal monthly principal installments of $50,000 over five years commencing January 2006.  This term loan was paid in full during the second quarter of 2010 without any prepayment charge.
 
During 2006, the credit facility was amended whereby the Company obtained an additional $2,500,000 and $1,600,000 of term loans, the proceeds of which were utilized to finance certain acquisitions.  These term loans are payable over five years in equal monthly principal installments of $41,666.67 and $26,666.67, respectively. Additionally, certain of the covenants were amended.  The $2,500,000 term loan was paid in full during the second quarter of 2010 without any prepayment charge.
 
In December 2006, the credit facility was amended to reduce the interest rates charged by the bank such that borrowings under the term loan will bear interest at either (a) LIBOR plus 2.00% or (b) the prime rate or the federal funds effective rate plus .5%, whichever is greater, and the revolving credit line will bear interest at either (a) LIBOR plus 1.75% or (b) the prime rate or the federal funds effective rate plus .5%, whichever is greater.  The LIBOR interest rate charge shall be adjusted in .25% intervals based on the Company’s ratio of Consolidated Funded Debt to Consolidated EBITDA. In the third quarter of 2007, the interest rate was reduced by .25% based on this ratio.  The Company has the option to choose between the two interest rate options under the amended term loan and revolving credit line.  Borrowings under the credit facility are collateralized by substantially all of the assets of the Company.

 
14

 
 
On April 30, 2007, the Company amended its credit facility whereby the term of the revolving credit line was extended through June 2010 and the amount of credit available under the revolving credit line was increased to $2,500,000.  In June 2010, the term of the revolving credit line was extended through June 2013.
 
On May 12, 2010, the Company’s credit facility was amended whereby the Company obtained an additional $2,000,000 in the form of a term loan, the proceeds of which were utilized to partially finance its investment in Lifecomm relating to the development of a mobile PERS system.  This term loan is payable over five years in equal monthly principal installments of $33,333.33, commencing June 1, 2010.  The interest rate is the same as the previous term loans secured by the Company, as described above.
 
As of June 30, 2011 and March 31, 2011, the Company was in compliance with its financial covenants in its loan agreement.  As of June 30, 2010 and March 31, 2010, the Company was in compliance with its financial covenants in its loan agreement.

10.
Provision for Income Taxes:

The Company records its tax provision (or benefit) on an interim basis using an estimated annual effective tax rate.  For the six and three months ended June 30, 2011 the Company increased the estimated effective tax rate to reflect the impact of certain non-deductible expenses.

11.
Dividends:

On December 16, 2009, the Company declared a dividend in the amount of $0.10 per share, or $950,364, which was accrued as of December 31, 2009.  The dividend was payable to the shareholders of record as of December 28, 2009.  The dividend was paid on January 15, 2010.
 
12.
Segment  Reporting:

The Company has two reportable segments, (i) Health and Safety Monitoring Systems (“HSMS”) and (ii) Telephone Based Communication Services (“TBCS”).
 
The table below provides a reconciliation of segment information to total consolidated information for the six and three months ended June 30, 2011 and 2010:
 
2011

   
HSMS
   
TBCS
   
Consolidated
 
Six Months Ended June 30, 2011
                 
Revenue
  $ 10,429,165     $ 10,522,135     $ 20,951,300  
Income before provision for income taxes*
    550,221       1,121,727       1,671,948  
Total assets
    17,300,149       20,637,989       37,938,138  

 
15

 

   
HSMS
   
TBCS
   
Consolidated
 
Three Months Ended June 30, 2011
                 
Revenue
  $ 5,180,396     $ 5,139,171     $ 10,319,567  
Income before provision for income taxes*
    70,087       422,282       492,369  

2010
 
   
HSMS
   
TBCS
   
Consolidated
 
Six Months Ended June 30, 2010
                 
Revenue
  $ 10,233,896     $ 9,389,496     $ 19,623,392  
Income before provision for income taxes*
    1,906,142       823,133       2,729,275  
Total assets
    18,840,211       18,461,741       37,301,952  
                         
   
HSMS
   
TBCS
   
Consolidated
 
Three Months Ended June 30, 2010
                       
Revenue
  $ 5,083,836     $ 4,628,309     $ 9,712,145  
Income before provision for income taxes*
    846,764       385,139       1,231,903  
 
* Income before provision for income taxes within the HSMS segment includes the Company’s share of equity in net loss from its investment in limited liability company as follow:
   
June 30, 2011
   
June 30, 2010
 
Six Months Ended
  $ 1,071,912     $ 116,127  
Three Months Ended
  $ 512,030     $ 116,127  

13.
Commitments and Contingencies:

The Company is aware of various threatened or pending litigation claims against the Company relating to its products and services and other claims arising in the ordinary course of its business.  At June 30, 2011 and 2010, no material liabilities have been recorded in the accompanying financial statements.  The Company has given its insurance carrier notice of such claims and it believes there is sufficient insurance coverage to cover any such claims.   In any event, the Company believes the disposition of these matters will not have a material adverse effect on the results of operations and financial condition of the Company.
 
 
16

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
 
The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of the Company’s results of operations and financial condition.  This discussion and analysis should be read in conjunction with the consolidated financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2010.
 
Statements contained in this Quarterly Report on Form 10-Q include “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including, in particular and without limitation, statements contained herein under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”  Forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance and achievements, whether expressed or implied by such forward-looking statements, not to occur or be realized. These include uncertainties relating to our investment in the Lifecomm joint venture, successful implementation of our acquisition strategy, risk of loss of key government customers, government regulation, new product initiatives and product liability risks   Such forward-looking statements generally are based upon the Company’s best estimates of future results, performance or achievement, based upon current conditions and the most recent results of operations.  Forward-looking statements may be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “believe,” “estimate,” “project,” “anticipate,” “continue” or similar terms, variations of those terms or the negative of those terms.
 
You should carefully consider such risks, uncertainties and other information, disclosures and discussions which contain cautionary statements identifying important factors that could cause actual results to differ materially from those provided in the forward-looking statements. Readers should carefully review the risk factors and any other cautionary statements contained in the Company’s Annual Report on Form 10-K, this Quarterly Report on Form 10-Q and other public filings.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
 
Overview:

The Company’s primary business consists of two operating segments. The first segment, Health Safety and Monitoring Services (“HSMS”), is comprised of the development and marketing of Remote Patient Monitoring (“RPM”) technologies that include personal emergency response systems (“PERS”), medication reminder and dispensing systems, telehealth/disease management technologies and safety monitoring systems to pharmacies.  The second segment, Telephony Based Communication Services (“TBCS”), provides centralized call center solutions primarily to the healthcare community, including traditional after hours services, daytime services applications, and pharmaceutical support and clinical trial recruitment call center services.  The Company markets its offerings directly to healthcare providers, pharmaceutical companies, managed care organizations and through a network of distributors.  The Company also offers certain products and services directly to consumers.
 
 
17

 
 
About HSMS:

Personal Emergency Response Systems (PERS)

PERS is the Company’s core product and service offering.  The system consists of a console unit and a wireless transmitter generally worn as a pendant or on the wrist by the client.  In the event of an emergency, the client is able to summon immediate assistance via a two-way voice system that connects the client’s home telephone with the Company’s emergency response center.  The ability to access and obtain assistance, particularly after a fall or during a medical emergency, has been proven to reduce overall healthcare costs and increase the ability of an individual to remain independent at home.  AMAC’s PERS is marketed directly to consumers, providers and by third party resellers under multiple brands, including VoiceCare®, Walgreens Ready Response™, Response Call®, ApriaAlert™ and most recently VNSNYAssist™ .

MedSmart

MedSmart is a powerful solution that organizes, reminds and dispenses pills in accordance with prescribed treatment regimens. Easy to set up and use, MedSmart improves adherence to medication regimens and reduces the risk of missed doses and overdosing errors to improve clinical outcomes and quality of life.  With MedSmart’s innovative event reporting and notification capability, family caregivers and healthcare professionals can proactively support independent living. MedSmart’s docking base serves as the gateway for remote programming and event reporting. When connected to a household phone, MedSmart transmits device and dispensing history to a secure server supported with a web application for review by authorized individuals, such as relatives or medical professionals. Through AMAC’s personalized notification system, alerts can be sent to track adherence, address dosing errors and predict refill requirements.  The ability to communicate these events creates a new capability to easily track adherence, proactively modify behavior and improve compliance.

MedTime

MedTime is an electronic medication reminder and dispensing unit marketed under an exclusive licensing, manufacturing and distribution agreement which began in 1999.  This agreement originates from PharmaCell AB, a Swedish company, with licensing rights extending throughout the United States, Canada and Mexico. The initial term of the agreement was five years requiring the Company to achieve certain purchase minimums in order to maintain exclusivity.  Thereafter, the agreement converted to an evergreen with annual purchase minimums of 1,500 units. The Company has met all minimums with PharmaCell to date and continues to maintain exclusivity.
 
 
18

 
 
Telehealth systems

Rounding out AMAC’s RPM portfolio is AMAC’s telehealth delivery capability. As a distributor of the Health Buddy® System, many of the Company’s customers have successfully demonstrated the value proposition of incorporating disease management technologies into a patient’s plan of care.  This AMAC operated telehealth platform is directed toward providers who require a low-cost solution, easy installation, reliable transmission of vital sign data in real-time and ease of use on the patient side.  The Company believes the telehealth market will continue to provide opportunities for AMAC’s expansion as a full source provider of remote patient monitoring technologies and first line support services.

About TBCS:

AMAC’s TBCS segment offers value added, customizable call center solutions that enhance the patient/provider communication experience. As part of our business development strategy, management continues to employ the most advanced telephony technology and information systems to develop services to respond to shifting market factors that affect healthcare client needs. In addition to technology, a critical component for successful expansion is the Company’s professionally trained call agent staff.  The Company allocates resources to enhance contact agent training and staff development, new communication technology, and continuous quality control to support TBCS’ expansion efforts. The overall infrastructure has allowed AMAC to expand its footprint of services beyond traditional telephone answering services to provide more innovative, clinically oriented call center offerings.

After Hours Answering Services

AMAC’s after hours services are classified as essential call center services with a fully customizable approach to communications support.  Basic services in this offering include traditional after hour answer and customized message delivery options, contact lists and on-call schedule management, all of which can be updated at the client’s convenience using the OnCall web portal.  Through this portal, clients can also access the account’s call history, specifications and messages.

Concierge Services/Daytime Solutions

AMAC’s Concierge Services focus on the delivery of enhanced communications and help to streamline workflow within provider organizations. These solutions primarily serve hospitals and health plans in the Northeast seeking to address staffing constraints in a variety of areas while extending first-class patient experience.  Services range from providing skilled contact agents to support insurance eligibility verification programs; enhancing patient self care activities through post discharge follow-up programs, and providing specialized emergency department programs with strict reach guidelines to facilitate better treatment and care. Through more efficient and effective call processing, these solutions improve patient satisfaction, reduce cost, and increase revenue by maximizing the ratio of patients to available resources.
 
 
19

 
 
Pharmaceutical Support and Clinical Trial Recruitment Services

Our clinical trial solutions service is an integral component of our overall growth strategy to drive revenue enhancement and expand our visibility. AMAC’s PhoneScreen is a leader in the field of patient recruitment, retention and contact center services.  Using centralized telephone screening of potential clinical trial study subjects, PhoneScreen provides valuable data to inform advertising and patient recruitment strategies.  As the trend towards more individualized healthcare communication becomes the norm, AMAC is leading this transformation with innovative contact solutions.  We anticipate that our pharmaceutical support programs will be increasingly utilized to deliver enhanced patient-centric healthcare communication experiences on behalf of certain brands.  Based upon new demand, we are recruiting nurses, health educators and other healthcare professionals that will allow us to provide additional turn-key solutions for our clients.

The Company has completed eleven acquisitions to date to facilitate growth within the TBCS division.  For the remainder of 2011, the Company will focus on growing this segment through internally driven sales and marketing efforts as well as continue to search for additional acquisition opportunities.
 
Operating Segments
 
For the six months ended June 30, 2011, HSMS accounted for 50% of the Company’s revenue and TBCS accounted for 50% of the Company’s revenue.  The Company believes that the overall mix of cash flow generating businesses from HSMS and TBCS, combined with its emphasis on developing products and services to support demand from customers and the emerging, home-based monitoring market, provides the correct blend of stability and growth opportunity. The Company believes this strategy will enable it to maintain and increase its role as a national healthcare communications provider.  Based on the Company’s growth strategy and the complementary nature of if its operating divisions, management believes the Company’s outlook is very positive.

Components of Statements of Income by Operating Segment
The following table shows the components of the Statement of Income for the six and three months ended June 30, 2011 and 2010.
 
In thousands (000’s)
 
Three Months Ended June 30,
   
Six Months Ended June 30,
 
                                                 
   
2011
   
%
   
2010
   
%
   
2011
   
%
   
2010
   
%
 
Revenues
                                               
  HSMS
    5,180       50 %     5,084       52 %     10,429       50 %     10,234       52 %
  TBCS
    5,139       50 %     4,628       48 %     10,522       50 %     9,389       48 %
                                                                 
     Total Revenues
    10,319       100 %     9,712       100 %     20,951       100 %     19,623       100 %
                                                                 
Cost of Services and Goods Sold
                                                               
  HSMS
    2,080       40 %     2,058       40 %     4,036       39 %     4,067       40 %
  TBCS
    2,831       55 %     2,465       53 %     5,736       55 %     4,979       53 %
                                                                 
     Total Cost of Services and Goods Sold
    4,911       48 %     4,523       47 %     9,772       47 %     9,046       46 %
                                                                 
Gross Profit
                                                               
  HSMS
    3,100       60 %     3,026       60 %     6,393       61 %     6,167       60 %
  TBCS
    2,308       45 %     2,163       47 %     4,786       45 %     4,410       47 %
                                                                 
     Total Gross Profit
    5,408       52 %     5,189       53 %     11,179       53 %     10,577       54 %
                                                                 
Selling, General & Administrative
    4,402       43 %     3,857       40 %     8,430       40 %     7,765       40 %
Interest Expense
    13       - %     14       - %     28       - %     26       - %
Equity in net loss from investment in    limited liability company
    512       5 %     116       1 %     1,072       5 %     116       1 %
Other Income
    (11 )     - %     (30 )     - %     (23 )     - %     (59 )     - %
                                                                 
Income before Income Taxes
    492       5 %     1,232       13 %     1,672       8 %     2,729       14 %
                                                                 
Provision for Income Taxes
    333               509               803               1,119          
                                                                 
Net Income
    159               723               869               1,610          
 
 
20

 
 
Results of Operations:

The Company has two distinct operating business segments, which are HSMS and TBCS.

Three Months Ended June 30, 2011 Compared to Three Months Ended June 30, 2010

Revenues:

HSMS

Revenues, which consist primarily of monthly rental revenues, increased approximately $96,000, or 2%, for the three months ended June 30, 2011 as compared to the same period in 2010.  The increase was primarily attributable to the following factor:

§  
The Company recognized an increase in its PERS service revenue of approximately $88,000 primarily from its long-term care programs and execution of a new agreement with a hospital organization.  By aligning itself with long-term care organizations in the interests of improving the business and operational efficiencies of such organizations, the Company experienced growth in the number of subscribers utilizing its PERS units under these programs.
 
§  
The Company recently entered into an agreement with a major multi-national conglomerate to provide the Company’s PERS product under a private label arrangement.  The Company is currently in the process of preparing for this endeavor which is anticipated to start generating revenue during fourth quarter of 2011.
 
 
21

 
 
TBCS

The increase in revenues of approximately $511,000, or 11%, for the three months ended June 30, 2011 as compared to the same period in 2010 was primarily due to:
 
·  
The Company recognized an increase in its non-traditional daytime service revenue of approximately $125,000 primarily due to hospital organizations expanding services with the Company.  The Company recently executed a contract with another hospital organization whereby services are expected to commence in the second half of 2011.  With this latest agreement and the continued expansion from existing hospitals, the Company anticipates that revenue growth from this offering will continue through the remainder of 2011.

·  
The Company recognized an increase in revenue within its pharmaceutical support services of approximately $319,000 primarily as a result of a significant agreement being executed with a large pharmaceutical company in 2010.  Under this agreement, the Company has been awarded with new projects which have continued to provide revenue into the second quarter of 2011.  Revenue growth in this offering is anticipated to continue throughout the year of 2011 as additional new projects under this agreement are scheduled to begin in the second half of 2011.

·  
The Company increased its revenue by approximately $202,000 as a result of the acquisition of a telephone answering service company in September 2010.  In 2011, the Company continues to consider acquisition opportunities that will benefit the Company.

These increases were partially offset by a decrease in revenue within the Company’s traditional after hours services of approximately $135,000 primarily due to customer attrition.  While the Company has been working on strategies to minimize this attrition, it is anticipated that some attrition will continue in this area as a result of current economic conditions and physicians now looking to bring these services in-house.
 
Costs Related to Services and Goods Sold:

HSMS

Costs related to services and goods sold increased by approximately $22,000 for the three months ended June 30, 2011 as compared to the same period in 2010, an increase of 1%, primarily due to the following:

 
·  
Payroll from service operations and telephone expense increased by approximately $37,000 primarily due to a corresponding increase in revenue.

·  
Service fees with respect to the Company’s use of a third party’s telehealth software increased by approximately $37,000 due to an increase in the monthly fee effective in late 2010.
 
 
22

 
 
These increases were partially offset by a decrease in depreciation expense of approximately $49,000 primarily due to the Company purchasing its PERS devices at reduced prices through an alternative supplier in the past three years.

TBCS

Costs related to services increased by approximately $366,000 for the three months ended June 30, 2011 as compared to the same period in 2010, an increase of 15%, primarily due to the following:

§  
The Company recognized an increase in payroll and related expenses associated with pharmaceutical support services and non-traditional daytime services of approximately $293,000 primarily due to a corresponding increase in revenue in these areas.  As the Company continues to grow in this area, it will continue to closely monitor the personnel requirements to perform these services efficiently.
 
§  
As a result of acquiring a telephone answering service company in September 2010, costs related services increased by approximately $97,000 from the operation of this newly acquired subsidiary.  These expenses primarily consisted of operators’ payroll and rent expense.

These increases were partially offset by a decrease in the payroll associated with the traditional after hours services of approximately $106,000 primarily due to a corresponding decrease in revenue in these areas.
 
Selling, General and Administrative Expenses:

Selling, general and administrative expenses increased by approximately $545,000 for the three months ended June 30, 2011 as compared to the same period in 2010, an increase of 14%.  The increase was primarily attributable to the following:

§  
Administrative payroll expense increased by approximately $99,000 primarily due to the Company hiring additional management and support level personnel to assist in expanding its business.  While the Company continues to grow, it will closely monitor the personnel requirements necessary to facilitate, manage and oversee this expansion effectively.

§  
Professional fees increased by approximately $331,000 in relation to certain business activities.  These fees are also expected to be a factor in the third quarter of 2011.
 
 
23

 
 
§  
Travel and entertainment as well as consulting expense increased by approximately $107,000 primarily due to increased marketing and sales activities as well as expansion of business.

§  
Research and development expense increased by approximately $64,000 primarily due to research relating to the development of a home-based cellular PERS device. The Company anticipates it will continue to incur additional research and development costs as it continues to enhance to its PERS device.

§  
As a result of acquiring a telephone answering service company in September 2010, selling, general and administrative expenses increased by approximately $101,000 from the operation of this newly acquired subsidiary.  These expenses primarily consisted of administrative payroll and consulting expense.

These increases were partially offset by a decrease in amortization expense of approximately $117,000 due to certain intangible assets being fully amortized and a decrease in advertising expense of approximately $148,000.

Equity in Net Loss from Investment in Limited Liability Company:

Equity in net loss from investment in limited liability company for the three months ended June 30, 2011 and 2010 of approximately $512,000 and $116,000, respectively, was related to the Company’s investment in Lifecomm in May 2010.  This equity loss represents the Company’s share of Lifecomm’s loss, which consists of research and development cost as well as other selling, general and administrative expenses incurred for the development of the next generation mobile PERS.  This equity loss, which is not related to the Company’s current business operations, is expected to continue throughout 2011 until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.

Income Before Provision for Income Taxes:

The Company’s income before provision for income taxes for the three months ended June 30, 2011 was approximately $492,000 as compared to $1,232,000 for the same period in 2010. The decrease of $740,000 for the three months ended June 30, 2011 primarily resulted from an increase in the Company's costs related to services and product sales, an increase in selling, general and administrative costs and an increase in equity in net loss which were partially offset by an increase in the Company’s revenue.

Provision for Income Taxes:

The Company’s provision for income taxes for the three months ended June 30, 2011 was approximately $333,000 as compared to $509,000 for the same period in 2010.  The estimated effective tax rate for the three months ended June 30, 2011 was approximately 68% as compared to 41% for the same period in 2010.  The increase in the Company’s estimated effective rate was due to the impact of certain non-deductible professional fees.
 
 
24

 
 
Six Months Ended June 30, 2011 Compared to Six Months Ended June 30, 2010

Revenues:

HSMS

Revenues, which consist primarily of monthly rental revenues, increased approximately $195,000, or 2%, for the six months ended June 30, 2011 as compared to the same period in 2010.  The increase was primarily attributable to the following factor:

§  
The Company recognized an increase in its PERS service revenue of approximately $180,000 primarily from its long-term care programs and execution of new agreements with hospital organizations.  By aligning itself with long-term care organizations in the interests of improving the business and operational efficiencies of such organizations, the Company experienced growth in the number of subscribers utilizing its PERS units under these programs.

§  
The Company recently entered into an agreement with a major multi-national conglomerate to provide the Company’s PERS product under a private label arrangement.  The Company is currently in the process of preparing for this endeavor which is anticipated to start generating revenue during fourth quarter of 2011.

TBCS

The increase in revenues of approximately $1,133,000, or 12%, for the six months ended June 30, 2011 as compared to the same period in 2010 was primarily due to:

·  
The Company recognized an increase in its non-traditional daytime service revenue of approximately $428,000 primarily due to hospital organizations expanding services with the Company.  The Company recently executed a contract with another hospital organization whereby services are expected to commence in the second half of 2011.  With this latest agreement and the continued expansion from existing hospitals, the Company anticipates that revenue growth from this offering will continue through the remainder of 2011.

·  
The Company recognized an increase in revenue within its pharmaceutical support services of approximately $592,000 primarily as a result of a significant agreement being executed with a large pharmaceutical company in 2010.  Under this agreement, the Company has been awarded new projects which have continued to provide revenue into the second quarter of 2011.  Revenue growth in this offering is anticipated to continue throughout the year of 2011 as additional new projects under this agreement are scheduled to begin in the second half of 2011.
 
 
25

 
 
·  
The Company increased its revenue by approximately $424,000 as a result of the acquisition of a telephone answering service company in September 2010.  In 2011, the Company continues to consider acquisition opportunities that will benefit the Company.

These increases were partially offset by a decrease in revenue within the Company’s traditional after hours services of approximately $311,000 primarily due to customer attrition.  While the Company has been working on strategies to minimize this attrition, it is anticipated that some attrition will continue in this area as a result of current economic conditions and physicians now looking to bring these services in-house.
 
Costs Related to Services and Goods Sold:

HSMS

Costs related to services and goods sold decreased by approximately $31,000 for the six months ended June 30, 2011 as compared to the same period in 2010, a decrease of 1%, primarily due to the following:

·  
Depreciation expense decreased by approximately $99,000 primarily due to the Company purchasing its PERS devices at reduced prices through an alternative supplier in the past three years.  This decrease was partially offset by an increase in service fees with respect to the Company’s use of a third party’s telehealth software of approximately $62,000 due to an increase in the monthly fee effective in late 2010.

TBCS:

Costs related to services increased by approximately $757,000 for the six months ended June 30, 2011 as compared to the same period in 2010, an increase of 15%, primarily due to the following:
 
 
§  
The Company recognized an increase in payroll and related expenses associated with pharmaceutical support service and non-traditional daytime services of approximately $656,000 primarily due to a corresponding increase in revenue in these areas.  As the Company continues to grow in this area, it will continue to closely monitor the personnel requirements to perform these services efficiently.
 
§  
The Company incurred costs of approximately $65,000 in the development and modification of certain project specific reports for pharmaceutical support service customers, whereby the projects commenced in late 2010 and during 2011.
 
§  
As a result of acquiring a telephone answering service company in September 2010, costs related services increased by approximately $196,000 from the operation of this newly acquired subsidiary.  These expenses primarily consisted of operators’ payroll and rent expense.
 
 
26

 
 
These increases were partially offset by a decrease in the payroll associated with the traditional after hours services of approximately $247,000 primarily due to a corresponding decrease in revenue in these areas.
 
Selling, General and Administrative Expenses:

Selling, general and administrative expenses increased by approximately $665,000 for the six months ended June 30, 2011 as compared to the same period in 2010, an increase of 9%.  The increase was primarily attributable to the following:

§  
Administrative payroll expense increased by approximately $224,000 primarily due to the Company hiring additional management and support level personnel to assist in expanding its business.  While the Company continues to grow, it will closely monitor the personnel requirements necessary to facilitate, manage and oversee this expansion effectively.
 
 
§  
Professional fees increased by approximately $351,000 in relation to certain business activities.  These fees are also expected to be a factor in the third quarter of 2011.

§  
Travel and entertainment as well as consulting expense increased by approximately $132,000 primarily due to increased marketing and sales activities as well as expansion of business.

§  
Research and development expense increased by approximately $71,000 primarily due to research relating to the development of a home-based cellular PERS device. The Company anticipates it will continue to incur additional research and development costs as it continues to enhance to its PERS device.

§  
As a result of acquiring a telephone answering service company in September 2010, selling, general and administrative expenses increased by approximately $181,000 from the operation of this newly acquired subsidiary.  These expenses primarily consisted of administrative payroll and consulting expense.

These increases were partially offset by a decrease in amortization expense of approximately $204,000 due to certain intangible assets being fully amortized and a decrease in advertising expense of approximately $119,000.

Equity in Net Loss from Investment in Limited Liability Company:

Equity in net loss from investment in limited liability company for the six months ended June 30, 2011 and 2010 of approximately $1,072,000 and $116,000, respectively, was related to the Company’s investment in Lifecomm in May 2010.  This equity loss represents the Company’s share of Lifecomm’s loss, which consists of research and development cost as well as other selling, general and administrative expenses incurred for the development of the next generation mobile PERS.  This equity loss, which is not related to the Company’s current business operations, is expected to continue throughout 2011 until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.
 
 
27

 
 
Income Before Provision for Income Taxes:

The Company’s income before provision for income taxes for the six months ended June 30, 2011 was approximately $1,672,000 as compared to $2,729,000 for the same period in 2010. The decrease of $1,057,000 for the six months ended June 30, 2011 primarily resulted from an increase in the Company's costs related to services and product sales, an increase in selling, general and administrative costs and an increase in equity in net loss which were partially offset by an increase in the Company’s revenue.

Provision for Income Taxes:

The Company’s provision for income taxes for the six months ended June 30, 2011 was approximately $803,000 as compared to $1,119,000 for the same period in 2010.  The estimated effective tax rate for the six months ended June 30, 2011 was approximately 48% as compared to 41% for the same period in 2010.  The increase in the Company’s estimated effective rate was due to the impact of certain non-deductible professional fees.

Liquidity and Capital Resources
 
The Company had a credit facility arrangement for $4,500,000 which included a revolving credit line which permitted borrowings of $1,500,000 (based on eligible receivables as defined in the credit agreement) and a $3,000,000 term loan payable.  The term loan was payable in equal monthly principal installments of $50,000, over five years, commencing January 2006.  This term loan was paid in full during the second quarter of 2010 without any prepayment charge.
 
During 2006, the credit facility was amended whereby the Company obtained a $2,500,000 and a $1,600,000 term loan, the proceeds of which were utilized to finance the acquisitions of MD OnCall and American Mediconnect, Inc.  These term loans are payable over five years in equal monthly principal installments of $41,666.67 and $26,666.67, respectively. Additionally, certain of the covenants were amended.  The $2,500,000 term loan was paid in full during the second quarter of 2010 without any prepayment charge.
 
In December 2006, the credit facility was amended to reduce the interest rates charged by the bank such that borrowings under the term loan will bear interest at either (a) LIBOR plus 2.00% or (b) the prime rate or the federal funds effective rate plus 0.5%, whichever is greater, and the revolving credit line bears interest at either (a) LIBOR plus 1.75% or (b) the prime rate or the federal funds effective rate plus 0.5%, whichever is greater.  The LIBOR interest rate charge shall be adjusted in 0.25% intervals based on the Company’s ratio of Consolidated Funded Debt to Consolidated EBITDA.  In the third quarter of 2007, the interest rate was reduced by 0.25% based on this ratio.  The Company has the option to choose between the two interest rate options under the amended term loan and revolving credit line.  Borrowings under the credit facility are collateralized by substantially all of the assets of the Company.
 
 
28

 
 
On April 30, 2007, the Company amended its credit facility whereby the amount of credit available under the revolving credit line was increased to $2,500,000.  In June 2010, the term of the revolving credit line was extended through June 2013.

On May 12, 2010, the Company’s credit facility was amended whereby the Company obtained an additional $2,000,000 in the form of a term loan, the proceeds of which were utilized to partially finance its investment in Lifecomm relating to the development of the mobile PERS system.  This term loan is payable over five years in equal monthly principal installments of $33,333.33, commencing June 1, 2010.  The interest rate is the same as the previous term loans secured by the Company.

As of June 30, 2011 and 2010, the Company was in compliance with its financial covenants in its credit agreement.

The following table is a summary of contractual obligations as of June 30, 2011:
 
   
Payments Due by Period
 
Contractual  Obligations
 
Total
   
Less than 1 year
   
1-3 years
   
4-5 years
   
After 5 years
 
Revolving Credit Line
  $ 750,000           $ 750,000              
Debt  (a)
  $ 1,700,000     $ 500,000     $ 1,200,000              
Operating Leases (b)
  $ 8,194,240     $ 1,526,163     $ 3,867,471     $ 2,130,935     $ 669,671  
Purchase Commitments (c)
  $ 1,767,720     $ 1,767,720                          
Interest Expense (d)
  $ 120,745     $ 55,924     $ 64,821                  
Acquisition Related
Commitment (e)
  $ 122,725     $ 98,625     $ 24,100                  
Total Contractual Obligations
  $ 12,655,430     $ 3,948,432     $ 5,906,392     $ 2,130,935     $ 669,671  
 
 
(a)     – Debt includes the Company’s aggregate outstanding term loans which mature in 2011 and 2015.
 
 
(b)      Operating leases include rental of facilities at various locations within the United States.  These leases include the rental of the Company’s call centers, warehouse and office facilities with various expiration dates.  The Company currently leases office space from the Chairman and principal shareholder pursuant to a lease.  This lease expires in December 2012.  The Company also leases office space from certain telephone answering service managers with expirations through March 2015.
 
 
29

 
 
 
(c)   – Purchase commitments relate to orders for the Company’s traditional PERS system and its MedSmart medication medical system.
 
 
 (d)  – Interest expense relates to interest on the Company’s revolving credit line and debt at the Company’s current rate of interest.
 
 
(e) – Acquisition related commitment represents estimated payments due based on collections of trade receivables relating to the acquisition of Alpha Message Center, Inc in September 2010.
 
The primary sources of liquidity are cash flows from operating activities.  Net cash provided by operating activities was approximately $4.2 million for the six months ended June 30, 2011, as compared to approximately $3.4 million for the same period in 2010.  During 2011, the cash provided by operating activities was primarily from net earnings of approximately $0.9 million, depreciation and amortization of approximately $1.5 million, equity in net loss from investment in limited liability company of approximately $1.1 million, and an increase in accounts receivable of approximately $0.5 million.  The components of depreciation and amortization primarily relate to the purchases of the Company’s traditional PERS equipment and the customer lists associated with the acquisition of telephone answering service businesses.  The net loss from investment in limited liability company represents the Company’s equity share of Lifecomm’s loss which consists of research and development cost as well as other selling, general and administrative expense incurred for the development of the next generation mobile PERS.  The decrease in accounts receivable was primarily as a result of certain significant projects which were billed in the last quarter of 2010 being collected in 2011.  During 2010, the cash provided by operating activities was primarily from net earnings of approximately $1.6 million and depreciation and amortization of approximately $1.8 million.
 
Net cash used in investing activities for the six months ended June 30, 2011 was approximately $0.6 million compared to $4.5 million for the same period in 2010.  The primary component of net cash used in investing activities in 2011 was capital expenditures of approximately $0.7 million.  The primary components of net cash used in investing activities in 2010 were the investment in a limited liability company of approximately $4.1 million for the development of the next generation mobile PERS system and capital expenditures of approximately $0.4 million.  Capital expenditures for both 2011 and 2010 primarily related to the continued production and purchase of the traditional PERS systems.
 
Cash flows used in financing activities for the six months ended June 30, 2011 were approximately $0.4 million compared to $0.3 million for the same period in 2010.  The primary component of cash flow used in financing activities in 2011 was the payment of long-term debt of approximately $0.4 million.  The primary components of cash flow used in financing activities in 2010 were the payment of long-term debt of approximately $1.3 million and the payment of a special dividend, which was declared on December 16, 2009, of approximately $1.0 million.  These financing cash outflows in 2010 were partially offset by the proceeds from long-term debt of $2.0 million which was obtained for the purpose of partially funding the investment in a limited liability company.
 
 
30

 
 
During the next twelve months, the Company anticipates it will make capital expenditures of approximately $1.75 – $2.25 million for the production and purchase of the traditional PERS systems, telehealth systems, Mobile PERS,  enhancements to its computer operating systems and build-out of its additional call center space.  Part of this amount is subject to fluctuations primarily based on customer demand.  The Company anticipates incurring approximately $0.1 - $0.2 million of costs primarily relating to research and development of its home-based cellular PERS and telehealth products.  The Company also plans to incur approximately $1.0 - $1.5 million of advertising expense for promotional campaigns related to its PERS system.  The Company is also considering acquisition initiatives which may require additional cash outlay.
 
As of June 30, 2011, the Company had approximately $7.2 million in cash and the Company’s working capital was approximately $12.5 million.  The Company believes that with its present cash balance and with operations of the business generating positive cash flow, it will be able to meet its cash flow needs for working capital and capital expenditures for at least the next twelve months. The Company also has a revolving credit line, which expires in June 2013 that permits borrowings up to $2.5 million, of which $750,000 was outstanding at June 30, 2011.
 
Off-Balance Sheet Arrangements:
 
As of June 30, 2011, the Company has not entered into any off-balance sheet arrangements that are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources  that is material to investors.
 
Other Factors:
 
Lease Commitments

On January 14, 2002, the Company entered into an operating lease agreement for space in Long Island City, New York in order to consolidate its HCI TBCS and PERS ERC/ Customer Service facilities.  The centralization of the ERC, Customer Service and HLINK® OnCall operations has provided certain operating efficiencies and allowed for continued growth of the HLINK and PERS divisions.  The fifteen (15) year lease term commenced in April 2003.  The lease calls for minimum annual rentals of $307,900, subject to a 3% annual increase plus reimbursement for certain real estate taxes.  

During 2005, the Company entered into two operating lease agreements for additional space at its Long Island City, New York location in order to consolidate its warehouse and distribution center and accounting department into this location.  The leases, which commenced in January 2006 and expire in March 2018, call for minimum annual rentals of $220,000 and $122,000, respectively, and are subject to increases in accordance with the term of the agreements.  The Company is also responsible for the reimbursement of certain real estate taxes.
 
 
31

 
 
In September 2009, the Company sublet a portion of its Long Island City, New York space under one of its operating leases which was entered into in 2005.  The space is being sublet to an independent third party and calls for minimum annual rentals of $125,000, subject to annual increases in accordance with the terms of the agreement.  The sublease expires in March 2018.

During 2010, the Company entered into an operating lease agreement for additional space at its Long Island City, New York location in order to provide space for the operation of its non traditional day-time services.  The lease, which commenced in January 2011 and expires in December 2015, calls for minimum annual rent of $65,000, subject to increases in accordance with the term of the agreement.  The Company is also responsible for the reimbursement of certain real estate taxes.

In June 2011, the Company entered into an operating lease agreement for additional space at its Long Island City, New York location in order to provide space primarily for the expansion of its non traditional day-time services and its pharmaceutical support services.  The lease will commence when the landlord’s build out is completed which is estimated to be in October 2011, and will expire after five years.  The lease calls for minimum annual rent of $215,375 and is subject to increases in accordance with the term of the agreement.  The Company is also responsible for the reimbursement of real estate taxes.

Investment in limited liability company
 
On May 12, 2010, the Company entered into a limited liability company agreement with Hughes Telematics, Inc. and Qualcomm Incorporated to design, develop, finance and operate a mobile PERS system.  The Company invested $4,000,000 and incurred $150,336 in professional fees to acquire a minority interest (approximately 10%) in the new company, Lifecomm LLC (“Lifecomm”). As part of this transaction, the Company borrowed $2,000,000 from its bank to partially finance this transaction.  In addition, pursuant to the limited liability company agreement, the Company has agreed to fund its share ($200,000) of a stand-by equity commitment for Lifecomm’s benefit, if required.  As of June 30, 2011, the Company’s exposure to loss is limited to the recorded equity investment balance of $1,898,298 and its share ($200,000) of a stand-by equity commitment, if required.
 
Hughes Telematics, Inc. (“HTI”), parent of Lifecomm and the party who has a controlling financial interest in Lifecomm, has determined that Lifecomm is a variable interest entity and that HTI is the primary beneficiary.  If HTI is unable to provide the financial and operating support that it is obligated to under the agreement, Lifecomm and the successful development of the next generation mobile PERS would likely be negatively impacted.

Lifecomm is a development stage company that has yet to generate any revenue, and has generated a pre-tax net loss of $4,312,480 and $2,356,758 during the six and three months ended June 30, 2011 ($7,934,372 during the period from inception, May 12, 2010 to June 30, 2011).  Lifecomm will continue to generate losses until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.  There is no assurance that Lifecomm will complete, in a cost effective or timely manner, the development of the operating systems to specifications that will allow it to successfully generate revenue.

 
32

 
 
In accordance with the limited liability company agreement, profits are generally allocated to members in the amount of and in proportion to their ownership of the outstanding membership units.  Losses are generally allocated to members in the amount of and in proportion to their unreturned capital contributions, which for the purposes of determining the allocation of losses is defined as the aggregate of (i) cash contributions, (ii) the fair value of other contributed assets and (iii) the value of in-kind services contributed by the members through the date of determination, less (iv) the fair value of any assets distributed to the members; provided, however, that any losses generated through May 12, 2012 will be generally allocated to the members first in the amount of and in proportion to the unreturned capital contributions attributable to only the cash contributions and the value of in-kind services contributed by the members through the date of determination and then in the amount of and in proportion to the unreturned capital contributions attributable to the fair value of other contributed assets.

During the six and three months ended June 30, 2011, the Company recorded a pre-tax net loss of $1,071,912 and $512,030, respectively ($2,252,038 during the period from inception, May 12, 2010 to June 30, 2011) for its share of losses from the equity investment in Lifecomm.  The equity loss primarily relates to research and development costs as well as other selling, general and administrative expenses incurred for the development of the next generation mobile PERS.  As the development continues to progress, the Company expects that its share of equity loss will continue throughout 2011 until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.
 
In connection with the formation of Lifecomm, the Company entered into a Value Added Reseller Agreement (“VAR Agreement”) with Lifecomm.  Under the VAR Agreement, the Company will be a reseller of the Mobile PERS Solution in the United States, as well as a preferred provider of the emergency assistance call center (“EACC”) component of the Mobile PERS Solution provided by Lifecomm to customers.  The Company will be the sole provider of the EACC to the customers to whom it resells the Mobile PERS Solution.  The term of the VAR Agreement is perpetual, subject to termination as set forth therein.  The VAR Agreement contains standard indemnification provisions for agreements of this nature.
 
Acquisition

On September 29, 2010, the Company acquired substantially all of the assets of Alpha Message Center, Inc. (“Alpha”), a New Jersey based company that provides telephone after-hours answering and pager services. The purchase price of this acquisition consisted of an initial cash payment of $577,977 and an accrual of $200,000, which represented the estimated fair value of the contingent consideration expected to be paid through September 2012.  The contingent consideration is based on the acquisition agreement that calls for the Company to pay the former owner of Alpha fourteen percent (14%) of the cash expected to be collected by the Company, excluding sales taxes, from certain revenue generated by Alpha through September 2012.  The Company estimated the future contingent consideration expected to be paid based upon Alpha’s historic revenue data.  The results of operations of Alpha are included in the Telephone Based Communications Services segment as of the date of acquisition.
 
 
33

 
 
Recent Accounting Pronouncements:
 
In December 2010, the FASB issued Update 2010-29, “Disclosure of Supplementary Pro Forma Information for Business Combinations.” The amendments in Update 2010-29 specify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. Update 2010-29 also expands the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributed to the business combination included in the pro forma financial data. The Company is required to adopt all the provisions of Update 2010-29 for any business combinations for which the acquisition date is on or after January 1, 2011. The impact of the provisions of this guidance on our consolidated financial statements depends upon the nature, terms and size of the acquisitions we consummate in the future.

In December 2010, the FASB issued Update 2010-28, “Intangibles --Goodwill and Other (Topic 350).” Update 2010-28 modifies the first step of the goodwill impairment test to include reporting units with zero or negative carrying amounts. For these reporting units, the second step of the goodwill impairment test shall be performed to measure the amount of impairment loss, if any; when it is more likely than not that a goodwill impairment exists. Update 2010-28 is effective for fiscal years and interim periods beginning after December 15, 2010.  The adoption of this guidance did not have a material impact on the consolidated financial statements of the Company.

Critical Accounting Policies:

In preparing the financial statements, the Company makes estimates, assumptions and judgments that can have a significant impact on our revenue, operating income and net income, as well as on the reported amounts of certain assets and liabilities on the balance sheet.  The Company believes that the estimates, assumptions and judgments involved in the accounting policies described below have the greatest potential impact on its financial statements due to the materiality of the accounts involved, and therefore, considers these to be its critical accounting policies.  Estimates in each of these areas are based on historical experience and a variety of assumptions that the Company believes are appropriate. Actual results may differ from these estimates.

Reserves for Uncollectible Accounts Receivable
 
The Company makes ongoing assumptions relating to the collectability of its accounts receivable.  The accounts receivable amount on the balance sheet includes a reserve for accounts that might not be paid.  In determining the amount of the reserve, the Company considers its historical level of credit losses.  The Company also makes judgments about the creditworthiness of significant customers based on ongoing credit evaluations, and it assesses current economic trends that might impact the level of credit losses in the future. The Company recorded reserves for uncollectible accounts receivable of $453,800 as of June 30, 2011, which is equal to 6% of the total accounts receivable.  While the Company believes that the current reserves are adequate to cover potential credit losses, it cannot predict future changes in the financial stability of its customers and the Company cannot guarantee that its reserves will continue to be adequate.  For each 1% that actual credit losses exceed the reserves established, there would be an increase in general and administrative expenses and a reduction in reported net income of approximately $74,000. Conversely, for each 1% that actual credit losses are less than the reserve, this would decrease the Company’s general and administrative expenses and increase the reported net income by approximately $74,000.
 
 
34

 
 
Fixed Assets
Fixed assets are stated at cost.  Depreciation for financial reporting purposes is being provided by the straight-line method over the estimated useful lives of the related assets.  The valuation and classification of these assets and the assignment of useful depreciable lives involves significant judgments and the use of estimates.  Fixed assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Historically, impairment losses have not been required.  Any change in the assumption of estimated useful lives could either result in a decrease or increase to the Company’s financial results.  A decrease in estimated useful life would reduce the Company’s net income and an increase in estimated useful life would increase the Company’s net income.  If the estimated useful lives of the PERS medical device were decreased by one year, the cost of goods related to services would increase and net income would decrease by approximately $154,000 per annum.  Conversely, if the estimated useful lives of the PERS medical device were increased by one year, the cost of goods related to services would decrease and net income would increase by approximately $112,000 per annum.
 
Valuation of Goodwill
Goodwill and indefinite life intangible assets are subject to annual impairment tests.  To date, the Company has not been required to recognize an impairment of goodwill. The Company tests goodwill for impairment annually or more frequently when events or circumstances occur indicating goodwill might be impaired. This process involves estimating fair value using discounted cash flow analyses. Considerable management judgment is necessary to estimate discounted future cash flows. Assumptions used for these estimated cash flows were based on a combination of historical results and current internal forecasts.  The Company cannot predict certain events that could adversely affect the reported value of goodwill, which totaled $10,842,352 at June 30, 2011 and December 31, 2010.  If the Company were to experience a significant adverse impact on goodwill, it would negatively impact the Company’s net income.

Investment in limited liability company
 
The Company owns a minority interest of approximately 10% and is not the primary beneficiary in an unconsolidated limited liability company.  The Company's investment in the unconsolidated limited liability company is recorded using the equity method of accounting, whereby the original investment is recorded at cost and subsequently adjusted for contributions, distributions, and net income (loss) attributable to such limited liability company.  All income and loss are allocated to the limited liability company members in accordance with the terms of the limited liability company agreement.  An impairment charge is recognized for an investment accounted for under the equity method when an other than temporary decline in its carrying value has occurred.  As of June 30, 2011, the equity investment balance was $1,898,298 and the Company has not recorded any impairment charges on its equity investment in the limited liability company.
 
 
35

 
 
Accounting for Stock-Based Awards
Stock based compensation is recorded in accordance with ASC Topic 718, Compensation – Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payments to employees, including grants of stock and employee stock options, based on estimated fair values.
 
Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period.  The Company recorded a pre-tax stock-based compensation expense which is included in selling, general and administrative expense in its consolidated financial statements of approximately $116,000 and $160,000 for the six months ended June 30, 2011 and 2010, respectively.
 
The determination of fair value of share-based payment awards to employees and directors on the date of grant using the Black-Scholes model is affected by the Company's stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to the expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.

Item 3.   Quantitative and Qualitative Disclosures About Market Risk.

Market Risk Disclosure

The Company does not hold market risk-sensitive instruments entered into for trading purposes, nor does it hold market risk sensitive instruments entered into for other than trading purposes. All sales, operating items and balance sheet data are denominated in U.S. dollars; therefore, the Company has no significant foreign currency exchange rate risk.

In the ordinary course of its business, the Company enters into commitments to purchase raw materials and finished goods over a period of time, generally six months to one year, at contracted prices.  At June 30, 2011, these future commitments were not at prices in excess of current market, or in quantities in excess of normal requirements. The Company does not utilize derivative contracts either to hedge existing risks or for speculative purposes.
 
 
36

 
 
Interest Rate Risk

We are exposed to market risk from changes in interest rates primarily through our financing activities.  Interest on the outstanding balances on our term loans and revolving credit line under our credit facility accrues at a rate of LIBOR plus 1.75% and LIBOR plus 1.50%, respectively.  Our ability to carry out our business plan to finance future working capital requirements may be impacted if the cost of carrying debt fluctuates to the point where it becomes a burden on our resources.

Item 4.  Controls and Procedures.
 
As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of its Chief Executive Officer and President and its Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, the Chief Executive Officer and President and the Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed by it under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company's management, including the Chief Executive Officer and President and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.

There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended June 30, 2011 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company is aware of various threatened or pending litigation claims against the Company relating to its products and services and other claims arising in the ordinary course of its business.  The Company has given its insurance carrier notice of such claims and it believes there is sufficient insurance coverage to cover any such claims.  Currently, no material liabilities have been recorded and in any event, the Company believes the disposition of these matters will not have a material adverse effect on the results of operations and financial condition of the Company.

Item 1A. Risk Factors
 
Management believes that there have been no material changes in the Company’s risk factors as reported in the Annual Report on Form 10-K for the year ended December 31, 2010, which was filed on March 31, 2011 with the Securities and Exchange Commission and amended on April 6, 2011
 
 
37

 
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 23, 2011, we issued time vested restricted stock units representing the right to receive 46,500 shares of our common stock to two executive officers, as required under such executives’ existing employment agreements.  On June 30, 2011, we granted 2931 shares of restricted stock to two non-employee directors.  Exemption from the registration provisions of the Securities Act of 1933, as amended (the "Act") for the foregoing grants is claimed under Section 4(2) of the Act, and Rule 506 promulgated thereunder.  The exemption was established by the representation of each recipient as to his status as an accredited investor by virtue of his position with the Company, and the acknowledgment by each recipient that the shares are “restricted securities” and that resale of the securities may not be made unless registered under the Act, or another exemption is available.  In addition, the securities will bear a legend indicating such restrictions on transferability. The foregoing issuances were compensatory in nature and were made without cost to the receipients.

Item 6.  Exhibits
 
No.
Description
   
10.1
Lease Modification II,  dated June 24, 2011, to the Lease, dated as of January 4, 2002, between CityView Plaza, LLC and American Medical Alert Corp.
   
10.2
Restricted Stock Unit Award Agreement, dated June 23, 2011, between American Medical Alert Corp. and Jack Rhian.
   
10.3
Restricted Stock Unit Award Agreement, dated June 23, 2011, between American Medical Alert Corp. and Frederic Siegel.
   
15.1
Letter from Margolin, Winer & Evens LLP, the independent accountant of the Company, acknowledging awareness of the use in a registration statement of a report on the unaudited interim financial information in this quarterly report.
   
31.1
Certification of CEO Pursuant to Section 302 of the Sarbanes Oxley Act of 2002
   
31.2
Certification of CFO Pursuant to Section 302 of the Sarbanes Oxley Act of 2002
   
32.1
Certification of CEO Pursuant to Section 906 of the Sarbanes Oxley Act of 2002
   
32.2
Certification of CFO Pursuant to Section 906 of the Sarbanes Oxley Act of 2002
 
 
38

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
AMERICAN MEDICAL ALERT CORP.
 
       
Dated: August 15, 2011 
By:
/s/ Jack Rhian  
    Name: Jack Rhian   
    Title: Chief Executive Officer and President  
       


       
 
By:
/s/ Richard Rallo  
    Name: Richard Rallo  
    Title: Chief Financial Officer  
       

 
39

 

EX-10.1 2 v230635_ex10-1.htm EXHIBIT 10.1 Unassociated Document
 
Exhibit 10.1
 
LEASE MODIFICATION II
 
AGREEMENT made this 24th day of June 2011, by and between CityView Plaza, LLC, a New York Limited Liability Company with its principal place of business c/o Alma Realty Corp., 31-10 37th Avenue, Long Island City, New York 11101 (hereinafter referred to as “Landlord”) and American Medical Alert Corp., a New York Corporation with its principal place of business at 36-36 33rd Street, Long Island City, New York (hereinafter referred to as “Tenant”);
 
WITNESSETH:
 
WHEREAS, Landlord’s predecessor in interest and Tenant are parties to a certain lease, dated January 14, 2002, a Lease Amendment and Modification, dated January 14, 2002 and a Lease Modification, dated September 22, 2010 (hereinafter collectively, the “Lease”), pursuant to which Tenant leased from Landlord approximately 11,000 and 2,600 square feet on the first floor of the building known as 36-36 33rd Street, Long Island City, New York (hereinafter referred to as the “Building”); and
 
WHEREAS, Tenant desires to lease an additional 8,615 square feet of space on the first floor of the Building; and
 
WHEREAS, Landlord and Tenant desire to modify the terms of the Lease in connection therewith.
 
NOW, THEREFORE, in consideration of their mutual promises and covenants each to the other, and for other good and valuable consideration, the parties hereto agree as follows:
 
 
1

 
 
1.           Landlord hereby leases to Tenant and Tenant hereby leases from Landlord approximately 8,615 square feet of additional space on the first floor of the Building as depicted on the floor plan attached hereto as Schedule “A” (hereinafter referred to as the “Additional Space”).
 
2.           Except as otherwise set forth herein, the Demised Premises, as referred to under the Lease with respect to the space in the Building rented by Tenant is hereby modified to include the Additional Space.
 
3.           “Tenant’s Proportionate Share” for the first floor space, inclusive of the Additional Space, is 12.7%.
 
4.           The term of the Lease with respect to the Additional Space only shall be for a period of five (5) years and shall commence on the “Commencement Date”, as herein defined, and terminate five (5) years after the Commencement Date (“Termination Date or Expiration Date”).  The Commencement Date shall be the date on which Landlord substantially completes the work to be performed by Landlord to the Additional Space (“Landlord’s Work”).   The term “substantially completed” shall mean completion of the work as set forth at Schedule “B” hereto (“Landlord’s Work”) but for minor insubstantial details of construction and mechanical adjustments (i.e. so-called “punch list” items).  Immediately following the determination of the Commencement Date, Landlord and Tenant shall execute an agreement setting forth both the Commencement Date and Term Expiration Date of this lease with respect to the Additional Space, however, this shall not be a condition thereof.  If the term of this Lease begins on a date other than the first day of a month, the Tenant shall pay pro rata portion of the rent from such date through and including the last day of such month.  Each succeeding Lease Year shall end on the anniversary date of the end of the previous Lease Year.
 
 
2

 
 
5.           The basic annual rent to be paid by Tenant with respect to the Additional Space only is as follows:
 
LEASE YEAR
 
ANNUAL RENT
   
MONTHLY RENT
 
                 
1st
  $ 215,375.00     $ 17,947.92  
2nd
  $ 215,375.00     $ 17,947.92  
3rd
  $ 215,375.00     $ 17,947.92  
4th
  $ 221,836.25     $ 18,486.35  
5th
  $ 228,469.80     $ 19,039.08  

6.           Provided Tenant fully performs and complies with all of the terms, conditions, provisions and covenants in this Lease on Tenant’s part to be observed and performed, Tenant shall have the option to extend the term of the Lease with respect to the Additional Space such that it runs concurrent with that of the original first floor space it occupies, pursuant to the agreement of January 14, 2002, such that the term for the Additional Space terminates on March 31, 2018.  In order to do so, Tenant must give to Landlord an irrevocable written notice of its election to exercise said option not less than six (6) months prior to the expiration of the initial term.  If Tenant exercises such option, the basic annual rent to be paid by Tenant with respect to the Additional Space only is as follows:
 
For the first year of the option period (or any portion thereof) - $235,361.80 ($19,613.48/monthly);
 
For the second year of the option period (or any portion thereof) - $242,426.16 ($20,202.18/monthly);
 
 
3

 
 
It is understood and agreed that in any and all events the term of the Lease with respect to the Additional Space shall expires on or before March 31, 2018.
 
7.           Tenant agrees to pay all utilities and additional rent associated with the Additional Space.  Specifically, Tenant shall pay 49.7% of the electric bill for the HVAC Unit “B” and 43% of the electric bill for the HVAC Unit “C” as it relates to the cooling system servicing the Additional Space and its revised Proportionate Share of the gas bill for the Building.  All other electricity will be provided and paid for on a sub-metered basis.
 
8.           Tenant shall deposit with Landlord upon execution of this Agreement, the sum of $35,895.84, as and for security deposit for the Additional Space.
 
9.           Tenant shall pay to Landlord upon execution of this Agreement the sum of $17,947.92, representing the first monthly installment of basic annual rent for the Additional Space.
 
10.           Landlord agrees to prepare and complete the Additional Space on a “built to suit” basis, as described at Schedule “B” thereof.
 
11.           In all other respects, the Lease shall remain in full force and effect and no other modifications, amendments or revisions shall be deemed effective or binding unless said modifications, amendments or revisions are in writing executed by all of the parties hereto.  It is further understood and agreed that a default hereunder shall be considered a default under the Lease with respect to the other first floor space rented by Tenant and vice versa.
 
 
4

 
 
IN WITNESS WHEREOF, the parties hereto have hereunto set their hand and seal the day and year first above written.

Witness for Landlord:
  CityView Plaza, LLC
       
/s/ Peter Kosteas
  by:
/s/ Steve Valiotis
    Name: Steve Valioits
       
Witness for Tenant:
  American Medical Alert Corp.
       
/s/ Marie T. Mueller
  by:
/s/ Jack Rhian
    Name: Jack Rhian
    Title: President/Chief Executive Officer
  
 
5

 
EX-10.2 3 v230635_ex10-2.htm EXHIBIT 10.2
Exhibit 10.2

AMERICAN MEDICAL ALERT CORP.
2010 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT

This Restricted Stock Unit Award Agreement (this "Agreement") is dated as of this 23rd day of June, 2011 (the "Grant Date"), and is between American Medical Alert Corp., a New York corporation (the "Company") and Jack Rhian ("Grantee").

Section 1.              Definitions.
 
(a)           “Affiliate” means any entity that the Company, either directly or indirectly, is in common control with, is controlled by or controls, or any entity that the Company has a substantial direct or indirect equity interest, as determined by the Board.
 
(b)           "Agreement" shall have the meaning ascribed to it in the Introductory paragraph of this Agreement.
 
(c)           “Applicable Laws” means the requirements relating to the administration of equity-based awards and any related matters under U.S. state corporate laws, U.S. federal and state securities laws, the Code, and any stock exchange or quotation system on which the Common Stock is listed or quoted, and all rules and regulations relating to any of the foregoing.
 
(d)           "Award" shall have the meaning ascribed to it in Section 2(a) of this Agreement.
 
(e)           “Board” means the Board of Directors of the Company.
 
(f)            “Code” means the Internal Revenue Code of 1986, as amended.  Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code.
 
(g)           “Common Stock” shall have the meaning ascribed to it in the Plan.
 
(h)           “Company” means American Medical Alert Corp., a New York corporation, or any successor thereto.
 
(i)            "Continuous Service" shall have the meaning ascribed to it in the Plan.
 
(j)            "Disability" shall have the meaning ascribed to it in the Plan.
 
(k)           "Grant Date" shall have the meaning ascribed to it in Section 2(a) of this Agreement.

 
1

 
 
(l)            "Granted Units" shall have the meaning ascribed to it in Section 2(a) of this Agreement.
 
(m)          "Grantee" shall have the meaning ascribed to it in the Introductory paragraph of this Agreement.
 
(n)           "Plan" shall have the meaning ascribed to it in Section 2(c) of this Agreement.
 
(o)           "Restricted Stock Unit" shall mean a right to receive one Share upon vesting pursuant to Section 4(a).
 
(p)           "Service Termination" shall have the meaning ascribed to it in Section 4(b) of this Agreement.
 
(q)           “Share” shall have the meaning ascribed to it in the Plan.
 
(r)            "Termination Date" shall have the meaning ascribed to it in Section 4(b) of this Agreement.
 
(s)           "Vesting Date" shall have the meaning ascribed to it in Section 4(a) of this Agreement.
 
Section 2.              Grant of Restricted Stock Units.
 
(a)           Award.  On the terms and conditions set forth in this Agreement, the Company has granted Grantee a total of 30,000 Restricted Stock Units (the "Granted Units" or the “Award”), each subject to vesting in accordance with Section 4(a).
 
(b)           Shareholder Rights.  Grantee (or any successor in interest) shall not have any of the rights of a shareholder (including, without limitation, voting and liquidation rights) with respect to the Granted Units until such time as Grantee becomes the record holder of the Shares to be delivered in settlement of the Granted Units, as described in Section 5(a).
 
(c)           Plan and Defined Terms.  The Award is granted under and subject to the terms of the American Medical Alert Corp. 2010 Equity Incentive Plan (the "Plan"), which is incorporated herein by this reference.  Capitalized terms used herein and not defined in this Agreement (including Section 1 hereof) shall have the meanings set forth in the Plan.  To the extent there is any conflict between the terms of this Agreement and the Plan, the terms of the Plan shall control.
 
(d)           Grantee Undertaking.  Grantee (or any successor in interest) agrees to execute such further instruments and to take such action as may reasonably be necessary to carry out the intent of this Agreement.

 
2

 

Section 3.              No Transfer or Assignment.  The Award and the rights and privileges conferred by this Agreement shall not be transferable or assignable by Grantee, and may not be made subject to execution, attachment or similar procedures, other than by will or the laws of descent and distribution or as determined by the Plan's administrator in accordance with Applicable Laws.  Any such purported transfer contrary to the restrictions set forth in this Agreement shall be void and unenforceable against the Company or any Affiliate.  Notwithstanding the foregoing, the Plan's administrator, in its discretion, may permit the transfer, solely as gifts or pursuant to a domestic relations order during Grantee's lifetime of all or a portion of the Award to Grantee's immediate family members.  For this purpose, immediate family member means Grantee's child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing Grantee's household (other than a tenant or employee), a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these persons (or Grantee) control the management of assets, and any other entity in which these persons (or Grantee) own more than fifty percent of the voting interests.  Any permitted transfer of the Award shall not be effective to bind the Company unless the Plan's administrator shall have been furnished with written notice thereof and a copy of such evidence as the Plan's administrator may deem necessary to establish the validity of the transfer and the acceptance by the transferee or transferees of the terms and conditions hereof.
 
Section 4.              Vesting; Termination of Service.
 
(a)           Vesting.  Subject to any acceleration provisions contained in the Plan and in Section 4(f) of that certain Employment Agreement, dated as of December 30, 2010, between the Company and Grantee, the Award shall vest as follows: 10,000 Shares on December 31, 2011, 10,000 Shares on December 31, 2012 and 10,000 Shares on December 31, 2013 (each, a "Vesting Date").  Shares scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in Grantee in accordance with any of the provisions of this Agreement unless Grantee shall have been providing Continuous Service from the Grant Date through and on the date such vesting occurs.  The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Award at any time, subject to the terms of the Plan.  If so accelerated, such portion of the Award will be considered as having vested as of the date specified by the Administrator.
 
(b)           Termination of Service.  The unvested portion of the Award shall be immediately forfeited, and therefore, there shall be no further vesting of the Award, as of the date (the "Termination Date") that Grantee actually ceases to provide Continuous Service to the Company or an Affiliate for any reason in its capacity as employee, director or consultant (irrespective of whether Grantee continues to receive severance or any other continuation payments or benefits after such date) (such cessation of the provision of services by Grantee being referred to as a "Service Termination").
 
(c)           Death/Disability.  In the event of Service Termination resulting from Grantee's death or Disability, the unvested portion of the Granted Units shall be immediately forfeited as of the Termination Date.

 
3

 
 
Section 5.              Settlement of Granted Units.
 
(a)           Settlement Amount.  Subject to Section 5(b) hereof, the Company shall deliver to Grantee as soon as administratively practicable (but in no event later than two and one half months following the end of the year in which such vesting occurs) after each Vesting Date (and any other date on which the Award vests pursuant to this Agreement or the Plan): (i) a number of Shares equal to the number of Granted Units that vested on such date and (ii) an amount in cash equal to the cash dividends paid, from the Grant Date through the applicable vesting date, on one Share for each Share represented by the Granted Units that vested on such date; provided, however, that no Shares will be issued in settlement of the Award unless the issuance of Shares complies with Applicable Laws.  No fractional Shares will be issued.  The Company will pay cash in respect of fractional Shares.
 
(b)           Withholding Requirements.  Subject to the Plan, the Company will have the power and the right to deduct or withhold, or require Grantee to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including Grantee's FICA obligation) required to be withheld with respect to the Award.
 
Section 6.              Adjustment of Granted Units.  Subject to Section 16(c) of the Plan, in the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property, but excluding regular cash dividends to shareholders of the Company), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and kind of Shares that will be paid to Grantee upon settlement of the Granted Units, as the Administrator, in its sole discretion, deems appropriate.
 
Section 7.              Representations of Grantee.  Grantee hereby represents to the Company that:
 
(a)           Grantee is an “accredited investor,” as such term is defined in Rule 501 of the Securities Act due to his status as an executive officer of the Company.
 
(b)           Grantee understands that this Agreement and the Plan contain substantial restrictions on the transferability of the Award and provide that, in the event that the conditions relating to the transfer of any portion of the Award in such document has not been satisfied, the holder shall not transfer any portion of the Award, and unless otherwise specified, the Company will not recognize the transfer of the Award on its books and records, or issue any certificates representing the Shares issued in settlement of this Award, and any purported transfer not in accordance with the terms of this Agreement, the Plan and Applicable Laws shall be void.  Grantee will sell, transfer or otherwise dispose of the Award only in a manner consistent with its representations set forth herein and then only in accordance with this Agreement, the Plan and Applicable Laws.

 
4

 
 
(c)           Grantee understands that, unless registered: (i) the Shares issued in settlement of this Award will be characterized as "restricted securities" under the U.S. federal securities laws and the certificates representing such Shares shall bear the following legends:
 
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE HELD BY AN "AFFILIATE", WITHIN THE MEANING OF PARAGRAPH (A) (1) OF RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY ONLY BE SOLD, TRANSFERRED OR ASSIGNED IF IN THE OPINION OF COUNSEL OF THE CORPORATION SUCH SALE, TRANSFER OR ASSIGNMENT IS IN COMPLIANCE WITH THE RULES AND REGULATIONS PROMULGATED UNDER THE SECURITIES ACT.”
 
and (ii) any Shares issued in settlement of this Award may not be sold, transferred or otherwise disposed of except in compliance with Applicable Laws.  In addition, Grantee acknowledges and agrees that stop transfer instructions shall be imposed with respect to each certificate representing the Shares issued in settlement of this Award.

 
5

 

(d)           Grantee understands that the Company is under no obligation to register for resale the Shares issuable in settlement of the Award.  The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by Grantee or other subsequent transfers by Grantee of any Shares issued in settlement of the Award, including without limitation (i) restrictions under an insider trading policy, (ii) restrictions that may be necessary in the absence of an effective registration statement under the Securities Act covering the Shares issuable in settlement of the Award and (iii) restrictions as to the use of a specified brokerage firm or other agent for such resales or other transfers.  Any resale of the Shares issued in settlement of this Award must also comply with all other Applicable Laws.
 
Section 8.              Miscellaneous Provisions.
 
(a)           No Retention Rights, No Future Awards.  Subject to any applicable provisions to the contrary in any written employment, consulting or other applicable written agreement for services between the Company and Grantee, nothing in this Agreement or in the Plan shall confer upon Grantee any right to any future Awards and to continue in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Affiliate employing or retaining Grantee) or of Grantee, which rights are hereby expressly reserved by each, to terminate Grantee's Continuous Service at any time and for any reason, with or without cause.
 
(b)           Award Unfunded.  Until vested pursuant to the terms and conditions of this Agreement, the Award represents an unfunded promise.  Grantee's rights with respect to the Award are no greater than the rights of a general unsecured creditor of the Company.  All payments, if any, to be made hereunder will be paid from the general funds of the Company and no special or separate fund will be established and no segregation of assets will be made to assure payment of such amounts.  Nothing contained in this Agreement or the Plan, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind, or a fiduciary relationship between the Company and Grantee or any of Grantee's beneficiaries, legal representatives or any other person.
 
(c)           Data Protection.  By participating in the Plan, the Grantee consents to the collection, processing, transmission and storage by the Company in any form whatsoever, of any data of a professional or personal nature which is necessary for the purposes of introducing and administering the Plan.  The Company may share such information with any Subsidiary, the trustee of any employee benefit trust, its registrars, trustees, brokers, other third party administrator or any Person who obtains control of the Company or acquires the Company, undertaking or part-undertaking which employs the Grantee, wherever situated.
 
(d)           Notice.  Whenever under this Agreement it becomes necessary to give notice, such notice shall be in writing, signed by the party or parties giving or making the same, and shall be served on the person or persons for whom it is intended or who should be advised or notified, by FedEx (or other similar overnight service) or by registered or certified mail, with postage and fees prepaid.  Notice shall be addressed to the Company at its principal executive office and to Grantee at the address that he or she most recently provided in writing to the Company.

 
6

 
 
(e)           Bound by Plan.  By Grantee’s signature and the signature of the Company’s representative below, Grantee and the Company agree that this Award is granted under and subject to the terms of the Plan and this Agreement.  Grantee has reviewed the Plan, a description of the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Plan and this Agreement.
 
(f)           Administrator Authority.  The Administrator has the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject to the Award have vested).  All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Grantee, the Company and all other interested persons.  No Administrator (or member thereof) will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement.
 
(g)           Entire Agreement.  This Agreement and the Plan constitute the entire agreement between the parties hereto with regard to the subject matter hereof.  They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof.
 
(h)           Waiver.  No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition whether of like or different nature.
 
(i)            Successors and Assigns.  Subject to the limitations on the transferability of this grant contained herein and in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of Grantee.
 
(j)            Choice of Law.  The validity, interpretation and enforcement of this Agreement (and any exercise notices relating hereto), matters arising out of or related to this Agreement (and any exercise notices relating hereto) or its making, performance or breach, and related matters shall be governed by the internal laws of the State of New York (without reference to choice of law doctrine).  Any legal action or proceeding concerning the validity, interpretation and enforcement of this Agreement (and any exercise notices relating hereto), matters arising out of or related to this Agreement (and any exercise notices relating hereto) or its making, performance or breach, or related matters shall be brought exclusively in the courts of the State of New York in New York County or of the United States of America for the Southern District of New York, and all parties consent to the exclusive jurisdiction of those courts, waiving any objection to the propriety or convenience of such venues.

 
7

 

(k)           Interpretation.  All pronouns and words used in this Agreement shall be read in the appropriate number and gender, the masculine, feminine and neuter shall be interpreted interchangeably and the singular shall include the plural and vice versa, as the circumstances may require.
 
(l)           Headings; Facsimile Signatures; Counterparts.  The section headings in this Agreement are for reference purposes only and shall not define, limit or affect the meaning or interpretation of this Agreement.  This Agreement may be signed in one or more counterparts and delivered by facsimile or electronic transmission in .pdf format, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.
 
[Signature page follows.]

 
8

 

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, on June 23, 2011.
 
GRANTEE:
 
AMERICAN MEDICAL ALERT CORP.
     
/s/ Jack Rhian
 
/s/ Richard Rallo
Signature
 
Name: Richard Rallo
   
Title: Chief Operating Officer
     
Jack Rhian
   
Print Name
  
 

Residence Address:
 
   
   
   
   
   
   
 
 
9

 
EX-10.3 4 v230635_ex10-3.htm EXHIBIT 10.3

Exhibit 10.3

AMERICAN MEDICAL ALERT CORP.
2010 EQUITY INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT

This Restricted Stock Unit Award Agreement (this "Agreement") is dated as of this 23rd day of June, 2011  (the "Grant Date"), and is between American Medical Alert Corp., a New York corporation (the "Company") and Frederic Siegel ("Grantee").

Section 1.              Definitions.
 
(a)           “Affiliate” means any entity that the Company, either directly or indirectly, is in common control with, is controlled by or controls, or any entity that the Company has a substantial direct or indirect equity interest, as determined by the Board.
 
(b)           "Agreement" shall have the meaning ascribed to it in the Introductory paragraph of this Agreement.
 
(c)           “Applicable Laws” means the requirements relating to the administration of equity-based awards and any related matters under U.S. state corporate laws, U.S. federal and state securities laws, the Code, and any stock exchange or quotation system on which the Common Stock is listed or quoted, and all rules and regulations relating to any of the foregoing.
 
(d)           "Award" shall have the meaning ascribed to it in Section 2(a) of this Agreement.
 
(e)           “Board” means the Board of Directors of the Company.
 
(f)            “Code” means the Internal Revenue Code of 1986, as amended.  Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code.
 
(g)           “Common Stock” shall have the meaning ascribed to it in the Plan.
 
(h)           “Company” means American Medical Alert Corp., a New York corporation, or any successor thereto.
 
(i)            "Continuous Service" shall have the meaning ascribed to it in the Plan.
 
(j)            "Disability" shall have the meaning ascribed to it in the Plan.
 
(k)           "Grant Date" shall have the meaning ascribed to it in Section 2(a) of this Agreement.

 
1

 
 
(l)            "Granted Units" shall have the meaning ascribed to it in Section 2(a) of this Agreement.
 
(m)          "Grantee" shall have the meaning ascribed to it in the Introductory paragraph of this Agreement.
 
(n)           "Plan" shall have the meaning ascribed to it in Section 2(c) of this Agreement.
 
(o)           "Restricted Stock Unit" shall mean a right to receive one Share upon vesting pursuant to Section 4(a).
 
(p)           "Service Termination" shall have the meaning ascribed to it in Section 4(b) of this Agreement.
 
(q)           “Share” shall have the meaning ascribed to it in the Plan.
 
(r)            "Termination Date" shall have the meaning ascribed to it in Section 4(b) of this Agreement.
 
(s)           "Vesting Date" shall have the meaning ascribed to it in Section 4(a) of this Agreement.
 
Section 2.              Grant of Restricted Stock Units.
 
(a)           Award.  On the terms and conditions set forth in this Agreement, the Company has granted Grantee a total of 16,500 Restricted Stock Units (the "Granted Units" or the “Award”), each subject to vesting in accordance with Section 4(a).
 
(b)           Shareholder Rights.  Grantee (or any successor in interest) shall not have any of the rights of a shareholder (including, without limitation, voting and liquidation rights) with respect to the Granted Units until such time as Grantee becomes the record holder of the Shares to be delivered in settlement of the Granted Units, as described in Section 5(a).
 
(c)           Plan and Defined Terms.  The Award is granted under and subject to the terms of the American Medical Alert Corp. 2010 Equity Incentive Plan (the "Plan"), which is incorporated herein by this reference.  Capitalized terms used herein and not defined in this Agreement (including Section 1 hereof) shall have the meanings set forth in the Plan.  To the extent there is any conflict between the terms of this Agreement and the Plan, the terms of the Plan shall control.
 
(d)           Grantee Undertaking.  Grantee (or any successor in interest) agrees to execute such further instruments and to take such action as may reasonably be necessary to carry out the intent of this Agreement.

 
2

 

Section 3.              No Transfer or Assignment.  The Award and the rights and privileges conferred by this Agreement shall not be transferable or assignable by Grantee, and may not be made subject to execution, attachment or similar procedures, other than by will or the laws of descent and distribution or as determined by the Plan's administrator in accordance with Applicable Laws.  Any such purported transfer contrary to the restrictions set forth in this Agreement shall be void and unenforceable against the Company or any Affiliate.  Notwithstanding the foregoing, the Plan's administrator, in its discretion, may permit the transfer, solely as gifts or pursuant to a domestic relations order during Grantee's lifetime of all or a portion of the Award to Grantee's immediate family members.  For this purpose, immediate family member means Grantee's child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing Grantee's household (other than a tenant or employee), a trust in which these persons have more than fifty percent of the beneficial interest, a foundation in which these persons (or Grantee) control the management of assets, and any other entity in which these persons (or Grantee) own more than fifty percent of the voting interests.  Any permitted transfer of the Award shall not be effective to bind the Company unless the Plan's administrator shall have been furnished with written notice thereof and a copy of such evidence as the Plan's administrator may deem necessary to establish the validity of the transfer and the acceptance by the transferee or transferees of the terms and conditions hereof.
 
Section 4.              Vesting; Termination of Service.
 
(a)           Vesting.  Subject to any acceleration provisions contained in the Plan and in Section 4(b) of that certain Employment Agreement, dated as of December 30th, 2010, between the Company and Grantee, the Award shall vest as follows: 5,500 Shares on December 31, 2011, 5,500 Shares on December 31, 2012 and 5,500 Shares on December 31, 2013 (each, a "Vesting Date").  Shares scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in Grantee in accordance with any of the provisions of this Agreement unless Grantee shall have been providing Continuous Service from the Grant Date through and on the date such vesting occurs.  The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Award at any time, subject to the terms of the Plan.  If so accelerated, such portion of the Award will be considered as having vested as of the date specified by the Administrator.
 
(b)           Termination of Service.  The unvested portion of the Award shall be immediately forfeited, and therefore, there shall be no further vesting of the Award, as of the date (the "Termination Date") that Grantee actually ceases to provide Continuous Service to the Company or an Affiliate for any reason in its capacity as employee, director or consultant (irrespective of whether Grantee continues to receive severance or any other continuation payments or benefits after such date) (such cessation of the provision of services by Grantee being referred to as a "Service Termination").
 
(c)           Death/Disability.  In the event of Service Termination resulting from Grantee's death or Disability, the unvested portion of the Granted Units shall be immediately forfeited as of the Termination Date.

 
3

 
 
Section 5.              Settlement of Granted Units.
 
(a)           Settlement Amount.  Subject to Section 5(b) hereof, the Company shall deliver to Grantee as soon as administratively practicable (but in no event later than two and one half months following the end of the year in which such vesting occurs) after each Vesting Date (and any other date on which the Award vests pursuant to this Agreement or the Plan): (i) a number of Shares equal to the number of Granted Units that vested on such date and (ii) an amount in cash equal to the cash dividends paid, from the Grant Date through the applicable vesting date, on one Share for each Share represented by the Granted Units that vested on such date; provided, however, that no Shares will be issued in settlement of the Award unless the issuance of Shares complies with Applicable Laws.  No fractional Shares will be issued.  The Company will pay cash in respect of fractional Shares.
 
(b)           Withholding Requirements.  Subject to the Plan, the Company will have the power and the right to deduct or withhold, or require Grantee to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including Grantee's FICA obligation) required to be withheld with respect to the Award.
 
Section 6.              Adjustment of Granted Units.  Subject to Section 16(c) of the Plan, in the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property, but excluding regular cash dividends to shareholders of the Company), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and kind of Shares that will be paid to Grantee upon settlement of the Granted Units, as the Administrator, in its sole discretion, deems appropriate.
 
Section 7.              Representations of Grantee.  Grantee hereby represents to the Company that:
 
(a)           Grantee is an “accredited investor,” as such term is defined in Rule 501 of the Securities Act due to his status as an executive officer of the Company.
 
(b)           Grantee understands that this Agreement and the Plan contain substantial restrictions on the transferability of the Award and provide that, in the event that the conditions relating to the transfer of any portion of the Award in such document has not been satisfied, the holder shall not transfer any portion of the Award, and unless otherwise specified, the Company will not recognize the transfer of the Award on its books and records, or issue any certificates representing the Shares issued in settlement of this Award, and any purported transfer not in accordance with the terms of this Agreement, the Plan and Applicable Laws shall be void.  Grantee will sell, transfer or otherwise dispose of the Award only in a manner consistent with its representations set forth herein and then only in accordance with this Agreement, the Plan and Applicable Laws.

 
4

 
 
(c)           Grantee understands that, unless registered: (i) the Shares issued in settlement of this Award will be characterized as "restricted securities" under the U.S. federal securities laws and the certificates representing such Shares shall bear the following legends:
 
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE HELD BY AN "AFFILIATE", WITHIN THE MEANING OF PARAGRAPH (A) (1) OF RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY ONLY BE SOLD, TRANSFERRED OR ASSIGNED IF IN THE OPINION OF COUNSEL OF THE CORPORATION SUCH SALE, TRANSFER OR ASSIGNMENT IS IN COMPLIANCE WITH THE RULES AND REGULATIONS PROMULGATED UNDER THE SECURITIES ACT.”
 
and (ii) any Shares issued in settlement of this Award may not be sold, transferred or otherwise disposed of except in compliance with Applicable Laws.  In addition, Grantee acknowledges and agrees that stop transfer instructions shall be imposed with respect to each certificate representing the Shares issued in settlement of this Award.
 
(d)           Grantee understands that the Company is under no obligation to register for resale the Shares issuable in settlement of the Award.  The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by Grantee or other subsequent transfers by Grantee of any Shares issued in settlement of the Award, including without limitation (i) restrictions under an insider trading policy, (ii) restrictions that may be necessary in the absence of an effective registration statement under the Securities Act covering the Shares issuable in settlement of the Award and (iii) restrictions as to the use of a specified brokerage firm or other agent for such resales or other transfers.  Any resale of the Shares issued in settlement of this Award must also comply with all other Applicable Laws.

 
5

 
 
Section 8.              Miscellaneous Provisions.
 
(a)           No Retention Rights, No Future Awards.  Subject to any applicable provisions to the contrary in any written employment, consulting or other applicable written agreement for services between the Company and Grantee, nothing in this Agreement or in the Plan shall confer upon Grantee any right to any future Awards and to continue in Continuous Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Affiliate employing or retaining Grantee) or of Grantee, which rights are hereby expressly reserved by each, to terminate Grantee's Continuous Service at any time and for any reason, with or without cause.
 
(b)           Award Unfunded.  Until vested pursuant to the terms and conditions of this Agreement, the Award represents an unfunded promise.  Grantee's rights with respect to the Award are no greater than the rights of a general unsecured creditor of the Company.  All payments, if any, to be made hereunder will be paid from the general funds of the Company and no special or separate fund will be established and no segregation of assets will be made to assure payment of such amounts.  Nothing contained in this Agreement or the Plan, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind, or a fiduciary relationship between the Company and Grantee or any of Grantee's beneficiaries, legal representatives or any other person.
 
(c)           Data Protection.  By participating in the Plan, the Grantee consents to the collection, processing, transmission and storage by the Company in any form whatsoever, of any data of a professional or personal nature which is necessary for the purposes of introducing and administering the Plan.  The Company may share such information with any Subsidiary, the trustee of any employee benefit trust, its registrars, trustees, brokers, other third party administrator or any Person who obtains control of the Company or acquires the Company, undertaking or part-undertaking which employs the Grantee, wherever situated.
 
(d)           Notice.  Whenever under this Agreement it becomes necessary to give notice, such notice shall be in writing, signed by the party or parties giving or making the same, and shall be served on the person or persons for whom it is intended or who should be advised or notified, by FedEx (or other similar overnight service) or by registered or certified mail, with postage and fees prepaid.  Notice shall be addressed to the Company at its principal executive office and to Grantee at the address that he or she most recently provided in writing to the Company.

 
6

 

(e)           Bound by Plan.  By Grantee’s signature and the signature of the Company’s representative below, Grantee and the Company agree that this Award is granted under and subject to the terms of the Plan and this Agreement.  Grantee has reviewed the Plan, a description of the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Plan and this Agreement.
 
(f)           Administrator Authority.  The Administrator has the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject to the Award have vested).  All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Grantee, the Company and all other interested persons.  No Administrator (or member thereof) will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement.
 
(g)           Entire Agreement.  This Agreement and the Plan constitute the entire agreement between the parties hereto with regard to the subject matter hereof.  They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof.
 
(h)           Waiver.  No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition whether of like or different nature.
 
(i)            Successors and Assigns.  Subject to the limitations on the transferability of this grant contained herein and in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of Grantee.
 
(j)            Choice of Law.  The validity, interpretation and enforcement of this Agreement (and any exercise notices relating hereto), matters arising out of or related to this Agreement (and any exercise notices relating hereto) or its making, performance or breach, and related matters shall be governed by the internal laws of the State of New York (without reference to choice of law doctrine).  Any legal action or proceeding concerning the validity, interpretation and enforcement of this Agreement (and any exercise notices relating hereto), matters arising out of or related to this Agreement (and any exercise notices relating hereto) or its making, performance or breach, or related matters shall be brought exclusively in the courts of the State of New York in New York County or of the United States of America for the Southern District of New York, and all parties consent to the exclusive jurisdiction of those courts, waiving any objection to the propriety or convenience of such venues.
 
(k)           Interpretation.  All pronouns and words used in this Agreement shall be read in the appropriate number and gender, the masculine, feminine and neuter shall be interpreted interchangeably and the singular shall include the plural and vice versa, as the circumstances may require.

 
7

 
 
(l)           Headings; Facsimile Signatures; Counterparts.  The section headings in this Agreement are for reference purposes only and shall not define, limit or affect the meaning or interpretation of this Agreement.  This Agreement may be signed in one or more counterparts and delivered by facsimile or electronic transmission in .pdf format, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.
 
[Signature page follows.]

 
8

 

IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, on June 23, 2011.
 
GRANTEE:
 
AMERICAN MEDICAL ALERT CORP.
     
/s/ Frederic Siegel
 
/s / Richard Rallo
Signature
 
Name: Richard Rallo
   
Title:Chief Operating Officer
     
Frederic Siegel
   
Print Name
  
 

Residence Address:
 
   
   
   
   
   
   

 
9

 
EX-15.1 5 v230635_ex15-1.htm EXHIBIT 15.1 Unassociated Document
 
Exhibit 15.1
 
August 15, 2011

American Medical Alert Corp.
Long Island City, New York

We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim financial information of American Medical Alert Corp. and Subsidiaries for the fiscal periods ended June 30, 2011 and June 30, 2010, as indicated in our report dated August 15, 2011.  Because we did not perform an audit, we expressed no opinion on that information.

We are aware that our report referred to above, which is included in your Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, is incorporated by reference in the following Registration Statements:

·  
Registration Statement No. 33-48385 on Form S-8;
·  
Registration Statement No. 33-91806 on Form S-8;
·  
Registration Statement No. 333-53029 on Form S-8;
·  
Registration Statement No. 333-70626 on Form S-8;
·  
Registration Statement No. 333-130811 on Form S-8; and
·  
Registration Statement No. 333-88192 on Form S-3.

We also are aware that the aforementioned report, pursuant to Rule 436(c) under the Securities Act of 1933, as amended, is not considered a part of the Registration Statements prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of the Securities Act of 1933, as amended.

/s/ Margolin, Winer & Evens LLP

Margolin, Winer & Evens LLP
Garden City, New York
 
 
 
 

 
 
EX-31.1 6 v230635_ex31-1.htm EXHIBIT 31.1 Unassociated Document
 
Exhibit 31.1
Certification

I, Jack Rhian, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of American Medical Alert Corp.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
         
Date: August 15, 2011
   
/s/ Jack Rhian
 
 
   
Jack Rhian
 
 
   
President and
Chief Executive Officer
(Principal Executive Officer)
 
 
 
 

 
EX-31.2 7 v230635_ex31-2.htm EXHIBIT 31.2 Unassociated Document
 
Exhibit 31.2
Certification

I, Richard Rallo, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of American Medical Alert Corp.;

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
         
Date:  August 15, 2011
   
/s/ Richard Rallo
 
 
   
Richard Rallo
 
 
   
Chief Financial Officer
(Principal Financial Officer)
 
 
 
 

 
EX-32.1 8 v230635_ex32-1.htm EXHIBIT 32.1 Unassociated Document
 
Exhibit 32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing of the Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2011 (the "Report") by American Medical Alert Corp. ("Registrant"), the undersigned hereby certifies that:

1.  
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2.  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Registrant.

Date:  August 15, 2011
 
         
 
   
/s/ Jack Rhian
 
 
   
Jack Rhian
 
 
   
Chief Executive Officer and President
 
 
 
A signed original of this written statement required by Section 906 has been provided to American Medical Alert Corp. and will be retained by American Medical Alert Corp. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
 
 

 
EX-32.2 9 v230635_ex32-2.htm EXHIBIT 32.2 Unassociated Document
 
Exhibit 32.2

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing of the Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2011 (the "Report") by American Medical Alert Corp. ("Registrant"), the undersigned hereby certifies that:

1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and

2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Registrant.

Date:  August 15, 2011

         
 
   
/s/ Richard Rallo
 
 
   
Richard Rallo
 
 
   
Chief Financial Officer
 

 
A signed original of this written statement required by Section 906 has been provided to American Medical Alert Corp. and will be retained by American Medical Alert Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

 
 

 
EX-101.INS 10 amac-20110630.xml XBRL INSTANCE DOCUMENT 9615280 4073441 1380647 90899 187000 136577 3470495 259153 1950000 98625 13959144 24100 1901732 339173 6986432 37938138 96316 928943 0 1000000 16102785 10842352 7124593 0 467905 0.01 16721947 453800 481135 -1196000 1898298 37938138 0 30640830 9631603 0.01 6623057 500000 20000000 7297308 565814 48573 30777407 710985 1090999 7193332 15212296 5498448 1371359 101499 219000 136577 3743633 231825 2150000 105807 13090196 72300 2013152 364747 7497367 37517485 96181 1005488 0 1000000 13787609 10842352 6864657 0 610479 0.01 16606018 452000 407615 -1228000 2970210 37517485 0 29655818 9618083 0.01 7195019 660000 20000000 7861667 566235 48573 29792395 732849 1350936 4090528 16534857 43985 -73346 38298 -4548165 -173530 167830 4370 1274617 19623392 3433920 4130731 160419 0.16 -5065 26267 1326667 21875 1610275 2729275 400624 0.17 1842231 358629 19264763 127069 7765084 1119000 9537894 206876 89685 59691 -1425007 26014 226445 -116127 950364 -30838 9835180 -310762 2000000 8878500 122566 Q2 AMAC AMERICAN MEDICAL ALERT CORP false Smaller Reporting Company 2011 10-Q 2011-06-30 0000700721 --12-31 0 -55382 0 <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td align="right" style="WIDTH: 36pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div> </td> <td align="left"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">General:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2010 included in the Annual Report on Form 10-K for the year ended December 31, 2010 of American Medical Alert Corp.</font></div> </div> -643898 -510935 182744 0 675204 20951300 <div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13.</font></div> </td> <td> <div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commitments and Contingencies:</font></div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is aware of various threatened or pending litigation claims against the Company relating to its products and services and other claims arising in the ordinary course of its business.&#xA0; At June 30, 2011 and 2010, no material liabilities have been recorded in the accompanying financial statements.&#xA0;&#xA0;The Company has given its insurance carrier notice of such claims and it believes there is sufficient insurance coverage to cover any such claims.&#xA0;&#xA0;&#xA0;In any event, the Company believes the disposition of these matters will not have a material adverse effect on the results of operations and financial condition of the Company.</font></div> </div> <div> <div> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12.</font></div> </td> <td> <div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Segment&#xA0; Reporting:</font></div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has two reportable segments, (i) Health and Safety Monitoring Systems (&#x201C;HSMS&#x201D;) and (ii) Telephone Based Communication Services (&#x201C;TBCS&#x201D;).</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The table below provides a reconciliation of segment information to total consolidated information for the six and three months ended June 30, 2011 and 2010:</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline"> 2011</font></font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div align="left"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="94%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> HSMS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> TBCS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> Consolidated</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six Months Ended June 30, 2011</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,429,165</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,522,135</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,951,300</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income before provision for income taxes*</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">550,221</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,121,727</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,671,948</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,300,149</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,637,989</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,938,138</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> </table> </div> <br /> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div align="left"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="94%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> HSMS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> TBCS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> Consolidated</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Three Months Ended June 30, 2011</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,180,396</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,139,171</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,319,567</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income before provision for income taxes*</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70,087</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">422,282</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">492,369</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline"> 2010</font></font></div> <div>&#xA0; <div align="left"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="94%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> HSMS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> TBCS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> Consolidated</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six Months Ended June 30, 2010</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,233,896</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,389,496</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,623,392</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income before provision for income taxes*</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,906,142</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">823,133</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,729,275</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,840,211</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18,461,741</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,301,952</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="55%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> HSMS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> TBCS</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> Consolidated</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Three Months Ended June 30, 2010</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,083,836</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,628,309</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,712,145</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="55%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income before provision for income taxes*</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">846,764</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">385,139</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> &#xA0;</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,231,903</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> </table> </div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* Income before provision for income taxes within the HSMS segment includes the Company&#x2019;s share of equity in net loss from its investment in limited liability company as follow:</font></div> <div align="left"> <table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="94%"> <tr> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> June&#xA0;30,&#xA0;2011</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2" nowrap="nowrap"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline"> June&#xA0;30,&#xA0;2010</font></font></div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="70%" nowrap="nowrap" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six Months Ended</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071,912</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">116,127</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="70%" align="left"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Three Months Ended</font></font></div> </td> <td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">512,030</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td valign="bottom" width="1%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#xA0;</font></td> <td style="TEXT-ALIGN: left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> $</font></td> <td style="TEXT-ALIGN: right" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">116,127</font></td> </tr> </table> </div> </div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td align="right" style="WIDTH: 36pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.</font></div> </td> <td align="left"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Long-term Debt:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company had a credit facility arrangement for $4,500,000 which included a revolving credit line which permitted borrowings of $1,500,000 (based on eligible receivables as defined) and a $3,000,000 term loan payable. The term loan was payable in equal monthly principal installments of $50,000 over five years commencing January 2006.&#xA0; This term loan was paid in full during the second quarter of 2010 without any prepayment charge.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2006, the credit facility was amended whereby the Company obtained an additional $2,500,000 and $1,600,000 of term loans, the proceeds of which were utilized to finance certain acquisitions.&#xA0; These term loans are payable over five years in equal monthly principal installments of $41,666.67 and $26,666.67, respectively. Additionally, certain of the covenants were amended.&#xA0; The $2,500,000 term loan was paid in full during the second quarter of 2010 without any prepayment charge.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2006, the credit facility was amended to reduce the interest rates charged by the bank such that borrowings under the term loan will bear interest at either (a) LIBOR plus 2.00% or (b) the prime rate or the federal funds effective rate plus .5%, whichever is greater, and the revolving credit line will bear interest at either (a) LIBOR plus 1.75% or (b) the prime rate or the federal funds effective rate plus .5%, whichever is greater.&#xA0; The LIBOR interest rate charge shall be adjusted in ..25% intervals based on the Company&#x2019;s ratio of Consolidated Funded Debt to Consolidated EBITDA. In the third quarter of 2007, the interest rate was reduced by .25% based on this ratio.&#xA0; The Company has the option to choose between the two interest rate options under the amended term loan and revolving credit line.&#xA0; Borrowings under the credit facility are collateralized by substantially all of the assets of the Company. <!--EFPlaceholder--></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 30, 2007, the Company amended its credit facility whereby the term of the revolving credit line was extended through June 2010 and the amount of credit available under the revolving credit line was increased to $2,500,000.&#xA0; In June 2010, the term of the revolving credit line was extended through June 2013.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 12, 2010, the Company&#x2019;s credit facility was amended whereby the Company obtained an additional $2,000,000 in the form of a term loan, the proceeds of which were utilized to partially finance its investment in Lifecomm relating to the development of a mobile PERS system.&#xA0; This term loan is payable over five years in equal monthly principal installments of $33,333.33, commencing June 1, 2010.&#xA0; The interest rate is the same as the previous term loans secured by the Company, as described above.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June 30, 2011 and March 31, 2011, the Company was in compliance with its financial covenants in its loan agreement.&#xA0; As of June 30, 2010 and March 31, 2010, the Company was in compliance with its financial covenants in its loan agreement.</font></div> </div> 4162084 0 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div> </td> <td> <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Earnings Per Share:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Earnings per share data for the six and three months ended June 30, 2011 and 2010 is presented in conformity with ASC Topic 250, Earnings Per Share.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;<br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table is a reconciliation of the numerators and denominators in computing earnings per share:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div align="left"> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Income</font></div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Shares</font></div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Per-Share</font></div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> &#xA0;</td> <td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (Numerator)</font></font></div> </td> <td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (Denominator)</font></font></div> </td> <td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Amounts</font></font></div> </td> <td nowrap="nowrap" valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six&#xA0;Months&#xA0;Ended&#xA0;June&#xA0;30,&#xA0;2011</font></font></font></div> </td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic EPS - Income available to common stockholders</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">868,948</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,576,622</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..09</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effect of dilutive securities - Options and warrants</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> -</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 247,914</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted EPS - Income available to common stockholders and assumed conversions</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 868,948</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 9,824,536</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..09</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Three Months Ended June 30, 2011</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic EPS -Income available to common stockholders</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">159,369</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,580,005</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..02</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effect of dilutive securities - Options and warrants</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> -</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 236,204</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted EPS - Income available to common stockholders and assumed conversions</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 159,369</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 9,816,209</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..02</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six Months Ended June 30, 2010</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic EPS - Income available to common stockholders</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,610,275</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,537,894</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..17</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effect of dilutive securities - Options and warrants</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> -</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 297,286</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted EPS - Income available to common stockholders and assumed conversions</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1,610,275</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 9,835,180</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..16</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Three Months Ended June 30, 2010</font></font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic EPS -Income available to common stockholders</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">722,903</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,549,355</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..08</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effect of dilutive securities - Options and warrants</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> -</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 279,118</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Diluted EPS - Income available to common stockholders and assumed conversions</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 722,903</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 9,828,473</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> ..07</font></font></td> </tr> </table> </div> </div> 116064 0.09 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.</font></div> </td> <td> <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investment in Limited Liability Company</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">On May 12, 2010, the Company entered into a limited liability company agreement with Hughes Telematics, Inc. and Qualcomm Incorporated to design, develop, finance and operate a mobile PERS system.&#xA0; The Company invested $4,000,000 and incurred $150,336 in professional fees to acquire a minority interest (approximately 10%) in the new company, Lifecomm, LLC (&#x201C;Lifecomm&#x201D;). As part of this transaction, the Company borrowed $2,000,000 from its bank to partially finance this transaction.&#xA0; <font style="DISPLAY: inline">In addition, pursuant to the limited liability company agreement, the Company has agreed to fund its share ($200,000) of a stand-by equity commitment for Lifecomm&#x2019;s benefit, if required</font>.&#xA0; As of June 30, 2011, the Company&#x2019;s exposure to loss is limited to the recorded equity investment balance of $1,898,298 and its share ($200,000) of a stand-by equity commitment, if required.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hughes Telematics, Inc., parent of Lifecomm and the party who has a controlling financial interest in Lifecomm, has determined that Lifecomm is a variable interest entity and that HTI is the primary beneficiary.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Lifecomm is a development stage company that has yet to generate any revenue, and has generated a pre-tax net loss of $4,312,480 and $2,356,758 during the six and three months ended June 30, 2011 ($7,934,372 during the period from inception, May 12, 2010 to June 30, 2011).&#xA0; Lifecomm will continue to generate losses until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In accordance with the limited liability company agreement, profits are generally allocated to members in the amount of and in proportion to their ownership of the outstanding membership units.&#xA0; Losses are generally allocated to members in the amount of and in proportion to their unreturned capital contributions, which for the purposes of determining the allocation of losses is defined as the aggregate of (i) cash contributions, (ii) the fair value of other contributed assets and (iii) the value of in-kind services contributed by the members through the date of determination, less (iv) the fair value of any assets distributed to the members; provided, however, that any losses generated through May 12, 2012 will be generally allocated to the members first in the amount of and in proportion to the unreturned capital contributions attributable to only the cash contributions and the value of in-kind services contributed by the members through the date of determination and then in the amount of and in proportion to the unreturned capital contributions attributable to the fair value of other contributed assets.<!--EFPlaceholder--></font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;<br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the six and three months ended June 30, 2011, the Company recorded a pre-tax net loss of $1,071,912 and $512,030, respectively ($2,252,038 during the period from inception, May 12, 2010 to June 30, 2011) for its share of losses from the equity investment in Lifecomm.&#xA0; The equity loss primarily relates to research and development costs as well as other selling, general and administrative expenses incurred for the development of the next generation mobile PERS.&#xA0; As the development continues to progress, the Company expects that its share of equity loss will continue throughout 2011 until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> In connection with the formation of Lifecomm, the Company entered into a Value Added Reseller Agreement (&#x201C;VAR Agreement&#x201D;) with Lifecomm.&#xA0; Under the VAR Agreement, the Company will be a reseller of the Mobile PERS Solution in the United States, as well as a preferred provider of the emergency assistance call center (&#x201C;EACC&#x201D;) component of the Mobile PERS Solution provided by Lifecomm to customers.&#xA0; The Company will be the sole provider of the EACC to the customers to whom it resells the Mobile PERS Solution.&#xA0; The term of the VAR Agreement is perpetual, subject to termination as set forth therein.&#xA0; The VAR Agreement contains standard indemnification provisions for agreements of this nature.</font></font></div> </div> -51491 28008 360000 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div> </td> <td> <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent Accounting Pronouncements:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In December 2010, the FASB issued Update 2010-29, &#x201C;Disclosure of Supplementary Pro Forma Information for Business Combinations&#x201D;. The amendments in Update 2010-29 specify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. Update 2010-29 also expands the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributed to the business combination included in the pro forma financial data. The Company is required to adopt all the provisions of Update 2010-29 for any business combinations for which the acquisition date is on or after January&#xA0;1, 2011. The impact of the provisions of this guidance on the Company&#x2019;s consolidated financial statements depends upon the nature, terms and size of the acquisitions it will consummate in the future.</font></div> &#xA0;<br /> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <!--EFPlaceholder-->In December 2010, the FASB issued Update 2010-28, &#x201C;Intangibles - Goodwill and Other (Topic 350)&#x201D;.&#xA0; Update 2010-28 modifies the first step of the goodwill impairment test to include reporting units with zero or negative carrying amounts. For these reporting units, the second step of the goodwill impairment test shall be performed to measure the amount of impairment loss, if any; when it is more likely than not that a goodwill impairment exists. Update 2010-28 is effective for fiscal years and interim periods beginning after December 15, 2010.&#xA0; The adoption of this guidance did not have a material impact on the consolidated financial statements of the Company.</font></div> </div> 0 868948 1671948 695389 0.09 1540028 376323 <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td align="right" style="WIDTH: 36pt"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div> </td> <td align="left"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results of Operations:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying condensed consolidated financial statements include the accounts of American Medical Alert Corp. and its wholly-owned subsidiaries; together the &#x201C;Company.&#x201D;&#xA0; All material inter-company balances and transactions have been eliminated.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position as of June 30, 2011 and the results of operations for the six and three&#xA0; months ended June 30, 2011 and 2010 and cash flows for the six months ended June 30, 2011 and 2010.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accounting policies used in preparing these financial statements are the same as those described in the December 31, 2010 financial statements.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The results of operations for the six and three months ended June 30, 2011 are not necessarily indicative of the results to be expected for any other interim period or for the full year.</font></div> </div> 20574977 -142574 8430381 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.</font></div> </td> <td> <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Goodwill</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Changes in the carrying amount of goodwill, all of which relates to the Company&#x2019;s TBCS segment, for the six months ended June 30, 2011 and 2010 are as follows:</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><br /></div> <div style="MARGIN-LEFT: 36pt" align="left"> <table cellpadding="0" cellspacing="0" width="55%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six Months Ended June 30, 2011</font></font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="17%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="17%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of January 1, 2011</font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,842,352</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional Goodwill</font></div> </td> <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> -</font></font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of June 30, 2011</font></div> </td> <td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 10,842,352</font></font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"> <font style="DISPLAY: inline">Six Months Ended June 30, 2010</font></font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of January 1, 2010</font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,255,983</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional Goodwill</font></div> </td> <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 38,298</font></font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="79%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance as of June 30, 2010</font></div> </td> <td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 10,294,281</font></font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The addition to goodwill during the six months ended June 30, 2010 related to the additional purchase price of American Mediconnect, Inc. based on the cash receipts from the clinical trials portion of the business.</font></div> </div> 803000 9576622 -25574 0 23310 3102804 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.</font></div> </td> <td> <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Provision for Income Taxes:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company records its tax provision (or benefit) on an interim basis using an estimated annual <!--EFPlaceholder-->effective <!--EFPlaceholder-->tax <!--EFPlaceholder-->rate.&#xA0; For the six and three months ended June 30, 2011 the Company increased the estimated effective tax rate to reflect the impact of certain non-deductible expenses.</font></div> </div> 30495 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.</font></div> </td> <td> <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Acquisition:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On September 29, 2010, the Company acquired substantially all of the assets of Alpha Message Center, Inc. (&#x201C;Alpha&#x201D;),<font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-FAMILY: Times New Roman">&#xA0;</font>a New Jersey based company that provides telephone after-hours answering and pager services.&#xA0; The purchase price of this acquisition consisted of an initial cash payment of $577,977 and an accrual of $200,000, which represented the estimated fair value (derived using significant unobservable inputs categorized within Level 3 of the fair value hierarchy) of the contingent consideration expected to be paid through September 2012.&#xA0; The contingent consideration is based on the acquisition agreement that calls for the Company to pay the former owner of Alpha fourteen percent (14%) of the cash expected to be collected by the Company, excluding sales taxes, from certain revenue generated by Alpha through September 2012.&#xA0; The Company estimated the future contingent consideration expected to be paid based upon Alpha&#x2019;s historic revenue data.&#xA0; As of June 30, 2011, $77,275 has been paid to the former owner based on cash receipts.&#xA0; The Company also incurred finder and professional fees of approximately $57,000, which were included in selling, general and administrative expenses for the year ended December 31, 2010.&#xA0; The results of operations of Alpha are included in the Telephone Based Communications Services (&#x201C;TBCS&#x201D;) segment as of the date of acquisition.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the estimated fair values of the assets acquired at the date of acquisition.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="MARGIN-LEFT: 36pt" align="left"> <table cellpadding="0" cellspacing="0" width="55%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts receivable</font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4,906</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fixed assets</font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25,000</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-compete agreement</font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15,000</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Customer list</font></div> </td> <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">185,000</font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="79%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div> </td> <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 548,071</font><!--efplaceholder--></font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="79%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cost to acquire Alpha</font></div> </td> <td valign="bottom" width="2%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="2%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 777,977</font></font></td> <td nowrap="nowrap" valign="bottom" width="2%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;<br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The purchase price of the acquisition exceeded the fair value of the identifiable net assets acquired inasmuch as the acquisition was consummated to enable the Company to strengthen its position in the area where it was already operating.&#xA0; Furthermore, the acquisition was for the business' future cash flows and net earnings as opposed to solely for the identifiable tangible and intangible assets.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The results of operations for Alpha are included in the condensed consolidated statements of income for the six and three months ended June 30, 2011.&#xA0; On a pro forma basis, had the Alpha acquisition taken place as of the beginning of 2010, the Company&#x2019;s results of operations for the six&#xA0; and three months ended June 30, 2010 would not have been materially affected.</font></div> </div> -3025 -1071912 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div> </td> <td> <div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounting for Stock-Based Compensation:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock based compensation is recorded in accordance with ASC Topic 718, Compensation &#x2013; Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payments to employees, including grants of stock and employee stock options, based on estimated fair values.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company granted options to purchase 10,000 shares of common stock during the six months ended June 30, 2011.&#xA0; No options were granted during the six months ended June 30, 2010.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt"> The following tables summarize stock option activity for the six months ended June 30, 2011 and 2010</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">.</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline"> 2011</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div align="left"> <table cellpadding="0" cellspacing="0" width="97%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number&#xA0;of</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Options</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Option&#xA0;Price</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Term&#xA0;(years)</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Value</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="40%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at January 1</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">718,343</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.85</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,000</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.85</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="40%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expired/Forfeited</font></div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (25,650</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 6.86</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at June 30</font></div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 702,693</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 3.77</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1.49</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1,339,659</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and exercisable</font></div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 678,419</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 3.69</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1.42</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1,339,659</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> </table> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline"> 2010</font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#xA0;</div> <div align="left"> <table cellpadding="0" cellspacing="0" width="97%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Number&#xA0;of</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Options</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Option&#xA0;Price</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Term&#xA0;(years)</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Value</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="40%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at January 1</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">894,785</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.29</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="40%"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(10,325</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.26</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expired/Forfeited</font></div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at June 30</font></div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 884,460</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 4.29</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 2.00</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1,565,633</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Vested and exercisable</font></div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 851,760</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 4.23</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1.92</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 1,561,911</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> </table> </div> &#xA0;<br /> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No options were exercised during the six months ended June 30, 2011.&#xA0; The aggregate intrinsic value of options exercised during the six months ended June 30, 2010 was $24,560.&#xA0; There were 24,274 and 32,700 nonvested stock options outstanding as of June 30, 2011 and 2010, respectively.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes stock-based compensation expense related to all share-based payments recognized in the condensed consolidated statements of income.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div align="left"> <table cellpadding="0" cellspacing="0" width="97%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three&#xA0;Months</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three&#xA0;Months</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Ended&#xA0;June&#xA0;30,</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Ended&#xA0;June&#xA0;30,</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 2011</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 2010</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,310</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock grants &#x2013; other</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,384</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,882</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Service based awards</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,599</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,037</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Performance based awards</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,294</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tax benefit</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (28,341</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (33,098</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense, net of tax</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18,952</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,115</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div align="left"> <table cellpadding="0" cellspacing="0" width="97%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Six&#xA0;Months</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Six&#xA0;Months</font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Ended&#xA0;June&#xA0;30,</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> Ended&#xA0;June&#xA0;30,</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 2011</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> 2010</font></font></div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36,101</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock grants &#x2013; other</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32,765</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21,759</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Service based awards</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,198</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">64,072</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Performance based awards</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> &#xA0;</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">74,588</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> <tr bgcolor="#CCFFCC"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tax benefit</font></div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (55,743</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"> (65,772</font></font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="70%"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock-based compensation expense, net of tax</font></div> </td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,321</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> $</font></td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">94,647</font></td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#xA0;</font></td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stock Grants - Other</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The non-employee members of the Board of Directors have an option to elect at the beginning of each calendar year to receive either shares of common stock or cash at the end of each quarter as compensation for services provided as members of the Board of Directors and other committees.&#xA0; Share grants issued vest immediately, but are subject to a one-year restriction on transfer.&#xA0; In addition, stock grants may be issued to employees at the Board of Directors&#x2019; discretion.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#xA0;<br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Service Based Awards</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><!--EFPlaceholder--><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January 2006, May 2007, January 2009 and December 2010 the Company granted 50,000, 22,000, 12,000 (net of 9,500 shares waived by an executive) and 46,500 restricted shares, respectively, to certain executives in respect of services rendered but at no monetary cost.&#xA0; These shares vest over periods ranging from 2 to 5 years, on December 31 of each year.&#xA0; The Company records the compensation expense on a straight-line basis over the vesting period.&#xA0; Fair value for restricted stock awards is based on the Company's closing common stock price on the date of grant.<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#xA0;</font>There were 84,000 shares and 63,000 shares vested as of June 30, 2011 and 2010, respectively.&#xA0; The aggregate grant date fair value of restricted stock grants was $830,845.&#xA0; The vesting period of the January 2006 and May 2007 grants expired on December 31, 2010.&#xA0; As of June 30, 2011 and 2010, the Company had approximately $236,000 and $68,000, respectively, of total unrecognized compensation costs related to nonvested restricted stock units expected to be recognized over a weighted average period of 2.5 years.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Performance Based Awards</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In January 2006 and May 2007, respectively, the Company granted share awards for up to 90,000 shares (up to 18,000 shares per year through December 31, 2010) and 46,000 shares (up to 11,500 shares per year through December 31, 2010) to certain executives.&#xA0; Vesting of such shares was contingent upon the Company achieving certain specified consolidated gross revenue and Earnings before Interest and Taxes (&#x201C;EBIT&#x201D;) objectives in each of the fiscal years ending December 31, 2006 through December 31, 2010.&#xA0; The fair value of the performance shares (aggregate value of $909,400) was based on the closing trade value of the Company&#x2019;s stock on the date of grant and assumed that performance goals would be achieved.&#xA0; The fair value of the shares was expensed over the performance period for those shares that were expected to ultimately vest.&#xA0; If such objectives were not met, no compensation cost was recognized and any recognized compensation cost was reversed.&#xA0; All performance based awards were either earned or forfeited as of December 31, 2010.&#xA0; During 2011, there were no performance shares vesting and there were no unrecognized compensation costs related to performance share awards.&#xA0; As of June 30, 2010, 57,250 shares were vested and there was approximately $75,000 of total unrecognized compensation costs related to nonvested share awards.</font></div> </div> 0 27328 9824536 -415382 0 9589617 -144304 <div> <div> <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 36pt"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.</font></div> </td> <td> <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dividends:</font></div> </td> </tr> </table> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br /></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On December 16, 2009, the Company declared a dividend in the amount of $0.10 per share, or $950,364, which was accrued as of December 31, 2009.&#xA0; The dividend was payable to the shareholders of record as of December 28, 2009.&#xA0; The dividend was paid on January 15, 2010.</font></div> </div> 75346 9712145 0.07 13836 722903 1231903 0.08 156113 9556032 3857251 509000 9549355 29863 -116127 9828473 4447545 66809 10319567 0.02 13348 159369 492369 0.02 142464 10177103 4401965 333000 9580005 10962 -512030 9816209 4844008 0000700721 2011-04-01 2011-06-30 0000700721 2010-04-01 2010-06-30 0000700721 2011-01-01 2011-06-30 0000700721 2010-01-01 2010-06-30 0000700721 2010-12-31 0000700721 2009-12-31 0000700721 2011-06-30 0000700721 2010-06-30 0000700721 2011-08-10 shares iso4217:USD iso4217:USD shares EX-101.SCH 11 amac-20110630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Results of Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Accounting for Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Earnings Per Share link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Goodwill link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Acquisition link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Investment in Limited Liability Company link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Long-term Debt link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Provision for Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Dividends link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 12 amac-20110630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 13 amac-20110630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 14 amac-20110630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 15 amac-20110630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 16 R3.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Jun. 30, 2011
Dec. 31, 2010
Accounts receivable, allowance for doubtful accounts $ 453,800 $ 452,000
Intangible assets, accumulated amortization 7,124,593 6,864,657
Other assets, inventory $ 481,135 $ 407,615
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, authorized 1,000,000 1,000,000
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, authorized 20,000,000 20,000,000
Common stock, issued 9,631,603 9,618,083
Treasury stock, shares 48,573 48,573
XML 17 R4.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
Revenues:        
Services $ 10,177,103 $ 9,556,032 $ 20,574,977 $ 19,264,763
Product sales 142,464 156,113 376,323 358,629
Revenues, Total 10,319,567 9,712,145 20,951,300 19,623,392
Costs and Expenses (Income):        
Costs related to services 4,844,008 4,447,545 9,589,617 8,878,500
Costs of products sold 66,809 75,346 182,744 167,830
Selling, general and administrative expenses 4,401,965 3,857,251 8,430,381 7,765,084
Interest expense 13,348 13,836 28,008 26,267
Equity in net loss from investment in limited liability company 512,030 116,127 1,071,912 116,127
Other income (10,962) (29,863) (23,310) (59,691)
Income before Provision for Income Taxes 492,369 1,231,903 1,671,948 2,729,275
Provision for Income Taxes 333,000 509,000 803,000 1,119,000
NET INCOME $ 159,369 $ 722,903 $ 868,948 $ 1,610,275
Net income per share:        
Basic $ 0.02 $ 0.08 $ 0.09 $ 0.17
Diluted $ 0.02 $ 0.07 $ 0.09 $ 0.16
Weighted average number of common shares outstanding:        
Basic 9,580,005 9,549,355 9,576,622 9,537,894
Diluted 9,816,209 9,828,473 9,824,536 9,835,180
XML 18 R1.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Document and Entity Information
6 Months Ended
Jun. 30, 2011
Aug. 10, 2011
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2011
Document Fiscal Year Focus 2011  
Document Fiscal Period Focus Q2  
Trading Symbol AMAC  
Entity Registrant Name AMERICAN MEDICAL ALERT CORP  
Entity Central Index Key 0000700721  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   9,615,280
XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 20 R12.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Acquisition
6 Months Ended
Jun. 30, 2011
Acquisition
7.
Acquisition:

On September 29, 2010, the Company acquired substantially all of the assets of Alpha Message Center, Inc. (“Alpha”), a New Jersey based company that provides telephone after-hours answering and pager services.  The purchase price of this acquisition consisted of an initial cash payment of $577,977 and an accrual of $200,000, which represented the estimated fair value (derived using significant unobservable inputs categorized within Level 3 of the fair value hierarchy) of the contingent consideration expected to be paid through September 2012.  The contingent consideration is based on the acquisition agreement that calls for the Company to pay the former owner of Alpha fourteen percent (14%) of the cash expected to be collected by the Company, excluding sales taxes, from certain revenue generated by Alpha through September 2012.  The Company estimated the future contingent consideration expected to be paid based upon Alpha’s historic revenue data.  As of June 30, 2011, $77,275 has been paid to the former owner based on cash receipts.  The Company also incurred finder and professional fees of approximately $57,000, which were included in selling, general and administrative expenses for the year ended December 31, 2010.  The results of operations of Alpha are included in the Telephone Based Communications Services (“TBCS”) segment as of the date of acquisition.

The following table summarizes the estimated fair values of the assets acquired at the date of acquisition.

Accounts receivable
  $ 4,906  
Fixed assets
    25,000  
Non-compete agreement
    15,000  
Customer list
    185,000  
Goodwill
    548,071  
Cost to acquire Alpha
  $ 777,977  
 
The purchase price of the acquisition exceeded the fair value of the identifiable net assets acquired inasmuch as the acquisition was consummated to enable the Company to strengthen its position in the area where it was already operating.  Furthermore, the acquisition was for the business' future cash flows and net earnings as opposed to solely for the identifiable tangible and intangible assets.

The results of operations for Alpha are included in the condensed consolidated statements of income for the six and three months ended June 30, 2011.  On a pro forma basis, had the Alpha acquisition taken place as of the beginning of 2010, the Company’s results of operations for the six  and three months ended June 30, 2010 would not have been materially affected.
XML 21 R17.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Segment Reporting
6 Months Ended
Jun. 30, 2011
Segment Reporting
12.
Segment  Reporting:

The Company has two reportable segments, (i) Health and Safety Monitoring Systems (“HSMS”) and (ii) Telephone Based Communication Services (“TBCS”).
 
The table below provides a reconciliation of segment information to total consolidated information for the six and three months ended June 30, 2011 and 2010:
 
2011

   
HSMS
   
TBCS
   
Consolidated
 
Six Months Ended June 30, 2011
                 
Revenue
  $ 10,429,165     $ 10,522,135     $ 20,951,300  
Income before provision for income taxes*
    550,221       1,121,727       1,671,948  
Total assets
    17,300,149       20,637,989       37,938,138  


   
HSMS
   
TBCS
   
Consolidated
 
Three Months Ended June 30, 2011
                 
Revenue
  $ 5,180,396     $ 5,139,171     $ 10,319,567  
Income before provision for income taxes*
    70,087       422,282       492,369  

2010
 
   
HSMS
   
TBCS
   
Consolidated
 
Six Months Ended June 30, 2010
                 
Revenue
  $ 10,233,896     $ 9,389,496     $ 19,623,392  
Income before provision for income taxes*
    1,906,142       823,133       2,729,275  
Total assets
    18,840,211       18,461,741       37,301,952  
                         
   
HSMS
   
TBCS
   
Consolidated
 
Three Months Ended June 30, 2010
                       
Revenue
  $ 5,083,836     $ 4,628,309     $ 9,712,145  
Income before provision for income taxes*
    846,764       385,139       1,231,903  
 
* Income before provision for income taxes within the HSMS segment includes the Company’s share of equity in net loss from its investment in limited liability company as follow:
   
June 30, 2011
   
June 30, 2010
 
Six Months Ended
  $ 1,071,912     $ 116,127  
Three Months Ended
  $ 512,030     $ 116,127
XML 22 R8.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Recent Accounting Pronouncements
6 Months Ended
Jun. 30, 2011
Recent Accounting Pronouncements
3.
Recent Accounting Pronouncements:
 
In December 2010, the FASB issued Update 2010-29, “Disclosure of Supplementary Pro Forma Information for Business Combinations”. The amendments in Update 2010-29 specify that if a public entity presents comparative financial statements, the entity should disclose revenue and earnings of the combined entity as though the business combination that occurred during the current year had occurred as of the beginning of the comparable prior annual reporting period only. Update 2010-29 also expands the supplemental pro forma disclosures to include a description of the nature and amount of material, nonrecurring pro forma adjustments directly attributed to the business combination included in the pro forma financial data. The Company is required to adopt all the provisions of Update 2010-29 for any business combinations for which the acquisition date is on or after January 1, 2011. The impact of the provisions of this guidance on the Company’s consolidated financial statements depends upon the nature, terms and size of the acquisitions it will consummate in the future.
 
In December 2010, the FASB issued Update 2010-28, “Intangibles - Goodwill and Other (Topic 350)”.  Update 2010-28 modifies the first step of the goodwill impairment test to include reporting units with zero or negative carrying amounts. For these reporting units, the second step of the goodwill impairment test shall be performed to measure the amount of impairment loss, if any; when it is more likely than not that a goodwill impairment exists. Update 2010-28 is effective for fiscal years and interim periods beginning after December 15, 2010.  The adoption of this guidance did not have a material impact on the consolidated financial statements of the Company.
XML 23 R14.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Long-term Debt
6 Months Ended
Jun. 30, 2011
Long-term Debt
9.
Long-term Debt:

The Company had a credit facility arrangement for $4,500,000 which included a revolving credit line which permitted borrowings of $1,500,000 (based on eligible receivables as defined) and a $3,000,000 term loan payable. The term loan was payable in equal monthly principal installments of $50,000 over five years commencing January 2006.  This term loan was paid in full during the second quarter of 2010 without any prepayment charge.
 
During 2006, the credit facility was amended whereby the Company obtained an additional $2,500,000 and $1,600,000 of term loans, the proceeds of which were utilized to finance certain acquisitions.  These term loans are payable over five years in equal monthly principal installments of $41,666.67 and $26,666.67, respectively. Additionally, certain of the covenants were amended.  The $2,500,000 term loan was paid in full during the second quarter of 2010 without any prepayment charge.
 
In December 2006, the credit facility was amended to reduce the interest rates charged by the bank such that borrowings under the term loan will bear interest at either (a) LIBOR plus 2.00% or (b) the prime rate or the federal funds effective rate plus .5%, whichever is greater, and the revolving credit line will bear interest at either (a) LIBOR plus 1.75% or (b) the prime rate or the federal funds effective rate plus .5%, whichever is greater.  The LIBOR interest rate charge shall be adjusted in ..25% intervals based on the Company’s ratio of Consolidated Funded Debt to Consolidated EBITDA. In the third quarter of 2007, the interest rate was reduced by .25% based on this ratio.  The Company has the option to choose between the two interest rate options under the amended term loan and revolving credit line.  Borrowings under the credit facility are collateralized by substantially all of the assets of the Company.
 
On April 30, 2007, the Company amended its credit facility whereby the term of the revolving credit line was extended through June 2010 and the amount of credit available under the revolving credit line was increased to $2,500,000.  In June 2010, the term of the revolving credit line was extended through June 2013.
 
On May 12, 2010, the Company’s credit facility was amended whereby the Company obtained an additional $2,000,000 in the form of a term loan, the proceeds of which were utilized to partially finance its investment in Lifecomm relating to the development of a mobile PERS system.  This term loan is payable over five years in equal monthly principal installments of $33,333.33, commencing June 1, 2010.  The interest rate is the same as the previous term loans secured by the Company, as described above.
 
As of June 30, 2011 and March 31, 2011, the Company was in compliance with its financial covenants in its loan agreement.  As of June 30, 2010 and March 31, 2010, the Company was in compliance with its financial covenants in its loan agreement.
XML 24 R15.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Provision for Income Taxes
6 Months Ended
Jun. 30, 2011
Provision for Income Taxes
10.
Provision for Income Taxes:

The Company records its tax provision (or benefit) on an interim basis using an estimated annual effective tax rate.  For the six and three months ended June 30, 2011 the Company increased the estimated effective tax rate to reflect the impact of certain non-deductible expenses.
XML 25 R13.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Investment in Limited Liability Company
6 Months Ended
Jun. 30, 2011
Investment in Limited Liability Company
8.
Investment in Limited Liability Company

On May 12, 2010, the Company entered into a limited liability company agreement with Hughes Telematics, Inc. and Qualcomm Incorporated to design, develop, finance and operate a mobile PERS system.  The Company invested $4,000,000 and incurred $150,336 in professional fees to acquire a minority interest (approximately 10%) in the new company, Lifecomm, LLC (“Lifecomm”). As part of this transaction, the Company borrowed $2,000,000 from its bank to partially finance this transaction.  In addition, pursuant to the limited liability company agreement, the Company has agreed to fund its share ($200,000) of a stand-by equity commitment for Lifecomm’s benefit, if required.  As of June 30, 2011, the Company’s exposure to loss is limited to the recorded equity investment balance of $1,898,298 and its share ($200,000) of a stand-by equity commitment, if required.

Hughes Telematics, Inc., parent of Lifecomm and the party who has a controlling financial interest in Lifecomm, has determined that Lifecomm is a variable interest entity and that HTI is the primary beneficiary.

Lifecomm is a development stage company that has yet to generate any revenue, and has generated a pre-tax net loss of $4,312,480 and $2,356,758 during the six and three months ended June 30, 2011 ($7,934,372 during the period from inception, May 12, 2010 to June 30, 2011).  Lifecomm will continue to generate losses until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.
 
In accordance with the limited liability company agreement, profits are generally allocated to members in the amount of and in proportion to their ownership of the outstanding membership units.  Losses are generally allocated to members in the amount of and in proportion to their unreturned capital contributions, which for the purposes of determining the allocation of losses is defined as the aggregate of (i) cash contributions, (ii) the fair value of other contributed assets and (iii) the value of in-kind services contributed by the members through the date of determination, less (iv) the fair value of any assets distributed to the members; provided, however, that any losses generated through May 12, 2012 will be generally allocated to the members first in the amount of and in proportion to the unreturned capital contributions attributable to only the cash contributions and the value of in-kind services contributed by the members through the date of determination and then in the amount of and in proportion to the unreturned capital contributions attributable to the fair value of other contributed assets.
 
During the six and three months ended June 30, 2011, the Company recorded a pre-tax net loss of $1,071,912 and $512,030, respectively ($2,252,038 during the period from inception, May 12, 2010 to June 30, 2011) for its share of losses from the equity investment in Lifecomm.  The equity loss primarily relates to research and development costs as well as other selling, general and administrative expenses incurred for the development of the next generation mobile PERS.  As the development continues to progress, the Company expects that its share of equity loss will continue throughout 2011 until the next generation mobile PERS is completed and commercialized, which is anticipated to be in early 2012.

In connection with the formation of Lifecomm, the Company entered into a Value Added Reseller Agreement (“VAR Agreement”) with Lifecomm.  Under the VAR Agreement, the Company will be a reseller of the Mobile PERS Solution in the United States, as well as a preferred provider of the emergency assistance call center (“EACC”) component of the Mobile PERS Solution provided by Lifecomm to customers.  The Company will be the sole provider of the EACC to the customers to whom it resells the Mobile PERS Solution.  The term of the VAR Agreement is perpetual, subject to termination as set forth therein.  The VAR Agreement contains standard indemnification provisions for agreements of this nature.
XML 26 R6.htm IDEA: XBRL DOCUMENT  v2.3.0.11
General
6 Months Ended
Jun. 30, 2011
General
1.
General:
 
These financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2010 included in the Annual Report on Form 10-K for the year ended December 31, 2010 of American Medical Alert Corp.
ZIP 27 0001144204-11-046835-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-11-046835-xbrl.zip M4$L#!!0````(`+QH#S^+%G1RG%$``(\Z!0`1`!P`86UA8RTR,#$Q,#8S,"YX M;6Q55`D``_-124[S44E.=7@+``$$)0X```0Y`0``[%UK<^K(T?[N*O\'O22[ MM9L2]HSN\CEG4]C89_W&MV"2;/+EE(P&HXV0B"1\R:]/CR1@),1%@(!C9FNK MC@%IYIF>9[I[NGNDSW]^Z[O""PE"Q_>^U/`)J@G$Z_BVXSU_J0W#NA5V'*^1+[9V$M3__&R^;71$NX]U_&(<%V_)5'@O`F_=8A+ M`BN"KSQZ:X<(3;\S[!,O$H4G*R2VX'O";^>M&T$ZP8+0BZ+!V>GIZ^OK";&? MK:#NQPV>=/S^J5"OCSK[>X+S3!"T$RR=&,Q/+7_HV6>"Q'QU$1`K@LL%&X#` M3PCC.C+J6&E+\AE6SB3M7^S5_N`]<)Y[D?!3YV>X&*EU>D=F@"(,IW,B-%Q7 M:-%+0Z%%0A*\$/LD;>GM*7`%$*D7?JDQ@Z)?G_C!\RFT*Y\ZJ4QJR95G]%=W MSO70];^IT,;7TR\RU[_*\=78-,W3^-?1I4[H*Q+6YX%)KABW'3I%+<.E^/2W MVYO'3H_TK7I^!%;?ZF1NHU]80($HGD(J2*3):'1Y!R8K"M['=\2(0M(Y>?9? M3M,?3Y/YPG49CVZSB5-\"_Q0<+GCO9`P*KXC^:W@)L_WO&&_6%YV%)Q&[P-R M"A?5X2H2.)WQ?8MORMX`:^O9L@;CF[I6^!3?D/Y0@`U^H2V%A??$OQ3<1('8 M.;FE,ZJ=)C]F+HT*+U632Z,:D%P08IJ[9V%,AA;I"C'GSBB$+[70Z0]X^1W_GW8\\*2'@_C&(="'I1Z/A>1-ZB%L5)?/?;PR569;D._V'`6_\K@L:_ M/;:;W]"W>`0&1M^`^T//2>X)XQ9K@DTZ3M]R83ZO[ZYJOY@:5B4#?3Y=#D8" M.67+V845]DH"0U2T&6"I+OCVM\$I8-I"GZ!%(A@)R4AF'DPS)LDH$?.EL":B+#-!G)S<20 MQ=HD70)?VVWK+1T4B2ZJEZJAP\T3M'-09.&VP=J&P^`])NO?+7=(*IU[3=69 MJ9_N/`ONQK&>'->)'!)6+T)9T9%BJA-TT[T7SW2+O!!O2*I'**DF-#4]R5D` M.1'ZWG.;!/TF>8JVL[Y-%66H6(P@B_)\&(*?%H:-SG^&#JPN^?!L0+R0-SV:L[!94J6P"Z@GH)=!,B9IN)\(6Z1#GQ7IR MR5:LJ`8+7LE)>R:.'.)X,%7*5#=E`YPG!ES<951MS4Y.QQOA'N9ZS MN*YAX^9%?O`.\JL2DV28"D,\MMMI03D1C6R$P,>Q4NC`@JH0'\K*:P:`J:6< MF'EF/]$81CT_2'VM0?[PF<'-$L"G3&]C;X?1,Y_DV!8 M=:!U+"FJR2R:\N@6$W:=??B2C%W`U9E;\-0XP4ZITJ6O:+J)U"F;&'<[4X<_ M6,%]\!A1><=*]8$$\6@VB?/;@`3?IF4J@41/$"Y4\+-@Y;2`;<<>E^4^P$"O MO0MKX$16I>M/TR5LLL&%&1AR0%W7?Z5QT2L_:/K#IZ@[=*\D'N^"QN@,+E]J\[K(C"+3H^^U.*-(49,B,E!9-X51,O-KY MBW1&L,CHM`ZH8JMV$:9HD(U5GL<_& M,3M:6;V]57-;G(+>%W"X^GV8A/(;L3D@9NK[*KP_6^W:<:ATC,Q,A*`20]YZSVU[04Y=O'7=(-X];"2.8R&1SC\O@ M63NO7$ZHIBRS@=))7IE6`)RU?=AD,4'>*H6E2EB23.WS:6'/ZXH%F5B2\;(: M1S$-13&*Q++)=#LJ`0G+.FS-&"YM,]U>"BC"RF[S[6702MC<4;Z]W.1O.=]> M!IRL*[(FRX6.0W7Y]E*3+&.#S?]N+=]>CHG[G6\OIP-4@_4O]CCA7FX9@D'' M)I,LV^^$>YFQZ;#7V_>$>ZGEA+",U7U(N)?2I9JB*YD=]^X2[J78H\#F4=.G MO?.*$N[E[).*=64ZN;C1A'L90*:&C>)\S&83[N4T-E(5PV"W*M5GW,L`W'G& M?1KLOF7<2VXG#%U#9GY1;#+C7HY_>Y)Q+P-:,S1%8P.D^Y5Q7YJQ.\BXEQ(S M1HIN3AG%K63-> M!G0=2Y*Q/QGW4ML"4T<29I#O(N.^GO>ZHXS[IJQ)-1GW!2*M..->CH&:JAJL MIMU.QGWI^:/;$V3L1<9](]9WQQGW4MMH>N@&9UR=[67<2[EDVLXR[DOS>"<9 M]U*S;6C@=NF%FGWS&?1,:]W)Y/E>E: M6BKC#I:H0X@=7@5^/R;G_8#N#L/+-Q)TG+",&L<&+GW^7<[4?BP$,QL[D#=V M\&%C&(_URO%@GPAL:'0BYZ6DRE]A)'5=EA6M>"A+8,L.C"ICH,]]`%Y-E'Y@ M,C;I0@UA/H=]8N/J!I;4%65KF4N"RXV,1'1A@'1>')O8Y^]_"VE,+=FA;7&V M%%4Q8)TPHUH:6%XQ=JAJ)TV2_'OM3<B0NC^RY5F^$C MF*Y*X6)-SY0EY_K.+?!TX=QWQTN&7E\M-Q199[>Z,R!,L<#ODSAR2:-JU4I0 MTA4-ZYD)9SO/)];C6HAJ189-\"MEDXGRC[I=:O7?#^*<\]96OZQ0L&CAXB_` M5]CE]AAALIVA:NF26925=@!1V M5UP,(1=:3"LR1OO[IN,.HTU[*?-"$.R9ZAE@BDD"UI]U"F)/8.MV3T6LT2L) M;6I+0$!`45K$4"EN29.TC,;+=)W7>(.QSF;C%]5269:TS)Y_%HH%"B06_P(TEH4TI^L0JW?AAQ:8G/F*>=>0F71=9:?H]97E28#`$AJ=Z'C8: MR6:=,:B7;U%@^0%L*ZW@_3HB_;C.%>X,?->%6T=,K-@%EW3)S(RRPJ$L8.AN MR*G`Q9(RAYU+$C.OL<':.)TM&@]]MO&(H>23@H,`&DCJ\;P5RQ]6652&(DFL M2S$'2,Z+L&#KESI_L5-?*K"^BB^G&IK$^A`%`&9#?"3!B],AE:/$IJ0INB87 MXV10+-I$$55.+V0; M+H.N:RHR&)6Q'*89^[KTUW.XN5NF%GD5KN#--4>91(TA![MI;M=]$Z&]4J5;T9E<`F*NJ\ MY<0@F>?)[R+J`DUH8"%G>>1+A5PFL<6F0P-/GETM9E-%LE;@1#/]+^)&[HA5 MM2*6D2$;\_B10[.414QC-&L4X9:TB8:L8@,MM(FS<"T50=UZMDO&2->DA1'4 MA9DN-NQ$RX]H;><6PS;2=$W_(CQ%J9.1`U^MS39T0T53J9-1WTRN>78&*$W. MI74?J7L2COR3E05$MOE)[VGY MTV0&UAX^7"#5Y;3W6Q=14ZY)_VPJ>MU MJG%HV`6\_P?P.$$:H^CNH_/L.5VG0P/IB2D&P3SXKD-/8K9A5.=NJ<+*_'KX MT8T^V<[+C\_1I^.C](,01N_T=3;-Z\>'F\8_SX0GVLFW05Q?4X M3WY@DX"R1.@0UQU8=O)BKO1S.+`ZH\^OCAWUOM3`O_FA-@)Y=7_7KC]>_^OR M3,`Q@OB+J\;M]0T@CYP^,-LCKP(0S?+27Y>]G,4:""_I0")_P/Y@CP88OUEK MC.L?U\WVKV>"K($(MBQ=VE$7"#'5DQ._X6N1$-JQ$.Y`"*VQ$/`);?24MCKJ MX31#F]/(+I*)2[H?8?AIG/JLC!!.HX#]0+G.?-[^FOO1Z@\^_>&M@0J`?Z_S MTNZ!LCP^ZB86PW+I._PBD@2'X$'5*+1")?Z/H!_5MX!S=!`)\8S#[LD@B-%QP?R5BD[]Y#T`NM M>R9Q=_3JAN<-H>7$LZ7O`P0CUX?1U?^2:?#X*-NB,&[0[PJ-^)UJEB?<$AO^ M=84&?>G<\=&%'PP6+LOT$_/0D37,S-;*1TNY%IHB&YF:V'VJ'BWG)&%DRG.# ML%57CY9[L+*DLR_&V4[UZ*J^\U9*1TL]^557):049!8W6CE:ZGU`R%1QY@E% MQ96C/P5]YL0+''U+/ MB;Z<&#QG6P!79T"2S`Z-$C^G55.NY?3IQ#U;]&6[L3RDGEDX"O'3#S[UT(Z/DL8$Z#NDMZ7^UZC$#I30,`AC>+2UI_3):R<3 MIUAH@$OU_T./"#**?2\]0(;6$(\P-NA.L4^ M/DI[ML!2QT.A:(I\3*;OR5_MB0B.CWI6*#P[H(%CS""B81"_9KIC!8$#3B(X MJ"`%.J9PV.D)(PD`:@?&\D1R#3F)ZDO*NCX;X&* MGS8XDFDAT,E?UUY\![44D9B90Q;!\9'MA/'#2>G,`^2(NNY4JB#64(B/+,)X M$HE:$VE;-GUQ-]Q.NEW2B5UHV@5XKT,7A`(-^>,JRWCH$U&#W;'9[L9L+>\T ME[-X^?*K9WKC.+C-3>2',9'2)DSD.$12`<*4>Y/%>GPTYB&WCENSCE211Z\^ M:"TJ^V11)C,3BL)/SL_"K\1RHUZLOQZM+HE`^=_ZX+#[`;4>C^\AK1`7?DKG M$13`Q:=?'V\?)Y^;GWZ.[_[)@=;:Q"6#G@^F+#Z_$^/H@__?2::]] M?I%M;Q&WMS,SRP6MOC]JI+%OXOJOU+>AD0JP7[$;`6;%3:J[8].>$`7ZZ_I! M/_DZ\J$!/WU86>B[CDT?M9*Y9!1="IVWF!C4&0-S"R/IA4GX:I:WLT@O?-QY M9VQ6!=.^L,EX,,W+B_M6HWU]?W<&6W:PP/2WU(31:9J>G(W,U)*:N#BJOXZ; ML:1O82H_9'R)(O?AH=%L7M]]K9_?M]OWMV>"-'BKC7V.)S^*_/ZX/57]826_ M8.&`"LB;F:!'B MXNKJXB(;=YKC'"XN8-DLMU:,`BVN;UJXJUB&=X^PB[Q-]HZ7<:'":.M8?E.2 M)^)\G;5;C;6V*MJYLLVO[^]H*7-N<&YP;G!N;,P%>.TY$3DT!R!N,BWC^4"6 M>06:5K:ZCH_^N`K>M%Q\%F"I0L08B8IDBEA3#T`?<"9_;":KDB1BF3-YY]@X MD]=!+"'15+$H(W0`3.9AF@+A)07@M'"//BPPJ0H(1[E\)WG23T3+P__$';F* ME,9ZP'>H/505B9)4$(C[<*J#\_D0^(Q%+&%1EW3.Z%UCXXS>$*,U'8NF8AP` MHWD(;KKHDY9K'A]9\1,=N?_&M4-..^ATYR=BQ3P`]<`I?0B4EI"HR;IH&IS2 M.\?&*;T1Z)3.LB%B^>"1[G\1*3]VP!<&7QC\V`%? M&'QA++!YK/WM"Q@W9\:)T?/.`%Q'LB?\X-S@W.#<;ES;)S(:QZ@D;$IJMHA5%KR M,`T_=K"/2N.[+8C0D8B,0]`79WF'Z@7T4_4A^O+R/%VMDD?-B#5[>QQ<&7QB\O(\O#+XP M>'G?/NTN>-QX.T\5+K6[^)Z"&[Q(9S_ES[G!N<&YP;E1S@7@Q7T?QS+O5]KA M.RPED619-'AUW^ZQ<2:O@]@49<,4%4[DW6/C1%Y+)9NB)LFB;!Y"30./TO#J MOGU4&M]M^0@63:2)6#D$Y<$9?0B,-L`88EGF?-XU-L[GS3QC4=0E4Y3T0WC[ M"8_`\8<*<^U0RG\S1$-!HE3TG)0/IQXXI0^$THJ&15WAE-XY-D[I33U46$:P MU58/89N](2=N]^3G"_/#+\R#JF_@E.:4YI3>#G%S>$ MG)]&F2')^4VF`^3G%_G"X`N#GU_D"X,OC.46!C^_N)K;>*"5<5MZ/<&'/<'( MMZ[?@<3W3`=Q2G-*J%CSZ'QFR:,C\<.#.L7$B MK_5T6%&3#%%&A_!\6$[D#TQD4]2Q)&+EH$]!'&@H+VZ2'W+=N<[X;K=WAJ*) MNJ8<@.K@?#X$/LM&_&XRSN==8^-\WM!#""29/HC@$`YMEWB+Q9;>0O'[,(R< M[GO1*'8`H-3,+/4>C#\='R7.H[#0=P3:1#W'$Z(>$6B%FA"2YS[QHN,CN,H= MVG`%_>G"[P\L[ST5EH2P^2D4PIX%;?M=@?QGZ$3OT"Y0)A)"KC_B:X6MFWII9JTSJ@ZZ9C83YJ,7,C^N# MA/TJ>@/!.DSD>]&/FE_`(M)A"XH/X8#^7")O(Y;/6;TM5F--Q-(AO+QY`T5- ML2GEIG-&\?OQ4876DRN=#Z1T5"R)2"[P^#^,]-)^RX?C@,2)N\1>?4M/QR?"0(GTW,`^(@P]G8O3K&Q'ZEZ?' MS4Z[W8`_S6;3;?SNNF[[\OSBZ++9:UYB,\OMMMU+]\T'$^8J8][]$6XQ*J[6 M[B]VJ@=A!"&JLMT\WXY.5>YBR"YVN(LA<,V(>=?MI29W!L`XG)83"_.]P:FA MZ[\G1Q>__F2C&)STEW-$)8*86YU1>_#VELSZ-^;4.T4^VATC1BLKEY# MN[MO<>:A[N$.\8VJ5+AD-Q0C&'+XGO$` M)H2'V_@@/8R@87[(`S;E,WQ@CP%_A:]OX'ES"9<&Q5\)OO=W@LFW/V/3"!B1 M4^[#-15SWT>6D4+VMJ,G"*]%Q$;R6K"9X!'DZUXX@9O09[)_\R#AT8RU7+>[ MER<-0(%4"R3((BH!L67(@*P(GL"9L:]+*Z9A$C/4T302 MP(%>,/7&/+H2]WF+IX'F:HO:.V4;1Z08/(+L=AW2S[QIH#(YZ`*Q?S,6D1C, MBHO7+!S$',%:KX'F,=;&,@P`7V];&>`1Q8#_KOD(*L^PHO2DTRCTA!@"VN"B MMJ0;F(HE,1#Q-\P$"@BG)%Q[Z]$*II.E<$H%!A\/@7#!?74).;@ MG9D(6[`0M/DY$]D')KK=O>Z!9JG5-1\=,&`U%5X,X_JSO7KM,).#/W,RBI%Q ME##0`*S`F,2C$>X<"V#TN0"7FQ:[R[+TR?(EIL6L96W4LDX"C.V>F`Q`%ZN9 M%X`,SC8KBA%HT>H@`< M"6`9`.19-BP\)0`:<.\[_IY].?GX_8Q-_42QUAXDQ`S"X+O!>QB#[!,X)#KP M:_QF)&`2,)L1S*:8&(TT^O4]-,I>YY].O4;&+-#H($1<10(N1PZ9#XZR))2F MM!9DL)38YMY!)R66+="JR5^-6%:DM5XSQ,[9I9FZI!NC&MRZ0X2#&T1P";32 M>FVO!?31_9#P*Y8%_Z4[@&!(&:*S*+ZJI%[[G!!(,%]$I!0OLN./)Q='AWOL M1`\;CV4T%V+=`T?+HDPYPD]CCH!%M!8HE(::@A#JM8N"]Q]SO94IG**[0[J\ M<1@JW",5WPAAR+D)R]."FZ?["UC-C2"#+()D'B#U&B*DJ)./%<"OR._0[?H^ M*I131*G7@%V5#,##![%$/\U0><9%ZY])2#\99O>8]DC_:#2./Y_ZW!/CT(<9 M&XT5FIC6CS[0CWX'$SH$F_;Q72D:R*7\(\6-!'TM.-<\7S&^T&ATB=\!,(O; MV.!P'(7)U5B_I@7C*"8X0P/5,`$>82SS-+_FTJ?T(H=@Y13@#SGF'/`5&1G8 M2Q[FBZ@&0\XFUOP6R*_7'D!_VT;Z#2+T*Y^Q9LLIZ*O2M=\1_3%4+L^NV4)R MG1:$9ILI5*T3RIYY[D'+N35;GEI/(5"0#ZS7TBP;S:F\R?2+A+`)M2`@&_PH M)9TA33"$D.F'4[H/"4?YT=OP&P\.8'D&)OR'_:;W9;;V\])7YVN,C^GNM!5%^$AM@HB M<4P[ZK\**(?A^=2W;98;-^=C57K*7!SS*,#L]E1$YW@T8$-K-/.K*.4MH2]@ M4675992'^;UU5@S7\G2=-1=*RCP];.UX+0)3?-9K@%!&$'V&Y0P;+E?3$?A, M<\)HR&-.:QV4\\A;TY/!G3H3O'9X_HE=A%/IL58'GDY)8("2>HU@\@/94?7J54ESS[".M4DSHY:P/LI%J;=> MWU&T'`6BQWJ"4PO&5+A!,L'P&$9*ZVPH@G`"Z05]8_*/A+)XD6HFP\8J9\4> M=UGQKI-G6QUO[MK$\PA(J)KZX;N*GI^@.\ZW5!&[87M=^[S+6F+1AT77W.9P MCU"6;K]ZE/S#HFUWT481==T?]K5HLVA[D%@@B6L0XEX+X.;.!928*B8ORSBJ M.F)H!BE3<,^^X'N&VQD+6/&P[,X;RCU#&@;??4NS]?>+0GYTZZH`CQ'9O,EM ME8>WV'^9V#_**U.+?HO^UX7^0]I*4)&WOT[<_]"[#-:'3'\!,HW^T[3X'H"8 M-8=\O-<>Y,K31SCSS_HH9_;QQ]YW\^`#H#OE_IZ?V)VMP:SFK>:W1YA6\\^: M$-S_/H;GE_K6$60Q:S5O-6\U;S7_O(7KG2L&9C]#=_^?2VOW_7SU8&>KW8]< M2:]>.SX]9PUF7JR<=+5582[-9XD0K*G\X$ M5GG+RA)Z^W=*NMQ^TF^[V!#8>MV>T]_O_;#_60E!V]=6L[;P:+;PXX1OC5'T MGCD!G6X;2C^AUQ30@4-]\*K!OIN3\[A=_X;>6U2U M?/C(>7%KMYU>MJR\??;Q<.>WA*DM\'V-I_9\6[F6;0UM1]2QNX;6VC]P^LV* M'Z2TYO;2S.W%U+@+X-FL'3U>[WE'[<)VIM>5[!'FW?A"EK5ZT_I=G4HE$WS4 M"X-K^!(S==NTMAV);4@6EO;`7V%7PMK9KNACAPVN[_1:^TZGW;4F9TW.AC;; M;-^J9OL=R?TV>XIMIFWG:_5JLWYNY[N^L6Z;75I$6T1;1&\%;1;1%M%/V"?= MX5[H!G[\4_]R=O9*07J3X'W'0C?^0]K6!UD?M"4^R"+:(MHB>BMHLXBVB+8] MMNVCS=JEM4N+:(MHB^CMIZ)5VAC]I"\/23_ M[$[/GMU]4M]G#\E;0]LA=>RNH;7:7:?EVD/RK\#<7DR-:P_);TD";AO32R1K M#\G;CL0+[$@L[8&_PJZ$M;-=T<<.&US?Z34Q/[DK<=B1?8D;BC"_X*^Q+6TG9%'SML7K<[+3;#?C3;#;=QN^NZ[8OSR^.+IN]YF7+A>^Z M;??2?<.20.JGI`KW6\V#RS_.C]ZPH?#DA/OJUS?NFP_-9M?M[N>45I-0)G.> M&Y/Z/BZ=EU,172H<7A5);KWYX.ZY_>6B-<3,4?Q7(N/95Q&/P^$)Y-@JGH@@ M5D=2>7ZHDH)"'LS$!U.ZE.J8@@51$6!LR(/)1?2&#<((B@#4`_.$[T_Y<`BL M9)_5E'OIY]1WN&YN<&N>7GM04:_+O]3XXW!:KOP,)?\].;KX[6?6[D[CZD*N M5+BY"X6;6UVW/8H3OR#&O@%C9QECO;WUZJLR3T88_TM4+$>SQW!B533F.*W7 M9,"^R(E$(_LB^4#Z@&:&!LJ#V3JWG24J]=%!B0 MA#$8_NV^`XX-_Z/!9.`E$7+VMMEQG7:["]_4:],H'`F%[0GNLY$`!I!M#WQK M1//*((R0:TEB43%[QZ?PS"VX[ECX((6F^\_W<)5DB'(VXG$`U".!/,._OGQB M[PRY(/!/OZ27\N^.?GF_QPX5T,.CF(4C&$X"*1&'8.5AM"HK"9QL%-X@+ZV, MQQ%HF,D8QACPX$]D`\>2W/=GF5#G1RT(D:V28)P$#/VY)FB:1"KA\`!,A<0M M0`6;/YK>#"IE-L96A.-;B]U@6S`?=(*3/FVZ?3Z/:?5 M[VFLIE)@M`J#@"A4X9#$Q7`RTRUTRX&?F0&!ZO7TM'>%YUAALH;Z?M40TA@ MM"0!Y`D$F\`EOU[3(?`V3J]CG5<,W"!GE*DO2#C!D'R7B-!:Y-]BZ-1K-V/I MCR?K$.GC$/T?U$A@P:?TJXID1T+3VA2L\.9G1W*CMP4B%$4OINJ`G$S%ZSR;7C M\2'+AHFNJX@C'&ERAE*ELX!#"8O3_(*JN);@`B&,0O9[+2)'.V=\WH@M\[[H MCC15!9?7TKYLL!0-A>GJM9&,=/BN0NHB+NY'!>.Q_I"NGH:!KR6YJ,HTW:C7 M,C$]4"6@"@.:DDK2"8(5.,Q4LC^$BOYM8TFFT])%S'ZR%V@#`"Z0_-R88Z2CES2% MM@VN?PH9!/`&Q+4T]-@C(1%<[EB(6%P577E5KKR:=\IG M=./G,#J-0D^(H?H,MOP=^=?C0&`YQ,"JC[]L_`8N^9\&BA-XAACID0]96)H1AU0F2,0LJ$M<+I\G`EUZZ>#+%/`:?I<:EJ<7RU1J% MF1\-;A;\S&,*ZAQ_B&TI9`W7\ZC=3P6,,-MTTF3'(_)QK8^>I>P1\H"T,S8P M?)K[M`"H\@H]4PD6:F3Z!LUG!M.P,1_F=_%LQH&XD@$U$G,2D#ETU5#24J(3 M!)!M`=W4RH$[3?&-K:>]>2E"G`JQ*`3NE!:#RI7H8Q*E*X-4'J!JRA6AE/63 MH:!E%.5%H>"%$+\`9JO:QD*)-%J>Q5(G4#/PR*U='J/5*[M>2'4A,Y1@]W@R_O_"<$BB1_U0FL[>7813?,E4 MN^.^+[G68H%=1'2/3<(AU$]"5WZZ%ZYB,$H(RK$8ERN+CB$W.W0 MTHQN,/PMP,C1(`)Z7"@]C\XLV58#I_`+U,+;*J8B=A!$NB?TIJ'O/ M(6H&86R6(BK)$+=2(5=S$H:A!+WE`&1`[@G$K#PP0?3YRK3AT4U.C-=6!8^O M/44&FF;'O&I_OE0F)Y:YXZ)S&$K<8X]KV]>TU\EXY-R_!":FW.5MT4^6=NU@SKTA6F:=O M(M9G[7#Y_T[P+DB+N?WI=.+"[=CBSR14J;V2$#.#ZX*%0H\'4XPC/S]!,!8N-G$S:?%A:;8;O?_3+?ZX-+*_?"=BKIOG>UMQX1PDTIO=8W^"JQ7"%_-M46Z:4 MT;DT9>6'$\CH/1ZPKV(HL;`X]"',,\BJIWO91O/_;^]*G]LVDOUW5O%_P+J\ M6W85*.'D$3NIDB4[3_L2R\_6)A]=(W)((DL"7`#4L7_]ZY[!28*73%`@T:F4 M;5Z#GIY?']/3T_T`^]#)4PN3[`;B4"YP!@[S8>?W#O9)(R[VCSAR=L.9N/J9 MO60V'P$/3^,-A=S$M.*,P2CM/.&^T/X2,VRIRJYQ`Y=]E\X$27(B4V,4>N`(_1<:R(G&7">,H;A+(CC@ME MZAN&B5V,RF&`,@X!PD/].7@H;\&<`4P"C![C;1;I78AL,IDUEWWZS(O":6SY M"D>2N>]+92@>ZR7*,,F_R:5*9<"\+OL:OR_RE41&"V;Q#2?>0W[,U;^7"4)R MUTXH+U>S1D=0,U"E?8QJS0,>93GR&8O#[D'QF8!,:1;KR;`"CHCK!SR*=M^E M<>8D'&/J41Y;,IRXNA.-1ZM=YFJG8JYLDO)BV10BJ8NL<8R/Q6H(TP,==R!2 M2NZ3F'?\-)FI)C/JA&:,#@1D:F`^CH>1_IB>X7PB`WZ[A\WVO1E;O1O]%J4< ME[TA-32[8_4ZG>(M:8:*I=B4SUG`0?S$W]?N%Y1J9R!B-R6'EUJZ90#5N?#2 M&FH6F"Q31G^5":,8'3[;$=3?A[QD0.5'ZAI1DK["#)2 M8I`>?O=;I;SC?=7<*>)P='PCJCO(>RVY@SVTF?'YF"JV!_"&/!;/Y-VOOG!] M^^'RFQ+PD=RA;/2Q8SN>^.B^\-V&L-\%'WU3$.0P"[#ZPLM6T,A1(I3%B@"6 MU)9;ZD3;?@F5^.,%.3N]YW1C?S$)*J<9^S<0A]6MV/6=\INW*YAE5*%5'6`' MD.SB6='6E>,Z?]^/03Q,P5WC")N^;=\P-Y;=EUT*0C@A?#>$U]18B2$_R%"^ MR'3%J*M,6U2B;,43,B[/Q&LI8O<#;0AUNYC@DON?ZIK:M;#,B5%G1?',/D^= M]2T$CEV%7$3UQ#!`_IS]^5;">63=+HQ3;"Z3U3U'UEVFG#9.Z_%9O:7=S0,B M+_\D7(W]ROU1]UPGG^,'&MM4RN=8W+9D4S)*]STJ7LE_D^]Q5)7\-_H<%2[E MOV[35*[W41]5$0KD/=!WD?YWL?Q>A@'.<73-M@$"K22_B']0ZX!B2:) M9B5%LY:NP>8STP*[3J:\KF>FAFVKO6Y!T\SZJ(D?2JZ@4U,Z-:53TQ<+8)JB MG]6A@Y?'=71*Z9&GZF_0_H0YO[T)'IW1T^H-'IT;/4HWNILLN-3PZ M/8DKC`>I&1%ML43#P[BFYT*'QI65/32L0C#)=A5CR8X-F\'UQRP0)9IE^]=\ MG1[9CT7%YBS],^4.&]3=2PRLN===5![RECU&U\,_R+Z[Y=YHRC\W3LFV^6;U,9B#*&V*(R:86@O(%%D2W1 MP[>*:'::E&`"APJ;$:)+-,+WL7_55#;LEKTRD.KBL@Q)M79%,K'X6TC)ZD^Q M.VVV1ONGM(J%+">WJ5-GKM^=$VG2J%=L.I>45"1'=.L6+2V'$]%R#89(NTCT MN8_U^K`6G]N"Y\WAAZ@.XU:5N[N-ZU1X<7^P+^`-E%OK6+-Z]G)S,'QNGJ*X M'TVF&PT9HIH:HLX15#6Z2)NND.DID]$WH"&_\5D8=6GIJ9E.+;$^9O&F!.OH MAMC)-FXRGG3)B#J=X[9_,ALSV/,'`6SYE$LA["KZ$F<+C4/%%W.=0]7MYO?G M1\FE.S!`6\QP142)-1OXO7]R/^!/44`BKN8KNIY$347!"/,)GXT]L%:B/4EK M[,U]T2."RN"L8N!G,UD^ZF"_V*UF.CF#7$JSAF?9,BNK(8EQD*$V[@XR6 MX9&HI:)H4VUW.FJOTY&]IUQ1"!1KRXK/#$U304FK20&JJ,*LM*49MR!M5@_+ M`GH8C.I`D>Y#`+@334;A>7/7N\-)"07NN+,Y;K)A@)'G8X-CT?M&]*/&)LV* M&=>/3$=7Q@YL_F'V3V_3?EZB:JEH!"8F/8A[*\>%)J.ZD[B93IJ^9T`JVB7G M&!QWTI:"&.;V0=7-IN5 M8!\"($)1X7G&_;YH#*Q;?T_GBPNX,+6^-YG(UU&/^^AA*K@[CUCX6BP$EHE$ M5P?;]XJX6.34)!W;HK[49'1 M&*.4D<15,Q;]X-(^Y8[HP"Q$V/>&H+:B#)0AYX(N-H/W'P6/0.>!\&7E"Q0` MS_5EB[NEQ_W-9;NJ5=W28Z2)=GC2*\X6VRWN?51<"38!(UN@2*CGVT2%?1#, M`EY,YV[41SA0XAJD^8;66)ANH8]U5*8NTZU/]'Y"-J5B=2*MS,O<:0N5)4OV MB="[4*^BH1RJU6"EKD[8+NUM9$!$_\2P$ MS4;HQ2?R\LBG=-5'5Y3HBM(V.J\C$Q.6IT[WD_::B)0CX?12DL3A:%'&3#YY M@S_V.1_$B0MIPDF5A=&::9C,Y+@NF\_Y8MK[-#_[``IF< M@F>R4;X#=\50"ZDA0>AS=P1ONB)C-^G9'!^],Y\SY6$L$@5"'!>X"&\-GN+3 M>W>4RYR=^WCI8>KY7(T&R).5)`W$]Y_^P>"9[Z+4C6R[9LP\@'DW&YSY+CPF M$,?V,_BVG`\X3IC2$(^7XU?(W)%(EQ7-G!TW?2V8>")'_"_;N'=EOD:V%WD_ M:8&+^7=I.W(8SI'Y^>MZ`,/:+^=:9^%VXRH,$U]$1@V3:>2J,F92JJ*,HBP" M0_9OS,5!!S:3!7+'1X[KBA;HPS2!<$7#PXVMC#/T)1-J-E;?2U0>O/ED(-H: MC]D]E^E"*+:^2%2$"8B\<3[8/>=[N[SI37?7KMU[6#3/=\KLVXM7U$S-L-?= M4,L04G0]Z31 MKLW-$+$'0B36[*N\MXK^=;'?V/=$9%$ MK5Q\NU1NO9G35SIZ5Y6F,_EM:D#-=Q(+.12DZ=["M0VD\9V"S@=-*!,VP8[B MTT>N$UVBSQ,7I:0**PPVL]D0-[Q;]Y,V'DU3=?-)S@V&S+#\0=<2T+FUI<,Q8KA,LA5$3GN\8Y+ M%U<(%'G'/T(*.%]R'9N-;&2'ZR!%-V"!LU!4;1^J9195: MR3$[,3B2JB+'C!!-B*X'-H[4^%)8A/!8)3Q^Y5/F8%(G`9(`605`7HQ&/A^Q ML'[[$_)!28SV5Y%%]&%)&>4-:R=/A,Q*(I/"3P3'"L'Q$H;S63^B['+ZD;AHPF M>",O12PSNTS1/HK2,"0;)!LH&RG7OV`E")(4DA22E`5)N>7^-.7Y&VPG$KPE M22%)(4E9D!31ZY@D8]/N:@]U1^/SAR.Y'%O$O`]L@O?SFPT6*O]D[ISY3TK! MW<2U>-F&596(J#PS(E"*5FSNHU3QBBJ_)9@*XRABEEDK!!V*@@-O9=Q/IYGG.O2I[SK[*Z#_G*Y"NO:^NA[;.K M1X4U!&&[=MBVR6>N`&WD%Q$V"!L5Q$95XLV5\IH_/G*_[P3D-Y-OL9;T5@T4 M!,&:8'V:L*XRDLDG(FP0-BJ(C3)BS-LE/!VI)SW#%E_GGSQ_R)W2(M&;.%A5 M9;)=3ECULI2VPY2M0I?Y6V8\WZK$ENV9T44@7AEX\[L)K]YV[0?"BZNF58'X M8D=#@D<"1Q9NT-+GGYF]4CR M2/+(U!U*X%33[*EMFZ1N[5Z:3GPH/$[A\V_L&#D`^:#>8.%"[OH#/8^"[SF,[8*A3[J'?4L=WIJI9.(1`2/@H\ M'NZ,K4T"1P)'UNXESM@,DCR2/#)U=,;VTOOI\U!L#M/7N5UA:1O@O^9!Z`R? MBN@^#`'[:U]S*Y;B,RS%UVUA&9%Z]?'RYNO%[?4-`&/N#KB?@:RAZ9N*"%1O MI1:C&Y$D(<*4/I],9FPP<-S1SZ^T5^)U,&/]^'4D3+U.*DT[B<`S(X`BI+2- M_J-#Y4VTT24$P@9A@[!Q<&P<@9-0Q*(_.7K&.U>S(CQ6'8^DJ_9VV$>>&2'Z MR!%-V"!LU!4;1^J97=QSGXUV39D@.%8=CJ2JR#$C1!.BZX&-(S6^%!8A/%8) MCU_YE#FNXXX(D`3(*@#R8C3R^8B%]=N?D`]*8K0W%GV>3^^XGS+*&]9.G@B9 ME40FA9\(CA6"XR4,Y[-^.&<3@B1!L@J0O`9$.F[@]&L'R&>ZP*L2E*O2E:.V M_436-ULZ?DG=,&0TP9M9Z'ANL,SL,D7[*%J@D&R0;*!LI%S_XCO]@KT!20I) M2LTEY9;[TY3G;YXX\X."7I4D*20I-9>4/]AD3C9DX^YJ0_G1;8L-'0!4!VO8 MP=PY\Y\4?4>\;'G-^Q@4(Q4HVX+T;L]2.UU[(]7''Y`A<#\7W'LI17!`3%MG M1D$!@5,$=)4Q3"F3A`W"1@6Q44:9SMT]YUZ5/.=??>;NGLE*[D2]?.56#90# MP9I@?9JPKC*2R1\B;!`V*HB-JL29*^4M?Y3%ZLE?)L=B+>EO=$TUC6..+1<< M2A.F:XUIZ\QH'S&@R2?Z0.Z5%H#=Q ML*K*9+MC65&VJG];?4"A17N@]OM6JK5WM17=.\;\DIVP27AH][3AY"YXENC)'`D M<)5:FA.4/.-,(U-'DD>F[E`"IZMVVU;;IDE2MVXO32<^%!ZG\'AE85-EV@C2 M!&F"-$&:(%UEV@C2!&DZ7]L#6__@0<@'S09S!PJ7M\,9;'R7>4QG;!6*?=0[ MZMBU=;5#9VPD?!1X/.09&\4<2>#(VAT^Y'_6,TCR2/+(U!WPC$U7>WI!`X8: M2EUN/WT>BLUA^CK=%>:&N_.5\P-LC/^:!Z$S?-H'BVX%BSX#B[XF+/KL-1N> M;)NG/'"?QQMD/E`&<]]Q1THXYDK@/"I3>/`X4+@[@,^B-%6UV3`T73]+.:/< MPM=9W%H>"(LZ;")4YESQADK\M.1!S<8V3U+@09KRP`+EM6$!>K6%A_J\V1`3 M@$^-CJ7@9M\TU(ZF`6K=>Q$"`+[!BB04>/,P".%[^&P8UQLV&]FGZ6(,?*RJ M^#R8\7[HW//)T]F&P,$:*"PN?+*J,9AV&JW2P((E:3:&WF3B/8BU1:%2@OET MRGSGO_!ML12M.X9(ZWO3&7<#ALL"N,!_@!R1,E&#.?1S^8L:/7D7+M=5+MNI-*?&9$6(08M[&''4HRV$!; M7?LLWXY]SE,^_2[T^X[AU^./VA,X"9R5!>O?I*W#S-^Q^Z]B[DH2&A(:$AJPG*8+:*P*,@9&PDV"08"P+QJ;,G#H* MQO[;T72.O^WY-XQS)V')QI1U=D_KA_[V"Y1IF+Q!Z8/Z"-'2F)!=(-4[5[!37;3DY)$)SK`&?3 M4#6S4P,XTX9OB75?N#_T_*DL4DQ6C]1$O4-"A.0Z(-GLJ$:O#C&+Z*0NGH=-37AC=%73.OBUSH/F([S=`UA) MS"HPJ2,6,]-4M5ZWSF)&^^3B@U%Y115OGRY?:E7A!R'>/PW9(^V=*8M"GB9U MU9Y=A],D0O$)H]CJJ+INUP#%VQ8+66_$J'X`U0^@*]K;^E7.8^TO:!,T"9H5 MA2;=?JP8Y73)BZY!D]"0T)#0'('0D/6L&.6D"*AV``D&"49I@D&U`PZ5A'0` M3%'M`#IJ.71F8EO5M0+K>G*!)4+Q":.X#IGBE"-#Q0.JHA^.-Q'?4#OM.F06 M$)SK`&=#5SMV'>X%TY:.B@>0DGA^-EU1>OG)*0F"[6P7^CX@%4/&`?6H5N-5?A5K-MJQW+7)[Y?G58E6\U MDYB1F)4N9FT0LZ+M<'W$C/;)5#R@DCN.8\NB:&NJ:5`N4(5I(Q1OIKAGJ6VK M=L5E#UT\H!23^-<\")WATSX8>RL8^QD8^W4Q7>A7F2[44FZVR!$BSHE`PY@W M&Z[GMOAT-O&>.%>F?'K'_4"X$&.N?/"8/\`75X[/^Z$'GXS9/5>8J\B,8R7T MF@T^@<\4%HJ?W/&1X[J..\*?<=8?*WTVX>Z`^&,9(A_S-G?LA]A04+?M`0?A3(\_-`F?G> MO3/`PX1@U<2:C71F#!^`%`DRG##D/#A+I5;YAF0J45::$P1S&/F>!V&SX4RG M?."PD$^>5.5N#KR`+P;SN[^0+S!AIG@N;XGIPT1#W^D+8CVWV0AAN&#(_>R# MKET%:W3@=]2(%]%3I^P)&!P_7/`^6KD@9M/RDJ4)=+UWRL`)^C['H<_V+2(Y M_79ZPI*D97P0!U07VQQ0'6RN?VNU/G[Z`IM:/O8F`^ZW6J>KM:Y!;/[)7%`! M3XJA:6U5^9V)?W54)?-^3PCT%>@:E'P%+]4(`;D$?<'1-MI7JJ#:\B'?7`0'$-E+LG&!R$[Y'WYR&\\U8\RVJ+K\8B#M^3 MOU+QK1D((WP3-01HA#[W0^9DAP"5XL;?P\@ENB&$B(W6R@7@(:02$E MS#+U1-7BIPM/B%F(BMP#(4"V%N]'<5`&2^\S=`Y;N.(*;%^=0)*%RX%$`DG- MAJ0Q^ZA/S/'1@9MSH=>S?!5*49X1@S94Y)FQT*?]@,R]X%RC]B1?@I'/& M908C"?+P!P-0W<(8"$B M"7""S<#R/SI389"5UX;9%GS$7[QN=Z60YR42O0(O9)-F8^XBJ$>N\U^.MQDS MD$910VF. M*[6_2FI^,_JFV?@CTFAHA^=@!!/K#]8$&`\?<6#_?!;9CY@98"\=?B^L6?P` MY)LS=(0R<<59@U`?(]\+4)G<0^,A]W36#+.'`/6'F-%Y'1@N.GM^P1 MIYRZ\I?O/GZXODU?7[U[JWABPQ'[$L)ZR^U.LS$$MY]-I#[!G11.;H$SL.A% M/%O6QJCR M;"0V/=W+!/$^,6?$(]N&3&.P39JB]AVS4"`C(7#DL0DLIS>?#%`QRW7C@XVS M3/:J2'ODXPQ27R;[B$B1HR2$8R]QRA#DX,0)BY\U#_-)&!LL-"JY[6`$PG1Y M(X_!]4+8UX8JNH1+IDJ0F+$X@B'H]JZS;]&/8#Y!GAL7DTEV=ODLO6@V8CTM>!X38N1H M1NN=#_C3[JB&G6H=\>S804LI@GDO^"(=6ZBP'_0W>17^:Q+?+`(=@@S^H4]34';!;?\,?R`INR79D-1WL># MQ1_?#*\X>7K)@_"4*S'UX M^A<`[-K]Y+@@@O#M"]1O3NCPWW.!\$GV$]?@[5! M17(S_,US1[?!`"+_TY'WR4EC>X<`@("-8"??F'.(%'!SY[E+]$F);=CR1R@B2K1^5(XRIWG#[B? MU(O>HGZTKF42-'S.$^]9;XO= M6B^_#Q]$FD)ARB!:%-P$XE?8%)62",N]ULYT36RXA;%7T4U_W;,UU6Q;JO(P M=F";(;Q6J;E6..Y:;W&CE#P2?SR3V@]=5GR\>)(\E1"CR:`Q>*_YL8VNG-:& MH1VQ6XQ#%;J=["2V=8)W5[9%AO-7SQL$WV!2VVOBGE#$V@[FIF.;5GO1;"9/ MSI,5^9`[V+_=Z>EU=$.W[)2B^*%Y4N)(QA?N"WIJ9\X;3 M!R_MJ*+WT=&\%+&P.3#X!M9#["&##R)\);\GHE8?'T.?@<2#+^T_78=\&GSV M7)R-[TU`(8Z2.%=9,[S^_`D8;YAZ;I(ESF2].,"FVND?3ABZJX5!4)(G]AN; M\"`2:Z%I``NERH/=UO7,JA0]?S6%\1:B9")[MMW63*.8R@P-"X1R`8I?N0N` MFH!1N1A,'=?!PU`,XAU`V9A=NV/8>H;NK4@JDGC`?_3I!WDOJ4RZ;:T'OUX4 MU242MHJ7+`4D]B1^Q<$2V^J9MKTQ6%),5'X^8JLH9UXFKXU>MYV1O\Q3URG^ MC_^9.^'3[SP<>X-K$944@;@R"841VKK16:7`5U!TH)C:;BCI&EVK8^XII/;< M0,[N*V!95L?.NG]%<9P]N70-7PVYW#N0GKR5MK6M@ M'-9/WHF'IFEU#^$G[T24W3/;O6/SD[>>H?"3K9Z1F^-QN#=R]MO%2?O).9U2V;FCF$BJJY"=O??2LMXVL9_>"?O).ZJ0+"B4;=RGR MDZ/G*\Y@I^>+'\//8!_PW]_7GZLWC@\]S([V464_HZJ*GFW84R9Z-,$<#)Q7@#F.BVH]E'/6C9:)@T3O[7G.6J]R<]9Z M)<^Y,CHBL\Z)Z)8,Z]QMZ3O-&;TP,>'(<8Q_,N4, M#_5_D6^_/X]?RR'P5PN_SWIQBX-$G_T$G^TV4C;0$`\JTQC2^>/OP('%((KG M)V]O\W3)F^+?BV&ON.O!=G75P$6\2<=<_O'[\PSMR=3?GS_>^1/XQ_\#4$L# M!!0````(`+QH#S^F!=ICMPL``%"9```5`!P`86UA8RTR,#$Q,#8S,%]C86PN M>&UL550)``/S44E.\U%)3G5X"P`!!"4.```$.0$``.U=46_;.!)^7V#_@];[ M<@>LXSCI=MN@V87CI(6!;!W8Z:*XET*1:)M8F?217HU\<\:_OP%=?KT:WSME)UW%F8;BXZ'2>GIY.D#]U69O* MRD\\.N\X[7;2\%\1Q`OG[4GW[.1=YI<171+_PCG+?-5G*&K9!TSPTVFWVSY] MU^Z^N3\[O^B^N3A[^Y^L-%T\,SR=A433M0]WDG$6S]^(,3"5^L.,X5 M>#I/Q+N=KW_>CKT9FKMM3'CH$B]74%165+3[_OW[COPUDN;X@LM:;JDG5:,! MT%%*B$_M1*PMOFIWS]KGW9,5]UN_BP8_,!J@$9HX$L-%^+Q`ERV.YXL`M>+O M9@Q-+EONW/6DND_?GI^*\C]?4V\Y1R1,_KK$OR$A#I\'9$+97*)O.:+^+Z-! MCH:HRX6!&,K!$\9#L2-$.UJU=O;%/H*2W\8AC#K1QG#R$1/H,>P&=Y1CT40_ M<#G'$XS\W2EHUON:).Y(#XF.&O'`OP-NU'0;P9QHB?D_7_;INDE^Y'//AY(Z!Y80' M4'1VC_AC/"70W9Y+PI[G@2T/8>JYHP'V,-2#5N%50+V_=Z=:$XZZE31D4Y?@ M_TE4?4HX`/`3B%G$F2I&ZJ;WB5+_"0=!S8:BK)G:9YDE!W^=43.\1FU^CA[`6 MKL4-U$TK\BQA85US3Y:V\YI3U#5^Q#XB/K]&7@#FT1?NA8O]VB>DZH;K5L,8 M3<7?$5I0)KR'FKM$CUO;1MP+`82,4$8;.!HB:D6D&'B0*P`':RK4=B)`39?EQ$CNN^B(\=-!0!NQT;WF2^"D4H!OP6%H5BPH\N9G^YP;+"&NY5I34ZJ'RV]ZW5 MA"9$Z%9!1_YD!!,X4Y2,0_"4I(I4^#;%C&!=\A"6.NP:_%[H.@@)B5,(Q0;$"*27%&`_`WXJAJ->SB8H:YE!N]AJS_LK'<"L`%DJ81 M5TZ5"F$3N(?A#+'8?E7!+I8U@?J.Q9-SI4M;)&D(\0*6^37%3L8143C8(F^&C/I`V9.[=A7*$)9>B>(99[@+!-=[,;DJ/Y:&[S$LJA/]N;:7D M>S(^*<7_"G'(]IS.;=S93CF^/C6+Y(2*G_>D342^.S*>6W M]E`NB'!E"1>%9-+9YOW1\-QA6V%-'S!DZ+>MYJ\*#*5D+9I]*[B6;=VE?"V: M>2OX*M)44JH63<`55/?>WT^58M&,K;L'H##L6=863=8O85TDM29_;N>JL%JVZ>I!IV-V%0C%D1P2O<-\_%EG22Y-$IW3-P+^'4M MF.>T^2G32E.Z%@2HM.DJ\IU2LB]9JC;SR%_^AA[30+>OX#%R#H(#%/%(\S', M`(K$@TTI,R+YC6X6Y:_7EES MK$#[\6;F%2+@(Y7WZ;:TH1,!9JH:AIS,GDI`<[*VT$.9+SP2

L3O^7-,,`^9=%G*38)F8:.+WU>8KO-+YN3)LC(IZ96UM>GS*9*<&AYI-**T MC$NOR(_ZKK5<:%_3T"DRK[XK<9!EVFZ'MSO6(/! MJ/#V/>>&;NRY0Z`EF'D\L0N(KE'T5Q5W51W-Q7V1T$;B" M0%F)[S%0Y1G+S=X>D(V\N#@U*C:X/#G!H;[LXF#5&NHU!>[T\)6ZTZJ+-H/3 M1N*7-J'-NR;3GA?BQ["J@'2IH$+]H^MF#7U$%#>(7+[U>SJ^H M@N_[:,J[3.+7;7RD#!3I(>1+AR=>^^L.M5UK,RI/.C"TF_NM7;P1W.0X5UYHH4NQHI9&,-V;9,/X98S5@/.E>-7B M<)(]AJ7B55W0-)^,398C2]\QVK46TTQE;O501I_XS0HQ#W.DRL*K+F^ZE%;?X5YT`;OJEVN$&BY<18><'-X72D M<'\4]]XVG@=*<$BMO4=U/ M'ZK8B97G&O93Q)8N%3CH`-O*[]OO-,!K)U.KWZ`.W@KFPPD\0%R\L#SV MY,9X2O`$>V*I&(T8T-D=#;!XLWKZ/O6&<1FRJ4MB_U/L M+\^;2B>YW^L.,8FZL4"3JZDL&-_)9:HP/!XPD4U;@%JQMK$`>79OJK$@UP?4 M+%!HUL:M@_3@1`1@('PQ"0F_O:G@QV@J_H[00D1QR-0"?8L[-W'TN(%VUQ&UL550)``/S44E.\U%)3G5X"P`!!"4.```$ M.0$``.U=W7/;-A)_[TS_!YWZ6[(SFW,@CN[W>O61H$I)Q MI0@5H&RK?_T!)"62$D`"$BF`"OK0).("W-^"W"\LEA]_?IOYK1>`"43!5?OL MY+3=`H&+/!A,K]J_/G1Z#_WAL/WS3]]^\_%OG4[K9O"I-VZ-`A\&H#7L_`)" M#-]:O[O`!]@)0>O1>4,!FBU;`S"!`0SIK*T[&/SQY!#P?8O]WVO1GWZ_'M^U MSD_.6JWG,)Q?=KNOKZ\GP)LZN(.BN4]<-.NV.IW5?7^+.;QL?3@Y.S_Y(7-E MC!:!=]DZS_S4Q\")[NQ1ENBET[.SSND/G;-WC^<7EV?O+L\__#=+C>9+#*?/ M8>OO[C\H\>G[#AN1@_I]:QBX)ZV>[[?&C)2TQH``_`*\DV0F/P'9HO(,R%4[ M@^OM"?LG"$^[=.Z+[HJP_>TWK9CX\HW`W(#7BQ7Y6??W7^X>W&T+,??_RQ&UW-4E,^O'!-GF7K?3>^&%,3>$FB>]XA-Q*D!)R6D(+] MJ[,BZ["?.F?GG8NSDS?BM7]B-_R(D0_&8-**.+X,EW-PU29P-O=!._GM&8/) M5=N9.6ZT.*# MS>70IS:,'K4P>6Z[C+0K-6MW7]['=.27AY`^H^P>H\DM#.CZ0L>_1R1Z<_J^ M0PB<0."I0Y"<]Y`@[AT,=E@,A.+9G MJYSAOD.>;WWT2H:!!S%PP[T8WIZM&H8_HQ"01[1>U_4MR;5#(!E-[C'5L_0% M9(O="[P'.`WH^1#%])YP%MX[2/W#W6H-?%1MY!&>.H$ M\*^(JSX*"&7`6[&8Y3CSYJ2#!Y"X/B(+#&H17.6\U2W,="'[STXP!80R>H,Q MPGV$V2-/>:WG$5.[<=UB2$5/7WLTFX.`1.LT!CXE\?J(A.3AF6K;:^;,W3O+ M:%0M@MF7E;I%=>/@@*X:N0\3PAYK]#W:U841;>IWK9K22=ZS]T?US0=U9&KX](V\8O``2'L(F*-RU;@')]#FJ@!?($>"#PR`*Y/U:/'W`L'>K4;I/(; MURV&!S!E?X[!'&'F/=2\Y#*WJQLRU9HS&"L-*F[J5C)&0,"\[IK1*]XY$82# M75E9"/(GJ\P,2YR\CT3D^'Z[E4R!8.PZ\%9-Z'IL@$U\D-O11TS:L`*= MM634..5-D/#KK?/'+'V@!VF5YC?^G$^>>S).7Y'?WI2X_>VF.WO_6=Z6HZWWD"_E5[ M^WJW=G[Z"\S29[=4DSG^?X"#;P)O0%4?AS4A:?UAR M_=Q$"HTE(ITGG\=._OJ!^%GVJ0"PXP^IZG[[%UB*^-JB.QA_U,-#P4-(W;Y3S5H7@; M@RDD].D*PL_.3/AJ;)+5S]T=F#I^?._>&^0IX$V*^GEZQ`Y[BA^6LR?DU$/8`OFJ?G9Z>G-+_ M*'7DTUZR``YX5^T0+T#Z(XWRJ+-YXT-A;MB.%-J'QD/C.Q(IPG\>"<(M=SV%^$/C(8KS'2G*'QN/ MDNN/KP&>G1X)P.+`+<6KR<'A9DDW47-#]A7,K>@@?4AUK>%6'GT3D""BR:_< M*G!5Q?.QFT\/UYLREBREW#D@FSCD*9+R@G2FCC./HS+@AV3URV9XEOS\):D< M(O?.DCTWB5;;B-5*B'PQ<`%\8-Y]!*,<]=X@F##16].Z@\P3]Z-TM M!2"@U\C]F-[_,PI<&ZI(4G_:,2Q;*WN+D]!+;5`EB)J'9RO"OX% MK*XOZ^!MR"K"II"&E^M'[N;-]1UW;V[ MW#+J4R"V+(5F#MFA1.8V/".?^I3)28MRMOG#3,12$DY)#]>,K=CD&9(=VF9# M7OHF1+39LSQ0^`YS8NS*V^;3&<%WRB!>/T8'B'B<. MS@BU^#V5&:D1$0U1A$Y"CD0/CV@.<+B\]UF[ M@L!C!G'.W'^Q/U@X1`>&,0AIH`6\U6GHGNLN9HOH&#CK-.1"$1*)@3KPK/<4 M[P1%]P6$6OGEU90+B/3P*>D#&^+U*ONYAGFVV^Q<@PG"X!$#ARSP,KHN#84W M5@W5]HE2]LN71Q0Z?L9D;'#$I]$ASQSV(I/.(3Q\O$,OA61> M":XRI.+ZH12J>;6XRE#SR=L4FGDUN,K0\K%3"LV\PMM=H14'NFO$[\RKQ%5& M7+B]ER(U[Y"1NO(1K:(N%T9O+:Z.M5+=*\@N7U%NV^038U5@5Z@P,/ED626/ M@2#A;O)ALRIP%Q7WF'P"K0KL@J)GDT^G50%[[]I&DP^W56P2S#[F5HD"**JE M-/GT6Q7@BZA-/AA7\5,N*!;1?E1.30(2OCJW$""%V0AUII`/V3P'EB)MA"Z3 M0+K?6854'HU0;W(K+SJ%M@9[W@A]II!CV"SL3I$>C=XJ7$]S@U.IPII\>E.F MWC9];X\(.@^>N;&V,CQA?7J*UMP(6QFMH`XNQ6IN1"V-5;"3GF+4%#YO]0@K M+[+)QP3YTI8C;!&F)I#-?=+4\)BKGN20R8=/*69-2JJT:TAQ99;!K4-D%E,E MKN66P:;K9Z[B5<_;Y$^0IAC-S5LJ)FA%_1U2J.:&[&I090I:4]3FAN_[YM^X MY8(I<'/C=#7@O+J^M.+A6%1Q85+Q0BXX-[&W4_[CDCH:B_@^>F4??[U%>(`6 M3^%DX6\7096T1U&:0W.3!"KQ$8X6QXO>EM77SP389$9J1A2WINLM:#R,X5_I MXRI&LC7""`1#0A;RW"?4QW)?P,L&4PVLP:VRIIAZ./H1V4V"BC<) MU"+2)E16RP'?Q7%N0C&U''JN&]V$FFDY>++^;1,JI7=!O.WY-J$X>G>D*]^X M"17.NZ/D?P_!X/IF.:A2Z<(F5#0KPRUX30TN7MX1YM8[:G!ULAQ$;@RCO<;- ME(H#;1M`PX!>!CT_!#B@CML+T+'3TT>$LL)J`\D#\L5Y]CR5GIT!QL,#P"_0 M+>C#G2/2Q2L! M]!>A,'TJHC9JATG3?@M3IG>(D%MJ/.(S&@LJJM$\.9]!XLJ/F"[J`7'S1A]6 M:BU@X.!E9#Q9D$E'4D5-^9O2MZGOCOHEJ-;N6VZL/E14^HE^O08! MM>S%:[I-K:DU>/0P)*P(.1#PF*70TP@S M.OLD$N'ZLD[>2KR4+3(M^UTT("`))Y$?+6Z&RB75S?/*I99C.TNMA7,0V=-/ M5'UCQZ?>=<^;T7".K3\+M(I5JN1@N\M[/+N\_P9P^LRV45[HDD_!YP5+N8PF MB7LM6Q>@.HM!2+>8*]&IRM.8C+4H4E2;0U\FL"SKD$]YYC,IVD_4U8(OD]-J M0@<&%8"RYJT)_1A4<&^%1$UHL*`&4"H&;T*K!178N3"H"=T5RO*DN8/I_+QD M$[;T]X&Y3F3JW]'_^AI6BB+CG!$117=-J)U2!9B&W$VHC9)!ER9FM)=#V5K' M:O?KMY?_>.J%Q&[!\10*U;H7=3P%1L*MF>,I+MK8A3B>DB*Q9ZB]KJ@RC.JI M,NV-M4RIJ=*QJ+MF-G=9\LT8SN#68C6*19P>5^U#IJT&CWVLYM9'KV1(.<>` MPM?1;<'[WR+)[3RB,:!FWX71)V92V_&(&*?W&+U`BOIZ^2MAQT$2AX(NGAO" ME[C/5''>OI9;::FRB[XRQ,487=+%$WN8F.M&_QJG[)C(`B]I]I$5WP`2%M$L M2JOL]IY6ERRH35:'U_Y<4(TKJG04T]O:N,IKXP!A_<_*:N(2*C5.!1_(W'S'A\%&3_&D MT?0Z39!\TBKWZ80IHZO:C M*#?&#!2I7\?]6F4I(M%XP]!E.['N#)$WB1DXD^__K5X4[G<`I?%*3684[N23 MCFKXXD$Z*[L+C6Z&Q-9TK[.IO-"4$P0)I*HP@=GX2G38#A,9A#<-<'=<3]X$ M9N/;;3V+)C((+R=UI(:3-X'9^'9;3]-R;,TX0Y.DQ4;XWL%A\H_,YYJ2P(]0 MOV4Q`]Z9"(?B+%JZU3G+*%EPBS!]=%P`O"BED%3/R2I-U5ET(F5[#.P5";PR M-%E*O1ROK6Q4ZE#*]@:Y3MX?49)D4TMP20\W`EOTG-,'G^K:<'GO.T'(JE'H MI?E,W*-5=18CD.X-TC!\&67%>K2P9G"C2?:+BR)X M"8>4#B4HD0)JPHFF0\E(^1"8N<6D!Q29[+Y6$SYK:X#8N!MF3?@R8U5%6+DR M;M444_H1*H-/5-<@J((JGU0DYAYA4=X>+WZ9>#4% M5(P_OTF="L#TN)_$,6]5C MJ2!TQ55?W\'RW4L4\DWCRU.Y33CG6(TTQ`G%)AR$K/Z)D$J&-^$H9?6B$63/ MFW#FLB)A"+=9M9^]U""#S.9X$XXB5@-?I0I0]1RB05*1J!+C/10RN[_:&X;H MDTK9[G\3NC+5))KR1+/!GV2J5B;2!59-Z,M2C6A4:G6;T,EE]UI.J?X>C7M3 M%('7LT/1A#Z=E3TXTJ72VKMXVOY>E7<%VOW5.#?79]L+?:$]2M&;ZY;MA;XP M!DK1FVM6)+N_%72%2%&:J_SE46;QF.L%22IPV2JQ-"-O;KY2?@GWVQQ/9:$I M0?DU]P)3K&OD]1B/#^D#O,!3@,X@2Y+\\0;K?2UO4<^=.E+^TA9N?:1^X>.EE][\9OP MLU&-N]>4Q]*@Z+@.O']59>]V;][&X(=S\/93P-K=`E.<.U/L_PA/G2`Y<=%' M`:%+YJT6-;O&ZWWC[.#4?:_`)[#VL,;/95:]RGP+5?EMK.]@?0?K.QR-[U"] M&K+^A&'^1.K]]9^=8!J58M]@C'`?8=8FG!7@:4T@J#'(UZ9J<]@4@8DND37S MULQ;,U^+F5=4L=:&&V;#4T]K-,EV&Q@#GY)X4=UXVH]@70^ITZKORS)?G>X[ MJ[7\UO);RV\M_U=C^?=6P]87,,P7V/Q>H58K+V:&KQ3%]-8R6\ML+;.US%^- M92Y0G=;F&F9S/R'DO4+?/^+M]=UU;I%P^`JX:(2UO-;R6LMK+6^-EK=085G; M:YCMO5X0NIB$]-'LB5YEMZ[4#.]1^2['&5\52@ZV8;$USM8X6^/\U1AG6:5J M[;1A=EK0=,>&S+RTN;RL!'ET^0FLS;8VV]IL:[/K3&4KJ#-KMPVSV]D^O4=G MHH_+A/&7BF\9^+36\%K#:PWOT1A>@4*P-M8P&[MN3F.C88["+90.7_T6#K'N M@C6\UO!:PUNCX2U66=;^&F9_LU7PZR]-#(#K.QAX[*@[^ZC9;@:9,10IM-,/ M%Z>1.HN^CZ5VQ[RJVV$"NTUL#;`UP-8`'[T!WD6Y6G-LF#E^B!_`,9BSC\L' MTR..BH_,H$DLG,!J2(RT)MJ::&NB&V^BE92%M8^FLU@O']//:D^BKK& M@,#-?1M`:]FU(H=\%:DXB8VOC71'K/&VQML:[UJ^&J.H9*T=%]OQCUUVBR>' M`/J/_P-02P,$%`````@`O&@//QU0N$1P'```D7$!`!4`'`!A;6%C+3(P,3$P M-C,P7VQA8BYX;6Q55`D``_-124[S44E.=7@+``$$)0X```0Y`0``U9WKD^(V MML"_;]7^#[I]4[63*NC'O#*93;)%`SU#7098H+/)3=U*N6U!>]?8K&5ZNO>O MOY)L@VWT,@\=Y\,D#1S)Y^C\CIZ6],/?GEL(Q\:/PQXN;R^L+A$,W\OQP M^>/%_:S=F74'@XN__?3G/_WP7^TVZO<^=:9H'`9^B-&@_04GL?^,?G%Q@&,G MP6CN/$=AM'I!0^4-0H])LOYX=?7U MZ]=+["V=N!WQ?"_=:'6%VNW\F3^GVGU$[R]O7E]^*/PRC3:A]Q&]+GS5C;&3 M4&GD477H3]O/WX^OW_%J6C]4OL+Q\3],K]E@I?OVNS M%"4S6V@0NI>H$P1HRD0)FF*"XR?L768Y!9F1B)9E2'Z\*-CU_!`'EU&\O*)Y MO[G*!2_^_">4"G]\)GXIP="'6(HCC*Y;^*L1+ZD"//>%#FSXD?<)_ M9U]?("9T/QUL<^$Y;,C5AK27CK-.,PD8A'E6%U>I>OQ+QF5)0?R9Y+1SRP#/,56;D7>$@V1K13NF]R8W/ MOOZ]X[H4_(2&:/?1"9>8=$*O'\=1W(WB&+O,QV1.#;JE.OPK5X";_>/%87E< M;:UDN93LC#&)-K&+:Q4/+!\5@'-A558.&S?SRY^FF(7APG:984F M,:V6-C2"5O0'\D.J0B8`KJ"8Y1,G!?G(<#=#=4M3-0^KPK;IZZB@02O7!BM4^D&X"0I9P$W(A,A M`6&QZC\QC48X,<-$F`0`%I$>.F3B;1KT*L0)BA;("8+H*VO=T2**D1=M'I+% M)D!.GH2*?//VW9O6A^MKY(0>^_"Z=7U]_6T3N%.Y3T2?M,R`&(PWV!OZSH,? M^(F/B19`B;Q=^L1*R-%C\@@_KW%(,'3CIR[P"C(*0P%YF5(=1M18$U8JLO8Y M*2L@8Z3;G=[W>VC:'\T[0S2^'0X^=>:#\:@!L(A+6P"*P%(02#S/9YTP)Y@X MOC<(N\[:3QRIER32-D$1JR!#92M-NS^^1X>FR$T3@+*B+O02+0IS87CYYX8D M?%PRCVCS2(WU>>LX"-UHA8<1H=]W'?)(QS!//AVBWK[<$TP5'Z_9G`L=!W1H MI_^)5Y"=!Y+$CBNMD\[Q**NDGEY_*>;;1Z$D8MVV]&&(==I\_CCV/?ODT@>B M=?9$]/""HOQIM`^7/^XC;'2<#[%R:)W)/R!QF7?+[Z*XEW7*]WNQF@YCK3QL M1E(=QP^5T9/+("8$P86T^)C/Q6:`U$.$X(3(XCC]T6;-P9\H M<>I\S(8/G=FL/Y^)7'JT9DE$NVK#S4AV--UXLL"UEG3]=S M:XA[E1VE?4/@W*WIPI1DK#M;W069L^H`93(H30%9[YQ&6[NT:!4VI4 M-U5EH:C5U%3=^RF;<&M,@R0I8BD1X/77K4-\,EY,J!.I.OSEAD[HS?QEZ"]\ MUZ$:;M=*)U'@NW18J5L7/RI+BYP=HZ<$QT\XI*-PT&F\4SBTB.O1I01"]8;X M(2:DX_Y[XQ,^5]F-N([4!OH7\3T^6T)M2>X8BCLK1)]1%ZFBU_ MH39R=IF#-K^G\',)]F,+[P\#NW;Q[=A_Y=)?S3K4^H[W;_?#V8# MZ$6]$_G[:.X;L%"8Z]V-5@]^R!7L^<0-(K*)L;:?8I88`&2U1M):>NN[)M!I MYA(1A`;60[#&%ETD?N,_6>2$/4\V(*(_G67XOL:Q'WG]T%,-X36*M1!-SU[& MFO#,SJCG+''BY"A-;_'2#T.V`JG4UU98%>DK!LW6#JB0N`NBKZPEH'\.PB=, M^!)DZ-W1"`[=TG+D+I@U,Q!'9VLY%(_15<+@['XR&?:_I.\2S;J?^[W[81^- M[]!H/.IV9I_18/1S?S8?C#ZASJB'[@:CSJC+/W7G@Y]I%Z4_`UTN/Q495=2/ M+FJH,$EKD$'HQM@AN(?3_RN@DB2PC+98"PFT(YR@7!2]RH6_17Z(SM8L:6>5 M;5AA,ZK4(%7C16$Y2"1$JY6?OMU"HW8[Q&"31C+W*5+8C`6Y&K)>Q/C+E\&< MU>`S7D5WQR-67;/)ZN&@)Q3`/3BSM"!BDM,RC M1AT%A%&("$O:0FLG1D\L%31^AEZI,F=2!L"@<45(9Y,\1K'_G]VF7+E']U+` M@%55PP@H9RO>$*)DQ2\A26AT(P@:$+(QIR>3AB0G5<&(&I^+-HJ8 MO[EIO;]^D_W`1HO\&`S6XZ(_WGQH77^H_'C=$/)*[I,@MRL_&-9(,EY\BB*/ MS*)`7AN5I:R25GJT%#22[D5>QY&W<>G?A`K#4B`LV#($^Z;!,3##\9/O*F8+ M2D+6"@6K#[")1L@R*`G]21[<+6K2+(Q"U3(=)! MR0=K,O($Z%6Z[^M;V-E\3CX9;Q4%* M44M;?&3/E\&1O?2W]TI9UO`U*:"E*7;&AW;X7C'EY'Q$^( M]G4H10*;]8E4"^G[T;/Y^$M_BGK]R7@V@'U%6E_HI8I$;2L$-3V\P%0#;XJ? M<*A[850B;)$6L0824G)AE$FW\ET69UFV>\+Q0T2P:N'N,.WC5!H2>TTT*A7-C1EA_7HMY>H`@T"HE(ZM_UY].^STT&'5I38KFG5^V"WB_ M'A<;!@'R^ZT8H-U;E"TW1NB@_B^3+#+3MS>N*\I"?2:-ZD.#97FS@> MIZKZ/!?VUC`[NX5/G;=Y#JCX$%!X3^/Y$N`G*,MZ0>"L')>C??W^S34'FWU3 M4J3GL^.10H_TL!O09WLT]-AI93*&#\C@Q+AZD;M9Y7LLC]9.5JEN\V`+$=M< M4)X-KVA91N@WEA7B>?W?6<:`HO`\H9U9.HA8.QQ&%E8'EL%I(BAC,/\_I:%/ MZ[/D91#2"FV5MF'B>??ZZ:W'3PWE9%AE25$;;?_D\_4\'U3("/V69V4[>AID MI9U`.X#979S5+:WS+V'DJJ2SY>D;W'?TN^JBIUK6TB*&5`$=6MDR1IH"\210 MJQC:`L^7,=3&VB:#K:.8<;&3!*%B^WA#)OC25H.(V"MH,0]E,^W14*BIAGZ( M!PE>J9`0BEOF0J2##HY2JS/DER>Q9"#MCFGQ5T&1VFV/EDF^CU>R*BZ6L\Q' MZ>$Z,+(F!'HM7%G`51#V#;1'P)QFJRA[_K-E?[-GZMS,9*!]6RRZJDNW-D#, MY_6=F.U5)_D6!,V[45)QBS-P,AT4VS*SM80UCM,W:4%?BM(5>7&&3&EK$WAA MIWRYAHY*90%)X0I(,,EE6:N`N'0+<7FHUQCJ*"]5%(KI$A8JH'=6-8'FGA]L MY*OG,FE`HC,5:C"=I6@*U6H#%,I"D5U!1,5VT;8FT*U;A9/+`Q*NFZ_?9[Q) MM"B7O]2FGK]?S^[_+NEGGWIH3*?9S+H-RX%-I(7%F#>O=\W MQ))'7[IT4!$[P2#T\//_X!=9(>_)V?1P]>$J3[^@3!AQ:43%03TN*^"2YX4& M6B.@NN=SO$G8+=;L:G&Y1U2)[+*AT$0#2KHE?DN%8%N(2N&5/5RPPI8O[_P`QUTGP?K;: M[SM9Q(1A'2\NV[+G!<:!C`G_O:'*?,')(SO=C1V$R-^IDPW&)-(VQX-B%61T M<&F4BJ."/-A\1RWU=Q+LJ(?`7_ELOW>0;4=X06ZT6CLA2#5G"%!I?*NPO4'L MFQ_X5B,#^`@Q/^A-&C2H\-+GV=_J/#R8S"TMQ][6$JZ'E1H$Q^S,I*]^(//_ M]F>+S.7/E%U?EOT,B4FUU(K.+ZD/Z5+SOJ8J!8#CS?M8>8JF=1X/MZ0)5!OV M_W1&0K"?'D0UC`BYHZ:EARUO_'`Y7F=70Y%;O(ABG,K-G6=,^L^T>Q3%GA\Z M\0M_V95MPJ+)G'TY!/V MVC3;DYK]QA\#GX3!'-"^DR:>L!MZ>" MNDG9B@-OA#4L]7U\Q/;"`4-;&O/!E3*)=73$>JCYH6F:-L`ZP)@F]ZC40.T' MA,)PT*C`A!WYH/-9)@7!?OIHV3FD[,["26?00[W[*;NG$@.M@[L23%+<2D8#`H&=E)R[ M.EFVML^F.8'.$@SGCY@/BMQ'^BU&WB9FQY/1M"C&:[9,0C^EER:S(1+[WEDN M8SY28VM'5`5V4I23:8/6J3KL"Z8/POE)]>R`F(BOEP8[G=B6S0U?''W8)"B, M$IK>]R[MGHASOK+M5$JEI2@6L/-Q3AAEVV-S3E6D0`VG1/EG;JWS`]:"!(E))6L'F[X8>[=@/TO)K: M?E*CIRJ/AF%8&'0//)4]N>*[BXK` M%V@,F#(*FIW9,,%1WI\QPDG_V0TV[-`+S=X(HZ16`T6OC^GN'/2*K<:D2RK" M33KLMV^^:]V\?MMZ]_T;7N%_\[[UX?W;UOMWWPG7/NVA:>[1,J"&Q0>$*7]M M-6M9Y`24I.S"5WRTG#,NE?<4@#D1%6D%B3VC(+VO?+FF(`+@]Z->JYGWI_W9 MO`DPR-^GJ9@)@T$V(4BK)JD["B)6,=@]5S>=V4)9VQ)&83L?'_!%?MB]GZ+B M+3-0L1&6`=U%MR))$")T%[V6]Z\W8G.ZHI3%1)SJVE;3;9-8`,]D)/7YPY&,4>#@FZ3X?O2/$ MR6#H%>IB2@KJC'IH]KDS[7\>#WO]Z>POJ/_W^Z,O7S\!Z_;,`H@,)7:2<)$7 M2!-C2+,6:)R\03&E6?_[H^.G6@:L533`.':5HPN!(`QB7>788LYJ2I3)H$(R M\'KYA'H#D-^5#XHD-C:#9O/JM)H`E&Y-E=F]GT[[HWFQY09]7T)?[FI@X*O! M*%S.<;SJX8=$4P\*)&VBLO]X&2/EB38V_Q;0Q.V$ID8>30X*C+R\2Z1(K(5& M1#L7)Q$&`D4[(S<#G:M6E+V/F9--TI\%& M=W*`6!8(&MWV^N&V,NDUJ#)1[J67FP=!!@VRKD,>^89<#WNW+_>$'1]YYX=. MZ+)76-W$?U)-`-;(P")#YEHI[M1D.2"6$`U"M$V*=FEANO-PMMF*I?I0%@.L M9ODT.^HT0X<#,FID%.J&&HS6NR#Z2A`[T$D(+.C8XW"''D8N^%A%HFIZO-81 M[88H`WAB!5J9UJW;I$UM-RS8!AR%"B@-HD]6/LV.NL/:#55&C8S"FNV&"-@F MMAL&#CV,W*:V&[LM

V&Z(,X(D5:*6K6_,LT,,+VB9O:MMAR3[@:%3`:1"% MLC)J=O0=UGZH,FID--9L/T3`-K'],'#H8>0VH?W8'>XK=W]!QBYWNPJK)SZ,JGOZ&VLC9Y4'0%7(\C__M!&B97[#21IT5CGW7 M"=$7[/D4FA"["3LP4GA.GC4R#W-YB=T#"O4D!TN.H@23>93-*3G!]I1K69-O MFLKVL9!ZE62U&TO(;J3;)MV=54XTAY6?)=#@S+%RR*(Y<=LS%`T+`Z*Z'\=+ M)\RVHW9IS14%OL<_=$)O0HG(D1TO!-J;G]]^\L=8;#!.K;L$_"DFFX!=.;E` MNZM9()N%MFS?OTBWL;Z^_:[V_>0>Z@5WICQ*!TK)H#$::R0MU&FBL-,W]>/ZY/T6= MV:P_!]TI9%3P6F[@FW.F53J*5#DID[#-1OI8944S.,%P((([:IIL/AN7Q7K1D1Z1*94'`3DL@ZRD^A2\73_B!.BQ?8%0)>E M`L?[7$;8AUY,D)A\@=60^,\C/H,>XWKWVQHG!P@/G4YZTG;"3;S8MA%VV@XR M4TY%06=44(T(0M[)H[V^-8Z3EPEU6]()/:;U>B6?Z:N;"V1(JE63=O37$?$I ML2'"N6A38N^L!H$%F1F'RE@S*)A&A-S1T=;,0*N+)#\XT_.3#=6,7S"Y\)_9 M0;)-F":P9Q18P!T7:PT,LS@[8)V?G#)QXG',E]2\GYU@@R56C M3@2&6E434\2<;8KF,"9SA9PMH?5-86I`R*863UD"8)92+4PY\KETTQ@J%[V. MGX+%36%GO$E(XH3L'8<:KBNF`J:HH(HI2M$N2=-X$KA#!U6U`.#)XJVOD0M3 M23""^.--J?GF\OIFUV%B;T!O6X,6NFE=7U^S?XAPI_R5'52.LTHKO=JHB="5 M/"4';5=.0'"Q527A!4GJ@[9,4MJ%3Z?.'_FRK!I^JJ!F5"J`Z*DNO8*ZXNH/ M>`&4[KJG1ESN5'S3@?77'&K6>%$\]DGJ$&U"JWCHM)%"DR9$S'<-.N[/W"]E MI(R*`1JTPILVO/8S/\"K;BY`"!JHIE\D=)2;T)H"9PU?RD@U+2UH;'GG<+SF MQ=]_QK'K$\4\A"X=$)I"9725XV;-5LPR:<8F'R2@:-TH%)7^D<$G+P\@W,0+ M"O+[K)1)[$(FU4/"U]W@EWXOVQZ`7HWVKU/T\#K&KI]>I\@&`<7[%4%WH)@X MJH*I1!ET\J;I$RF0[2;7?KXGMLNMZ=A;75\QI@"W\=.47T ME1;#8)\X?HB]OA.'M)=!.KL:IX<7ONO+`T";T&HHZ+21,I4F1#A+"4N2J3/* M3!G9#D/7$PXWTA',]F>KI*3/E/*0_@QSQHNA9#:!LW$#,=/OHL-L2A*`Y%14$$"1R[1%"X$12Q#HVH<"!UX MR7KDM&O.QM/ATORL%Y.4-JG1JR,EB*=$VZ2@*)G[HX25H?4PB`4TS^4G'.+8 M"3JAU_%6?NBSIC+QGW"V`"IUJU%BJZ"9:"1EC2=NH66:/)W+*F6P7>R&Q;". MS\HD&ATZ5T9(+H-R:*N"S(^7KZ$BYA(380 M%(GQ@IT\S(]8U@RSE4D@,!'HH06&W6>W.U,:]G#&.KX08B0K`&"@M@??3:)T M8=\<+'E2&,"D^IB`MCL/-$_=/."TOI*`IRX84`#G[.!>G6M3(0BH^)/U#1L7 M:P8EI0(5\K"S"<;SU0O5I3[8$[1*0/7IREO`>1\R$_\+2A/`K&:<27%[',OP M*+,L-+(9/&L;4&D"4+YUC>7GSK3_>3SL]:)7_COQMX3I07%2:"0:OJ@4@6A!YXD1%VI*C7H.VQJPO%R+ M2'5TR4H()-`VZW7`>SY.D`_!!B'5;^68C'<,4]L,-C.59$C>3R;#_I?^:-X9 MHMY@UAV.9_?3/AK?H6YG]AG=#@J^`U?5>"LD8IG>2N M$!Z_A^)96S?`U)50-DY3(\C[IS@))BZ]WLT2TUI$W&+S4]UEO+MN^GNY+AVP[ M%85<;"=E)H)SH3K60"`(187J4(,A)@0E%3*PIJYA1J9P,?BE+==+'H9+$8;F/1C5:K M*,Q;AL(Y/:`S#8>ZU@!C==DUF>-;A_CND:"D>3208*[8:9H2GE7#&I):]DH- M:%KXE8@\)/9VI9`BF1D]I/G1S_03_>/!(9A^^']02P,$%`````@`O&@//W1F MSA5'%```6HD!`!4`'`!A;6%C+3(P,3$P-C,P7W!R92YX;6Q55`D``_-124[S M44E.=7@+``$$)0X```0Y`0``[5U;<]LV%G[O3/^#UGW9G:DL7])LDDG:D24[ MHUDW]LANM[LO&9J$9&PI0@4H7_KK%R`ID10!$J!$`631AR81`?!\!R#PX>"< M@X\_O2S\WA/`!*+@T]'I\#>:3(Y^^O';;S[^K=_O M78X_#Z>]F\"'`>A-^C^#$,.7WF\N\`%V0M"[=UY0@!:OO5L,"`A")Z3M]JYA M\/N#0\#W/?9_KT=_^NUB>MT[.S[M]1[#V^/3L^-WF2=3M`J\#[VSS$\C#.(W>U0H^NCD]+1_\JY_^N;^ M[/S#Z9L/9V__FRV-EJ\8SA_#WM_=?]#")S_T68TU6A`/AUE<+T\8/\8X?F`MGT^6!<\^O:;7ESXPPN!N0K/ MY^OBIX/??KZ^,?#`%LUXDPX?P=0D^'1&X6/K@ M*/GM$8/9IR-GX;B1ND_>GI^P^M^-D;M:T+&S_M,)O,L@A.'K))@AO(BD/^JQ M]G^93G(P6%L.'8EA-'C"9"P.6-&!5*N#766?TII?[^BP!^P=-[,K&-`>@XY_ MBPADKQCY#B%P!H&G#D&RW4."N'4PJ-$9"HV'CR"$M*']PZ(?-%J`H1\"'-#N M?P([X2BVMG>!1PYYO/+1,YD$'L3`#7<2N-C:?@3^@D)`[M&F7S>O)!<.@>1F MEET:AH%W!^0N#XB*PP:4=S>96M:F6E'CAZ=8`X(%?02 M8X1'"+,A3V5M9HBIO;AI-:2JIY\]6BQ!0*)^F@*?%O%&B(3D[I'.MA>,GMTZ MKU&M1A2SJRA-J^K2P0'M-7(+<"1&(TH0OZ1I>)\1\IZA[S<\492]IO%59D4H M7R>$CJX'&$2#JV&TDF]L?.C^L:)TEF[)'I$W"9X`"0^Q)BB\M6D%7*-@?@_P M8@P>PD:P\E_0-*R86=*==<,]6?J>0RY18_@$/1!X9`QO0_IJC[W^RG?FZ^9\YP'XGXZ*SP>-RS-: M868&N*(]XOC_`0Z^#+PQ[4*.:,*B:E(6AS#[Y:M,]PP?2(@=MC//":=>OWF] MKL6(M46I*$3>%?V-I%,#F-")IDQ0;O'#21OW MH_ASXI<[G'SWM-D2L:+'S4L3?:/,!.0\^#QQ\L\/),_KB"H`._Z$+C8O_P*O M(KD*Y0XF'UU;47`7TH4SVN*2FU7(3B_8P9)8V+)*AY)\C!8.#(0R)H\/)P!W!TI$S_.^HMZ1J":4.?CLZ.>BM"945+UIJC M!ZWLJKT&EU^34FRG'<"VQ?A3<&<=`"<@.RG(\PZ!+'#D%.:;SL',;5E2H#]T M`.C6:I&">]L!<'SRD&+\9V[DQ%QX@GU:?DRNM^.JO?5QL&VH;]I\ M+^F>5WNK.7/(0Z3B%>G/'6<9[S>!'Y+U+]L;S^3GKXDW"KEU7ME(2N;MK5UH M1>'Z6^3=Y9X"%\`G)LT7$,I)SZVB"0->`>\:.@_0C[[F2@""\AJEG]+W?T&! M*R/Y5EDM4GL>C"<#=GH["4;.$H;.MMFEJK06R0D!X;;%:NNA/KD$IUN"0OKD MK/C"NSD-W3]6,%G6UF?F(7,'A1X+`F'<(;QR(/[5\5<5 M:\U.3;9&!Y4SYZZMZM`$:9%)[-`A$K6DABX$R0XLZN02L7/%M,BZ M(B%:`#P&2\9R2>4P+ZF@0_XQF`'Z=DI8GD!0-5,)"NN4^]YYB1>'#%>D9+>R M&^3K&X&NDO*7U>C*H7%]?0K\+S:]F(I:*[91T=SBBU_#N5J:D1$=VB"$E"KH@>&=$2X/#UUF& M*0CI1@MXZPC;H>NN%JLHM)AN$Z$+14@D*NK`LSE3O!:$$Y04U"HOYPRT8N*4 MJJH5$R\"0%!(CYR2O-X0)J_,W0UCZT5Q+L`,87"/@4-6^#5Z+@V%5WCS(LE7Z*P1=JXM)R;Z&@M#Z^< M.*0H3?2TED=9L1E(89KH::TZ5K-X$H?J9&MP'7^+0EDB04(VGT0E#=>$P&R1 M54A\T)FJPT07;&50Y9Y5*5@3?;&5P>8-VRDX$WVPE<'E=Y8I.!,=K^N"*S<$ M;#"_,='151ESZ0%HBM5$'VSU:4C4DV>=6G,:=W;6T\VJ1S'9GB\[.C`[`'$? MZ!5<.`J!BMQO(@*QVFRQXB\BVC8-`CKP0N;2WD$]BHY#S`Y[W`?R,NX)9N=ISD/H#O[']J=ICEGE<63L!E1QC%7J:0,F]9LR,X]P&_K+39P9U[ M_DH$+D&%<,_N?CH2.Q6NJTBJHI9,I@J6H>U8P12KR683-:R[1;2D&FG)%"G7 M^Z)HQ0W`'1$"G9K_2\=`M8XV2\U?>S"SC$Y[. M&B8;-Y3!\P":?-ZG#%`81Y'B?=/1N4)95P)OSU13)MLEI-$*O"M2E&\[.2^* M7=**EGW.CNK,Y%E!#IO\OBM%;;(=4L5I+[^#SCO&M>/4@N_.U](L0=6@RH:V MZ4F"Y#T%MPZ-B_[NZ9=H\MJC;L#+!XNG*$TV@"O:^D7)7%*P)EM?U,#*^*^G MN$VVQ.QJC.7ZTJ;0WW>46ZDHC>,/+0:_#&LV^ MJ4<-/Y=%ML-970Z@+,%KAXMZ';G?6\L)X7;;C/:!+0QV#H MAP`']$U/0,>AT0@1*@IS-"5WR!>;[/.E]!PR,!GN`'Z";LG5`[E"NN1D+FQ) M?H6J^UV$Q;7D-4\\)-8,I4)V87$39+]P"'0E!8_+FB#U&/JK4&@9%I6V1V?Q M9'J-"+FB*TD<<+2BJKI9)L%&)/9]BFX25:&"Q"`F3#5 MJJBTIGLOD"PO1S$N@N7T9;%N]8!H&,V1)ZLA9'X8ZY2M8CHJ%--R8$>W,B21)-H!B#-7`@;1I>YLBU@^I4I6MD?OW3FF_C>`\T=VO/=$NWP.OJP6#P#?S)*- M@:RSAFHK!B$M"%E15)`7MD;MR'>B!E'*CE#(?-*UF!H5G>5V4W)Y4EJLF2HK MF"OM>>\]W.^K-*;)\Y#I*M'MOA]>F M*L34J-(.KTP9?*GQK>"(V;GH8AEWFJ+.NN38)Z8Z7?+H:_2(L>`)^)?\3(1G M7@7_P MWO!W-B%D@TH5GP85LD\0DO<7H"5+4%Z^_$!;5EU!,VOEN")_B)(GEQUR-O$J+.VUT M4R`78_3(0)F^GFF3B@UQML6@?XVM[:PC`R^)@\AVZA@2UT=D5>GDNW.SNG1! MZ2!DAPXN"V4!8Q#_68)24$&'_&-`9T47QNM/()/RI:R&=0_>7#1P,UM'1O^Q MHNN`R-%:7-ZZYN[=P140EH2RRK$U*:4FJ>#Z[NUO?!)LW="17-FP,6@EEV3F MKD'*B;NW9C7UA$#N-'6"N'NJJYJ!:>M>"FE`V_7,0+/.>E`&R*O$3-P)C<*KS\4[LW"TGBE&C,*=W)-M!J^N)+.\(S2 M13=3Q`9F;&SOO`TS9Q,DT*I"`V;CJYC#:C1D$-YT@UNS/WD-F(VO7G^6-600 M7HY!2PTGKP&S\=7K3],L?^T(A$O,8C?XUL%A\H_,U8?)QH]0WK):`.]4A$.Q M%2UY0)W7R%APA3`=.BX`7F122'Q792=-U59T(F4G)^P3";PJ--F2>B7>K+*1 M4TZEV%O%=8"S"55U1-Y[,G!R-+/DMC6HKNI%&Z7F\E;8O0)BVL)JDTB.(`W0@MFUBD[T!(4ML'+2GG# M-WX/\OG"BU5L`':)G*OETH]DD)KU6\O>&EYQY MMR-.\E"J$DVD[;A._E!:4HY$[6B\Y0'U+7N\5[CGWBI.X>2P'?<^[\L?+1?_ MH&IM2^\E-#H_1`.J*G%Y2I5B64"#U9Z:CTFJU;)XAFYJM<3)B*EV?XZ/J9)-#NJMKREQ"P47 MPE05-<)VC0Y+ZFC^B?I.+OF;;*H/`]IQM\M^]"$V2LL%;K=X0M[_@)(ZC6G' M73/[5X[@`*<=@=Y[4H?PK+\0\&T_MG(%9MP[Y`*,__*Z4W&"W2FXN`79*>H[ M6/)&HXSCA%PRI>X-TEU56N5U(Y=.T.I5VE-++O&@5:BJ2V4A:YC5J\(J5:'2 M=W^E54KQB$J8>,KD8Y7]0&_F%+`=6;WW-GBD(S,*.;\[]CE*YWFK/Z+.VG_E M>9UE(,7?_NO/ZVS64OPFS\F2&45+\K>D.,LX4-=GB#@'4:J+&K/E,E(P?1T. MNZ*1KV=9G=0XDXEUHQE\MF-_##8S9.X$23CD"`6$#DAO/62S(WCC%92MG.YR]T"Y+-WXJ]*- MO8]!/@'8^VLL-;/4S-`ES5(S+C7;_TQCZ9J!H+I+U]*MP^C1">91)-4EQ@B/ M$&;7SS#_=:WF+S4!^_@I35L,3&$AM+;"RQZ3*Q*9TQ"]2F M,UE>+2WJ&"VZ6!$*A9`16CS0I^S5>V5(.\3;R4G&7P/TBKM9V.6UUA>8WF-Y35B7E,^9UKKCJ5&+:%& MV8C&S:VH8^#Z5%L>2[KE0*\F5Q*LHFIOY"RH:@U8UR#+C2PWLMS(HS0HL%C#W2*`T?H2@]*`CHL;VF2@:`.0),^#MC;'AP"Z#_^#U!+`P04````"`"\ M:`\_YO[#M5@'``##-```$0`<`&%M86,M,C`Q,3`V,S`N>'-D550)``/S44E. M\U%)3G5X"P`!!"4.```$.0$``.U:;8_B-A#^7NG^@\NG5KJ0S;[U%NU>Q0*[ M16*7%7#MJ5].)C%@U=C4=G:AO[YC)X$`V5P2]J2KRA=(XGG&,_-,_):Y_G4Y M9^B92$4%OZEY]9,:(MP7`>73F]JGH=,7.@FF6#K"JJO[8NXBQTFZ^CTRJH$NZ]YI_4.J92!"'C30:>I12Q*L M01H%8`4TG7B><_+!\OEG6EHL5I).9QK]Y/\,PB<7CD%L>?<> M=;E?1TW&T,"(*C0@BLAG$M1C3 M_8`BV<9R+!G=0I@G">;,I5QIS'V2@H!%?^4@3+.)=+J3/4ALEG=U=>7:UI1T MJ)PIQHNU_`2KL96.&]PHHIYSYFVC]&I!5";,MF3C\!S[6Z:9!QA22-LD,)B3 MR[.3%((+SL-Y=@0"+5W3F0M"#D@12?TT].NX/8R1"?0:E@[VA1LUIJ1]R$WB-)93HA_QG*@%]DG1N,,; M/2=(&9U0$M00UO#FCT--M@1"OA'Y:+1<8\Z%MJ^FO3=/ M%@O*)R*^A0VV"]2=WE,-H M1S%[$LH:TV)8J3C/#'$#`'PI",CG[PQ(6RN"ZU;_L=UY'';:YFK8[W7;S1'< MW#9[S<=6!PU_ZW1&PR.-A]+XA"6(S(BFH*@TIQ;]%6+/JQ"+?MHR[.45TT>#.F4PYCI8ZZ;OEUYPC[N23#J4]!#EOJ6"?^O%.W?J(/\A/G% M+)VH\IE0H21P6R MX\T[S<^8#[L9`WMQV'`H)":HOS!'#R"GCOE3)7\V[W%KAOF4**"P(Z60+2'- MZ&\B6RXYRFG,9_YJGWG?3#.;/M"3!#]#[D>='Y.@2A)L0@SSOY@O"%?6M0&! MX)"@)916PQFLEF_->=X37EE4N;0XM(_<1/%.=A,EE2&P(X<5"NAPK&J4[OV8 M+U7RI8,EA\BJ)R(M9>4RX75T/L?>+L>)(@2:D%5UI+,*G?="!"^4L:K+@3Q\ M/J6G>VO!6-61R$K;@E!13I2"$6Y,N?6J*J<%5>73>[8_*O\=TNB$Y\API9$7 MXJ=7#T3/1-"U!_X'+>1+J,MG^GR7Z8TV1#GJT3F%21[^\9@R03 M>KE+*.RAGJGYW&[7RI%F\S&?'/=3!^^GVO29!H0'JDU\!DO4P)R18!I4WSU] M76,^_7L'<&N%1[:KL#TD4_,_(`LAS8:SZAM=1$\^LWL'9;%*M-9Y9+@*P[!8 M@?5+=+K%@Y:PYPJ$FU/OJF275)G/^]XQ64J[K4[8TO\_R`'S8RJB!F2";+%3 MPY3ZW-04G2\8J<7/L/0-/K],REU(L8"$@<"YB=I$P1YZNR[+9M5._&*K$@TS M228W-9.53E)_\P40]>6<)2*::M-+:Z,'&47J/<*,U=SOU_-M&@LX#H`,Q]MK M-?\1OQD>$U;099#-<+EG-/Q'O-U]S0LX#9`,I],?CK)\OW;3M6-PMUU;=@VN MPQR'>&:IVRLEEBBJXNP)WRK*@9@[)\$YYI'CG3IG7GVI@MC$,A9L(EW.@@17 MUH+,&L:B?2<`T^E%H>YR*T%?Z]9VF5EZZA*FU5J7L]%5/OI[99^%@K"+,I&X M,N'W+@\Q(56Q6M(,P1^K69)7VGL`,>9)65Z^5BB;:TX6+KDYR)"=VMM"1B08 MLB,MZK1DPLY;?IIJ!_$M)7#0U137<#9T\[\)"V*S< M:@B/E9;8US>U"69V\C$5\@V8E*@(1A864P9QIY@LM0S-\AH"F.C2M M]U*$BYM:!*>@_Q6W"U0"-V.;TEZ7@D5.1Z;`,UA\9SD<^?"-_>UR7Q*8,X`A M^]_E\<=1]8171C?<@NZ@LS2?1>WW^KZ>$9D\H)4:P&UL550%``/S44E.=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`O&@//W1FSA5'%```6HD!`!4`&``````` M`0```*2!V8X``&%M86,M,C`Q,3`V,S!?<')E+GAM;%54!0`#\U%)3G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`+QH#S_F_L.U6`<``,,T```1`!@````` M``$```"D@6^C``!A;6%C+3(P,3$P-C,P+GAS9%54!0`#\U%)3G5X"P`!!"4. =```$.0$``%!+!08`````!@`&`!H"```2JP`````` ` end XML 28 R9.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Accounting for Stock-Based Compensation
6 Months Ended
Jun. 30, 2011
Accounting for Stock-Based Compensation
4.
Accounting for Stock-Based Compensation:
 
Stock based compensation is recorded in accordance with ASC Topic 718, Compensation – Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payments to employees, including grants of stock and employee stock options, based on estimated fair values.
 
The Company granted options to purchase 10,000 shares of common stock during the six months ended June 30, 2011.  No options were granted during the six months ended June 30, 2010.
 
The following tables summarize stock option activity for the six months ended June 30, 2011 and 2010.
 
2011
 
               
Weighted
       
               
Average
       
         
Weighted
   
Remaining
   
Aggregate
 
   
Number of
   
Average
   
Contractual
   
Intrinsic
 
   
Options
   
Option Price
   
Term (years)
   
Value
 
Balance at January 1
    718,343     $ 3.85              
Granted
    10,000       5.85              
Exercised
    -       -              
Expired/Forfeited
    (25,650 )     6.86              
                             
Balance at June 30
    702,693     $ 3.77       1.49     $ 1,339,659  
                                 
Vested and exercisable
    678,419     $ 3.69       1.42     $ 1,339,659  
 
2010
 
               
Weighted
       
               
Average
       
         
Weighted
   
Remaining
   
Aggregate
 
   
Number of
   
Average
   
Contractual
   
Intrinsic
 
   
Options
   
Option Price
   
Term (years)
   
Value
 
Balance at January 1
    894,785     $ 4.29              
Granted
    -       -              
Exercised
    (10,325 )     4.26              
Expired/Forfeited
    -       -              
                             
Balance at June 30
    884,460     $ 4.29       2.00     $ 1,565,633  
                                 
Vested and exercisable
    851,760     $ 4.23       1.92     $ 1,561,911  
 
No options were exercised during the six months ended June 30, 2011.  The aggregate intrinsic value of options exercised during the six months ended June 30, 2010 was $24,560.  There were 24,274 and 32,700 nonvested stock options outstanding as of June 30, 2011 and 2010, respectively.

The following table summarizes stock-based compensation expense related to all share-based payments recognized in the condensed consolidated statements of income.

   
Three Months
   
Three Months
 
   
Ended June 30,
   
Ended June 30,
 
   
2011
   
2010
 
Stock options
  $ 7,310     $ -  
Stock grants – other
    16,384       10,882  
Service based awards
    23,599       32,037  
Performance based awards
    -       37,294  
Tax benefit
    (28,341 )     (33,098 )
Stock-based compensation expense, net of tax
  $ 18,952     $ 47,115  

   
Six Months
   
Six Months
 
   
Ended June 30,
   
Ended June 30,
 
   
2011
   
2010
 
Stock options
  $ 36,101     $ -  
Stock grants – other
    32,765       21,759  
Service based awards
    47,198       64,072  
Performance based awards
    -       74,588  
Tax benefit
    (55,743 )     (65,772 )
Stock-based compensation expense, net of tax
  $ 60,321     $ 94,647  

Stock Grants - Other

The non-employee members of the Board of Directors have an option to elect at the beginning of each calendar year to receive either shares of common stock or cash at the end of each quarter as compensation for services provided as members of the Board of Directors and other committees.  Share grants issued vest immediately, but are subject to a one-year restriction on transfer.  In addition, stock grants may be issued to employees at the Board of Directors’ discretion.
 
Service Based Awards

In January 2006, May 2007, January 2009 and December 2010 the Company granted 50,000, 22,000, 12,000 (net of 9,500 shares waived by an executive) and 46,500 restricted shares, respectively, to certain executives in respect of services rendered but at no monetary cost.  These shares vest over periods ranging from 2 to 5 years, on December 31 of each year.  The Company records the compensation expense on a straight-line basis over the vesting period.  Fair value for restricted stock awards is based on the Company's closing common stock price on the date of grant. There were 84,000 shares and 63,000 shares vested as of June 30, 2011 and 2010, respectively.  The aggregate grant date fair value of restricted stock grants was $830,845.  The vesting period of the January 2006 and May 2007 grants expired on December 31, 2010.  As of June 30, 2011 and 2010, the Company had approximately $236,000 and $68,000, respectively, of total unrecognized compensation costs related to nonvested restricted stock units expected to be recognized over a weighted average period of 2.5 years.

Performance Based Awards

In January 2006 and May 2007, respectively, the Company granted share awards for up to 90,000 shares (up to 18,000 shares per year through December 31, 2010) and 46,000 shares (up to 11,500 shares per year through December 31, 2010) to certain executives.  Vesting of such shares was contingent upon the Company achieving certain specified consolidated gross revenue and Earnings before Interest and Taxes (“EBIT”) objectives in each of the fiscal years ending December 31, 2006 through December 31, 2010.  The fair value of the performance shares (aggregate value of $909,400) was based on the closing trade value of the Company’s stock on the date of grant and assumed that performance goals would be achieved.  The fair value of the shares was expensed over the performance period for those shares that were expected to ultimately vest.  If such objectives were not met, no compensation cost was recognized and any recognized compensation cost was reversed.  All performance based awards were either earned or forfeited as of December 31, 2010.  During 2011, there were no performance shares vesting and there were no unrecognized compensation costs related to performance share awards.  As of June 30, 2010, 57,250 shares were vested and there was approximately $75,000 of total unrecognized compensation costs related to nonvested share awards.

XML 29 R10.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Earnings Per Share
6 Months Ended
Jun. 30, 2011
Earnings Per Share
5.
Earnings Per Share:
 
Earnings per share data for the six and three months ended June 30, 2011 and 2010 is presented in conformity with ASC Topic 250, Earnings Per Share.
 
The following table is a reconciliation of the numerators and denominators in computing earnings per share:

   
Income
   
Shares
   
Per-Share
 
   
(Numerator)
   
(Denominator)
   
Amounts
 
Six Months Ended June 30, 2011
                 
                   
Basic EPS - Income available to common stockholders
  $ 868,948       9,576,622     $ ..09  
Effect of dilutive securities - Options and warrants
    -       247,914          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 868,948       9,824,536     $ ..09  
                         
Three Months Ended June 30, 2011
                       
                         
Basic EPS -Income available to common stockholders
  $ 159,369       9,580,005     $ ..02  
Effect of dilutive securities - Options and warrants
    -       236,204          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 159,369       9,816,209     $ ..02  
                         
Six Months Ended June 30, 2010
                       
                         
Basic EPS - Income available to common stockholders
  $ 1,610,275       9,537,894     $ ..17  
Effect of dilutive securities - Options and warrants
    -       297,286          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 1,610,275       9,835,180     $ ..16  
                         
Three Months Ended June 30, 2010
                       
                         
Basic EPS -Income available to common stockholders
  $ 722,903       9,549,355     $ ..08  
Effect of dilutive securities - Options and warrants
    -       279,118          
Diluted EPS - Income available to common stockholders and assumed conversions
  $ 722,903       9,828,473     $ ..07
XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 R18.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Commitments and Contingencies
6 Months Ended
Jun. 30, 2011
Commitments and Contingencies
13.
Commitments and Contingencies:

The Company is aware of various threatened or pending litigation claims against the Company relating to its products and services and other claims arising in the ordinary course of its business.  At June 30, 2011 and 2010, no material liabilities have been recorded in the accompanying financial statements.  The Company has given its insurance carrier notice of such claims and it believes there is sufficient insurance coverage to cover any such claims.   In any event, the Company believes the disposition of these matters will not have a material adverse effect on the results of operations and financial condition of the Company.
XML 32 R11.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Goodwill
6 Months Ended
Jun. 30, 2011
Goodwill
6.
Goodwill

Changes in the carrying amount of goodwill, all of which relates to the Company’s TBCS segment, for the six months ended June 30, 2011 and 2010 are as follows:

Six Months Ended June 30, 2011
     
       
Balance as of January 1, 2011
  $ 10,842,352  
Additional Goodwill
    -  
         
Balance as of June 30, 2011
  $ 10,842,352  
         
Six Months Ended June 30, 2010
       
         
Balance as of January 1, 2010
  $ 10,255,983  
Additional Goodwill
    38,298  
         
Balance as of June 30, 2010
  $ 10,294,281  

The addition to goodwill during the six months ended June 30, 2010 related to the additional purchase price of American Mediconnect, Inc. based on the cash receipts from the clinical trials portion of the business.
XML 33 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Cash Flows From Operating Activities:    
Net income $ 868,948 $ 1,610,275
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,540,028 1,842,231
Stock compensation charge 116,064 160,419
Equity in net loss from investment in limited liability company 1,071,912 116,127
Decrease (increase) in:    
Accounts receivable 510,935 173,530
Inventory 3,025 (226,445)
Prepaid income taxes 142,574 (127,069)
Prepaid expenses and other current assets 25,574 (206,876)
Increase (decrease) in:    
Accounts payable, accrued expenses and other (144,304) 122,566
Deferred revenue 27,328 (30,838)
Net Cash Provided by Operating Activities 4,162,084 3,433,920
Cash Flows From Investing Activities:    
Expenditures for fixed assets (695,389) (400,624)
Deposit on equipment 0 (21,875)
Payment of Investment in limited liability company 0 (4,130,731)
Decrease in other assets 51,491 5,065
Net Cash Used In Investing Activities (643,898) (4,548,165)
Cash Flows From Financing Activities:    
Proceeds from long-term debt 0 2,000,000
Repayment of long-term debt (360,000) (1,326,667)
Payment of accrued expense - acquisitions (55,382) (73,346)
Proceeds upon exercise of stock options 0 43,985
Payment of loan financing costs 0 (4,370)
Dividends paid 0 (950,364)
Net Cash Used In Financing Activities (415,382) (310,762)
Net Increase (Decrease) in Cash 3,102,804 (1,425,007)
Cash, Beginning of Period 4,090,528 5,498,448
Cash, End of Period 7,193,332 4,073,441
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
CASH PAID DURING THE PERIOD FOR INTEREST 30,495 26,014
CASH PAID DURING THE PERIOD FOR INCOME TAXES 675,204 1,274,617
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES:    
Accrued expense - acquisitions / additional goodwill - American Mediconnect Inc. 0 38,298
Other assets, deposits on product transferred to inventory $ 0 $ 89,685
XML 34 R7.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Results of Operations
6 Months Ended
Jun. 30, 2011
Results of Operations
2.
Results of Operations:
 
The accompanying condensed consolidated financial statements include the accounts of American Medical Alert Corp. and its wholly-owned subsidiaries; together the “Company.”  All material inter-company balances and transactions have been eliminated.
 
In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position as of June 30, 2011 and the results of operations for the six and three  months ended June 30, 2011 and 2010 and cash flows for the six months ended June 30, 2011 and 2010.
 
The accounting policies used in preparing these financial statements are the same as those described in the December 31, 2010 financial statements.
 
The results of operations for the six and three months ended June 30, 2011 are not necessarily indicative of the results to be expected for any other interim period or for the full year.
XML 35 R16.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Dividends
6 Months Ended
Jun. 30, 2011
Dividends
11.
Dividends:

On December 16, 2009, the Company declared a dividend in the amount of $0.10 per share, or $950,364, which was accrued as of December 31, 2009.  The dividend was payable to the shareholders of record as of December 28, 2009.  The dividend was paid on January 15, 2010.
XML 36 R2.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
Jun. 30, 2011
Dec. 31, 2010
CURRENT ASSETS    
Cash $ 7,193,332 $ 4,090,528
Accounts receivable (net of allowance for doubtful accounts of $453,800 and $452,000) 6,986,432 7,497,367
Inventory, net of non-current portion 928,943 1,005,488
Prepaid income taxes 467,905 610,479
Prepaid expenses and other current assets 339,173 364,747
Deferred income tax asset 187,000 219,000
Total Current Assets 16,102,785 13,787,609
FIXED ASSETS (Net of accumulated depreciation and amortization) 6,623,057 7,195,019
OTHER ASSETS    
Intangible assets (net of accumulated amortization of $7,124,593 and $6,864,657) 1,090,999 1,350,936
Goodwill 10,842,352 10,842,352
Investment in limited liability company 1,898,298 2,970,210
Other assets (including inventory of $481,135 and $407,615) 1,380,647 1,371,359
Total Other Assets, Total 15,212,296 16,534,857
TOTAL ASSETS 37,938,138 37,517,485
CURRENT LIABILITIES:    
Current portion of long-term debt 500,000 660,000
Accounts payable 710,985 732,849
Accrued expense - acquisitions 98,625 105,807
Accrued expenses 1,901,732 2,013,152
Deferred revenue 259,153 231,825
Total Current Liabilities 3,470,495 3,743,633
DEFERRED INCOME TAX LIABILITY 1,196,000 1,228,000
LONG-TERM DEBT, Net of Current Portion 1,950,000 2,150,000
CUSTOMER DEPOSITS 90,899 101,499
ACCRUED RENTAL OBLIGATION 565,814 566,235
ACCRUED EXPENSE - ACQUISITION 24,100 72,300
TOTAL LIABILITIES 7,297,308 7,861,667
COMMITMENTS AND CONTINGENT LIABILITIES 0 0
SHAREHOLDERS' EQUITY    
Preferred stock, $.01 par value - authorized, 1,000,000 shares; none issued and outstanding    
Common stock, $.01 par value - authorized 20,000,000 shares; issued 9,631,603 shares in 2011 and 9,618,083 shares in 2010 96,316 96,181
Additional paid-in capital 16,721,947 16,606,018
Retained earnings 13,959,144 13,090,196
Stockholders' Equity before Treasury Stock, Total 30,777,407 29,792,395
Less treasury stock, at cost (48,573 shares in 2011 and 2010) (136,577) (136,577)
Total Shareholders' Equity 30,640,830 29,655,818
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 37,938,138 $ 37,517,485
XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 9 112 1 false 0 0 false 3 true false R1.htm 101 - Document - Document and Entity Information Sheet http://www.amacalert.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information false false R2.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.amacalert.com/taxonomy/role/StatementOfFinancialPositionClassified CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.amacalert.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.amacalert.com/taxonomy/role/StatementOfIncomeAlternative CONDENSED CONSOLIDATED STATEMENTS OF INCOME false false R5.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.amacalert.com/taxonomy/role/StatementOfCashFlowsIndirect CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 107 - Disclosure - General Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock General false false R7.htm 108 - Disclosure - Results of Operations Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Results of Operations false false R8.htm 109 - Disclosure - Recent Accounting Pronouncements Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsAccountingChangesAndErrorCorrectionsTextBlock Recent Accounting Pronouncements false false R9.htm 110 - Disclosure - Accounting for Stock-Based Compensation Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Accounting for Stock-Based Compensation false false R10.htm 111 - Disclosure - Earnings Per Share Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Earnings Per Share false false R11.htm 112 - Disclosure - Goodwill Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock Goodwill false false R12.htm 113 - Disclosure - Acquisition Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisition false false R13.htm 114 - Disclosure - Investment in Limited Liability Company Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsEquityMethodInvestmentsDisclosureTextBlock Investment in Limited Liability Company false false R14.htm 115 - Disclosure - Long-term Debt Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-term Debt false false R15.htm 116 - Disclosure - Provision for Income Taxes Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Provision for Income Taxes false false R16.htm 117 - Disclosure - Dividends Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfDividendsDeclaredAndPaidTextBlock Dividends false false R17.htm 118 - Disclosure - Segment Reporting Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment Reporting false false R18.htm 119 - Disclosure - Commitments and Contingencies Sheet http://www.amacalert.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false All Reports Book All Reports Process Flow-Through: 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME Process Flow-Through: 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS amac-20110630.xml amac-20110630.xsd amac-20110630_cal.xml amac-20110630_def.xml amac-20110630_lab.xml amac-20110630_pre.xml true true EXCEL 38 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U.3AA9#,X,E\W,&4U7S1C-#E?864S95]B,C8Q M.#5E865C868B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQO;F=T97)M7T1E8G0\+W@Z3F%M93X-"B`@("`\>#I7 M;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-E M9VUE;G1?4F5P;W)T:6YG/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I3='EL97-H965T($A2968],T0B M5V]R:W-H965T&-E M;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U.3AA9#,X,E\W,&4U7S1C-#E?864S95]B,C8Q.#5E M865C868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3DX860S.#)? M-S!E-5\T8S0Y7V%E,V5?8C(V,3@U96%E8V%F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!);F9O'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA M2!296=I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U.3AA9#,X,E\W,&4U M7S1C-#E?864S95]B,C8Q.#5E865C868-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-3DX860S.#)?-S!E-5\T8S0Y7V%E,V5?8C(V,3@U96%E8V%F M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2P@;F5T(&]F(&YO;BUC=7)R96YT('!O&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XT-C'!E;G-EF%T:6]N(&]F("9N8G-P M.R0W+#$R-"PU.3,@86YD("9N8G-P.R0V+#@V-"PV-32!O9B`F;F)S<#LD-#@Q+#$S-2!A;F0@)FYB'!E;G-EF5D+"`Q+#`P M,"PP,#`@2!3 M=&]C:RP@5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#$R-"PU.3,\2!S=&]C:RP@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!C;VUP86YY/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3(L,#,P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S,L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAAF%T:6]N M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4T,"PP,C@\3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'!E;G-E6%B;&4L(&%C8W)U960@97AP96YS97,@86YD(&]T:&5R/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-#0L,S`T*3QS<&%N/CPO2!/<&5R871I;F<@ M06-T:79I=&EE6UE;G0@;V8@86-C'!E;G-E M("T@86-Q=6ES:71I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@U-2PS.#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M&5R8VES92!O9B!S M=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CQT86)L92!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL M6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SXQ+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX] M,T1L969T/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^1V5N97)A;#H\+V9O;G0^/"]D:78^#0H\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4 M:&5S90T*9FEN86YC:6%L('-T871E;65N=',@65A65A<@T*96YD960@1&5C96UB97(@,S$L(#(P,3`@ M;V8@06UE'10 M87)T7S4Y.&%D,S@R7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"CQD:78@3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^,BX\+V9O;G0^ M/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F=#X-"CQD:78@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S M='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$58 M5"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S M=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE#0IA M8V-O;7!A;GEI;F<@8V]N9&5N6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL M93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U) M3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF M>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^26X-"G1H92!O M<&EN:6]N(&]F(&UA;F%G96UE;G0L('1H92!A8V-O;7!A;GEI;F<@=6YA=61I M=&5D(&-O;F1E;G-E9`T*9FEN86YC:6%L('-T871E;65N=',@8V]N=&%I;B!A M;&P@861J=7-T;65N=',@*&-O;G-I2!O9@T*;F]R;6%L(')E M8W5R$$P.R!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,0T*86YD M(#(P,3`@86YD(&-A6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"F%C8V]U;G1I;F<@<&]L:6-I97,@ M=7-E9"!I;B!P6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z M(#!P=#L@34%21TE.+5))1TA4.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SX-"CQT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!4 M15A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J M=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY);@T* M1&5C96UB97(@,C`Q,"P@=&AE($9!4T(@:7-S=65D(%5P9&%T92`R,#$P+3(Y M+"`F(W@R,#%#.T1I2!S:&]U;&0@ M9&ES8VQO0T*87,@=&AO=6=H('1H92!B=7-I;F5S65A2X@57!D871E(#(P M,3`M,CD@86QS;R!E>'!A;F1S('1H90T*2!B=7-I;F5S28C>#(P,3D[F4@;V8@=&AE(&%C<75I6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX-"CPA+2U%1E!L86-E:&]L9&5R+2T^26X@ M1&5C96UB97(@,C`Q,"P@=&AE($9!4T(@:7-S=65D(%5P9&%T90T*,C`Q,"TR M."P@)B-X,C`Q0SM);G1A;F=I8FQE6EN9R!A;6]U;G1S+B!&;W(@=&AE2X\+V9O;G0^/"]D:78^#0H\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX- M"CQD:78^#0H\=&%B;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U=) M1%1(.B`S-G!T)SX-"CQD:78@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SY!8V-O=6YT:6YG#0IF;W(@4W1O8VLM M0F%S960@0V]M<&5N3XF(WA!,#L\+V1I=CX- M"CQD:78@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4 M:&4-"D-O;7!A;GD@9W)A;G1E9"!O<'1I;VYS('1O('!U"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q,2XF(WA!,#L@3F\@;W!T:6]N6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M="<^#0I4:&4@9F]L;&]W:6YG('1A8FQEF4@3XF(WA!,#L\+V1I=CX-"CQD M:78@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SX-"CQT$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M8V]L$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^ M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M-#`E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`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`[/"]F;VYT/CPO M=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO M='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY796EG:'1E9#PO9F]N M=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SY!9V=R96=A=&4\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,R4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@$$P.V]F/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3,E/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY!=F5R86=E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY#;VYT6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@8V]L$$P.SPO9F]N M=#X\+W1D/@T*/"]T"<^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*3W!T:6]N"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4G/@T*3W!T:6]N)B-X03`[4')I8V4\+V9O;G0^ M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@65A6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`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`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-& M1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0T,"4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY"86QA;F-E#0IA="!*86YU87)Y(#$\+V9O;G0^/"]D:78^#0H\+W1D M/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXS+C@U/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E/@T*/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#EP=#L@5$585"U)3D1% M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^1W)A;G1E9#PO9F]N=#X\ M+V1I=CX-"CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^,3`L,#`P/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXU+C@U/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3,E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4^#0H\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY%>&5R M8VES960\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO"<^#0H\9&EV('-T>6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY%>'!I6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`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`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*-BXX-CPO9F]N=#X\+V9O;G0^/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`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`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@"<^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@8V]L6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO M"<^#0H\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY"86QA M;F-E#0IA="!*=6YE(#,P/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4G/@T*-S`R+#8Y,SPO9F]N=#X\+V9O;G0^/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#L@5$585"U!3$E' M3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G M/@T*,RXW-SPO9F]N=#X\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H M="<^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ+C0Y/"]F;VYT/CPO9F]N=#X\ M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%, M24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4 M+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN M92<^#0HQ+#,S.2PV-3D\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN92<^#0HV-S@L-#$Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HS+C8Y/"]F;VYT M/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X M.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@86QI9VX],T1L969T M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U M8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@"<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\ M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`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`[/"]F;VYT/CPO=&0^ M#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P M)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O M;G0@$$P.SPO9F]N=#X\ M+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3,E/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY!=F5R86=E/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R M/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@8V]L$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,R4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L M$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS M<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3,E/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SY.=6UB97(F(WA!,#MO9CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\ M=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L$$P.SPO M9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CPO='(^#0H\='(^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$-#`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H\9&EV('-T>6QE/3-$)T1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN92<^#0I497)M)B-X03`[*'EE87)S*3PO9F]N=#X\+V9O M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4G/@T*5F%L=64\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#L@5$585"U!3$E' M3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T2`Q/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXX.30L M-S@U/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T* M/"]T$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,R4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X M03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO"<^#0H\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY%>'!I6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,B4@#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,G!X)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXM/"]F;VYT/CPO=&0^ M#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3,E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`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`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(] M,T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%, M24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(] M,T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-#`E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@"<^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*,BXP,#PO9F]N=#X\+V9O;G0^/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#L@5$585"U!3$E' M3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G M/@T*,2PU-C4L-C,S/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#0P)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@ M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N M=#X\+W1D/@T*/"]T"<^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q,B4@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4G/@T*.#4Q+##L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*-"XR,SPO9F]N=#X\ M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@#L@ M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@-'!X)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE/3-$)T1)4U!,05DZ M(&EN;&EN92<^#0HQ+CDR/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ+#4V,2PY,3$\ M+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A M8FQE/@T*/"]D:78^#0HF(WA!,#L\8G(@+SX-"CQD:78@&5R8VES960-"F1U$$P.R!4 M:&5R90T*=V5R92`R-"PR-S0@86YD(#,R+#3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^5&AE#0IF;VQL;W=I;F<@=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SX-"CQT$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/&1I=B!S='EL93TS M1"=$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1% M3E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY4:')E928C>$$P.TUO M;G1H6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0I%;F1E M9"8C>$$P.TIU;F4F(WA!,#LS,"P\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`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`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3,E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^ M#0HR,#$Q/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$ M,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HR,#$P/"]F;VYT/CPO M9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@ M8F=C;VQO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXW+#,Q,#PO M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@ M6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXQ-BPS.#0\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^,3`L.#@R/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXR,RPU.3D\+V9O;G0^/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,S(L,#,W/"]F;VYT/CPO=&0^#0H\ M=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\ M='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SY097)F;W)M86YC90T*8F%S960@87=A6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,S6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO`T*8F5N969I=#PO9F]N=#X\+V1I M=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T**#(X+#,T,3PO9F]N=#X\+V9O M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@#L@5$58 M5"U!3$E'3CH@;&5F="<^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXT-RPQ,34\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY3:7@F(WA!,#M-;VYT:',\+V9O M;G0^/"]D:78^#0H\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N M/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3,E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^ M#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0I%;F1E9"8C>$$P M.TIU;F4F(WA!,#LS,"P\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT M9"!N;W=R87`],T1N;W=R87`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`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3,E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HR,#$Q M/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1) M3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT M97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HR,#$P/"]F;VYT/CPO9F]N=#X\ M+V1I=CX-"CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXS-BPQ,#$\+V9O;G0^ M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX- M"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,B4@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^,S(L-S8U/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY3 M97)V:6-E#0IB87-E9"!A=V%R9',\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^-#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXM M/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY487@-"F)E;F5F:70\+V9O;G0^/"]D:78^#0H\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXI M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M"<^#0H\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T**#8U+##L@ M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SY3=&]C:RUB87-E9`T*8V]M<&5N6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\ M9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T M)SX\8G(@+SX\+V1I=CX-"CQD:78@3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE#0IN;VXM96UP;&]Y964@;65M M8F5R65A#(P,3D[(&1I6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SY397)V:6-E#0I"87-E9"!!=V%R9',\+V9O M;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1J=7-T:69Y/CPA+2U%1E!L86-E:&]L9&5R+2T^/&)R M("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SY);@T*2F%N=6%R>2`R,#`V+"!-87D@,C`P-RP@2F%N=6%R M>2`R,#`Y(&%N9"!$96-E;6)E&5C=71I=F4I(&%N9"`T-BPU,#`@2P@=&\@8V5R=&%I;@T*97AE8W5T:79E M0T*8V]S="XF(WA!,#L@5&AE$$P.R!&86ER('9A M;'5E(&9O$$P.SPO9F]N=#Y4:&5R90T*=V5R92`X-"PP,#`@$$P.R!4:&4@86=G65A6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SY097)F;W)M86YC90T*0F%S960@07=A M6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY);@T*2F%N=6%R M>2`R,#`V(&%N9"!-87D@,C`P-RP@2!G65A#(P,4,[14))5"8C>#(P,40[*2!O8FIE8W1I=F5S(&EN(&5A8V@@ M;V8@=&AE#0IF:7-C86P@>65A$$P.R!4:&4@9F%I$$P.R!4:&4@9F%I M'!E8W1E9"!T;R!U;'1I;6%T96QY('9EF5D(&-O;7!E;G-A M=&EO;B!C;W-T('=A'1087)T7S4Y.&%D,S@R7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX-"CQD:78^#0H\=&%B;&4@86QI9VX],T1C96YT97(@ M8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I M9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U=)1%1(.B`S-G!T)SX-"CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY%87)N:6YG3XF(WA!,#L\+V1I=CX-"CQD:78@"!A;F0@=&AR964@;6]N=&AS M(&5N9&5D($IU;F4@,S`L(#(P,3$@86YD#0HR,#$P(&ES('!R97-E;G1E9"!I M;B!C;VYF;W)M:71Y('=I=&@@05-#(%1O<&EC(#(U,"P@16%R;FEN9W,@4&5R M#0I3:&%R92X\+V9O;G0^/"]D:78^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ M(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SXF(WA!,#L\8G(@+SX\+V1I=CX- M"CQD:78@6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I M=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE(&-E;&QP861D:6YG/3-$ M,"!C96QL6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX- M"CQT$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE M/3-$)U!!1$1)3D"<^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HH M1&5N;VUI;F%T;W(I/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@ M;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`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`[/"]F;VYT/CPO=&0^#0H\=&0@8V]L M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&-O;'-P M86X],T0R(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M8V]L6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\ M='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXY+#4W-BPV,C(\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4G/@T*+C`Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO M='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=. M.B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U M8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4G/@T*.2PX,C0L-3,V/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HN,#D\+V9O;G0^/"]F;VYT M/CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L M;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0V-"4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@5$585"U$14-/4D%424]..B!U;F1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C M;VQO$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T* M/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0V-"4@"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^0F%S:6,-"D504R`M26YC;VUE(&%V86EL86)L92!T;R!C;VUM M;VX@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXY+#4X,"PP,#4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4G/@T*+C`R/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO M='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=. M.B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U M8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4G/@T*.2PX,38L,C`Y/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HN,#(\+V9O;G0^/"]F;VYT M/CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L M;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0V-"4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@34%21TE. M+5))1TA4.B`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`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L M;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W M(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%, M24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B8C M>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%, M24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`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`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN92<^#0HM/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F M;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\ M+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4@"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^1&EL=71E9`T*15!3("T@26YC;VUE(&%V86EL86)L M92!T;R!C;VUM;VX@"<^#0H\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ M+#8Q,"PR-S4\+V9O;G0^/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1) M3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@ M9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4G/@T*.2PX,S4L,3@P/"]F;VYT/CPO9F]N=#X\+W1D/@T* M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M"<^#0H\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HN,38\+V9O;G0^/"]F M;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\ M+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G M8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0V-"4^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@5$585"U$14-/4D%424]..B!U;F1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@ M8F=C;VQO$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@ M$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D M/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R M/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4@"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^0F%S:6,-"D504R`M26YC;VUE(&%V86EL86)L92!T;R!C M;VUM;VX@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!R:6=H="<^/&9O;G0@ M#L@5$585"U!3$E' M3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@#L@5$58 M5"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXY+#4T.2PS-34\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4G/@T*+C`X/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T1W:&ET93X-"CQT9"!A;&EG M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM M97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%, M24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)FYB6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^/&9O;G0@6QE/3-$)U!!1$1) M3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@-'!X)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@ M9&]U8FQE.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4G/@T*.2PX,C@L-#"<^#0H\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HN,#<\+V9O;G0^/"]F M;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U.3AA9#,X M,E\W,&4U7S1C-#E?864S95]B,C8Q.#5E865C868-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO-3DX860S.#)?-S!E-5\T8S0Y7V%E,V5?8C(V,3@U M96%E8V%F+U=O'0O:'1M;#L@8VAA6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!4 M15A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@6EN9R!A;6]U;G0@;V8@9V]O9'=I;&PL(&%L;"!O9B!W:&EC:"!R96QA M=&5S('1O('1H90T*0V]M<&%N>28C>#(P,3D[6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5. M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CPA+2U% M1E!L86-E:&]L9&5R+2T^/&)R("\^/"]D:78^#0H\9&EV('-T>6QE/3-$)TU! M4D=)3BU,1494.B`S-G!T)R!A;&EG;CTS1&QE9G0^#0H\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#4U)2!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M92<^4VEX($UO;G1H6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL M93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G M8V]L;W(],T1W:&ET93X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W M.24^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(] M,T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0W.24^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SY"86QA;F-E#0IA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q-24@6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HM M/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,G!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R M(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,B4@6QE/3-$)U!!1$1)3D$$P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SXF;F)S<#LD/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,34E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^/&9O;G0@6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,B4@$$P.SPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(] M,T1W:&ET93X-"CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-SDE/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@5$585"U$14-/4D%424]..B!U;F1E$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#(E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@ M$$P.SPO9F]N=#X\+W1D/@T*/"]T$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#(E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\ M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY"86QA M;F-E#0IA6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=415A4+4%, M24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N M)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q-24@$$P.SPO9F]N=#X\+W1D M/@T*/"]T6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^/&9O M;G0@$$P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@#L@ M5$585"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@$$P.SPO9F]N M=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0R)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^ M#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W.24@"<^#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N)SY"86QA;F-E#0IA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L M969T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)FYB6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^#0HQ,"PR M.30L,C@Q/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@-'!X.R!415A4+4%,24=..B!L969T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\+W1R M/@T*/"]T86)L93X-"CPO9&EV/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B M;&]C:SL@5$585"U)3D1%3E0Z(#!P="<^/&)R("\^/"]D:78^#0H\9&EV('-T M>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"F%D M9&ET:6]N('1O(&=O;V1W:6QL(&1U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=CX-"CQD M:78^#0H\=&%B;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U=)1%1( M.B`S-G!T)SX-"CQD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,BXF M(WA!,#L@5&AE($-O;7!A;GD@97-T:6UA=&5D('1H92!F=71U'!E8W1E9"!T;R!B92!P86ED(&)A$$P.R!4:&4@0V]M<&%N>2!A;'-O(&EN8W5R&EM871E;'D@ M)FYB#(P,4,[5$)#4R8C>#(P,40[*0T*6QE/3-$ M)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\+V1I M=CX-"CQD:78@6QE M/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@,'!T)SX\8G(@+SX\ M+V1I=CX-"CQD:78@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N)SX-"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q-24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY&:7AE9`T*87-S971S/"]F M;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0R)3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@ M6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SY. M;VXM8V]M<&5T90T*86=R965M96YT/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)2!S='EL93TS M1"=415A4+4%,24=..B!L969T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@ M;F5W(')O;6%N)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$U)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^,3@U+#`P M,#PO9F]N=#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0R)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT M/CPO=&0^#0H\+W1R/@T*/'1R(&)G8V]L;W(],T0C0T-&1D-#/@T*/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W.24@"<^#0H\9&EV('-T>6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@=&EM97,@;F5W(')O;6%N)SY';V]D=VEL;#PO9F]N=#X\+V1I=CX- M"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@"<^#0H\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,B4@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4G/@T*-30X+#`W,3PO9F]N=#X\(2TM969P M;&%C96AO;&1E6QE/3-$)U!!1$1)3D"<^#0H\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;B<^)B-X03`[/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,B4@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*-S#L@5$58 M5"U!3$E'3CH@;&5F="<^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T$$P.SQB3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^5&AE#0IP=7)C:&%S92!P6QE/3-$)T1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SY4:&4-"G)E"!A M;F0@=&AR964@;6]N=&AS#0IE;F1E9"!*=6YE(#,P+"`R,#$Q+B8C>$$P.R!/ M;B!A('!R;R!F;W)M82!B87-I'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/&1I=CX-"CQD:78^#0H\=&%B;&4@86QI M9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P M86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U=)1%1(.B`S-G!T)SX-"CQD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SY);G9E2!#;VUP86YY M/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^ M#0H\9&EV('-T>6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!415A4+4E.1$5.5#H@ M,'!T)SX\8G(@+SX\+V1I=CX-"CQD:78@&EM871E;'D- M"C$P)2D@:6X@=&AE(&YE=R!C;VUP86YY+"!,:69E8V]M;2P@3$Q#("@F(W@R M,#%#.TQI9F5C;VUM)B-X,C`Q1#LI+B!!2!B;W)R;W=E9"`F;F)S<#LD,BPP,#`L,#`P M(&9R;VT@:71S#0IB86YK('1O('!A2!F:6YA;F-E('1H:7,@=')A M;G-A8W1I;VXN)B-X03`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`Q,BP@,C`Q,"!T;R!* M=6YE#0HS,"P@,C`Q,2DN)B-X03`[($QI9F5C;VUM('=I;&P@8V]N=&EN=64@ M=&\@9V5N97)A=&4@;&]S2`R,#$R+CPO M9F]N=#X\+V1I=CX-"CQD:78@6QE/3-$)T1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4 M+4E.1$5.5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T M:69Y/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SY);@T*86-C M;W)D86YC92!W:71H('1H92!L:6UI=&5D(&QI86)I;&ET>2!C;VUP86YY(&%G M2!A;&QO8V%T960@=&\@ M;65M8F5R$$P.R!,;W-S97,@87)E(&=E;F5R86QL>2!A;&QO8V%T M960@=&\@;65M8F5R2!A6QE/3-$)T1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!415A4+4E.1$5.5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`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`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"CQT M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)SXY+CPO9F]N=#X\+V1I=CX-"CPO=&0^#0H\=&0@86QI M9VX],T1L969T/@T*/&1I=B!S='EL93TS1"=$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@5$585"U)3D1%3E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`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`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SY4:&4-"D-O;7!A;GD@:&%D(&$@8W)E9&ET(&9A8VEL:71Y(&%R6%B;&4N(%1H92!T97)M(&QO86X@=V%S('!A>6%B;&4@ M:6X@97%U86P-"FUO;G1H;'D@<')I;F-I<&%L(&EN2!P3XF(WA!,#L\+V1I=CX-"CQD:78@2!W87,@86UE;F1E9"!W:&5R96)Y('1H92!#;VUP86YY(&]B=&%I M;F5D#0IA;B!A9&1I=&EO;F%L("9N8G-P.R0R+#4P,"PP,#`@86YD("9N8G-P M.R0Q+#8P,"PP,#`@;V8@=&5R;2!L;V%NF5D('1O(&9I;F%N8V4@8V5R=&%I;B!A8W%U:7-I M=&EO;G,N)B-X03`[(%1H97-E#0IT97)M(&QO86YS(&%R92!P87EA8FQE(&]V M97(@9FEV92!Y96%R2X-"D%D9&ET:6]N86QL>2P@8V5R=&%I;B!O M9B!T:&4@8V]V96YA;G1S('=E3XF(WA! M,#L\+V1I=CX-"CQD:78@28C>#(P,3D[2`N,C4E(&)A2!H87,@=&AE(&]P=&EO;B!T;R!C:&]O$$P.R!";W)R;W=I;F=S('5N9&5R('1H92!C3XF(WA!,#L\+V1I=CX- M"CQD:78@3XF M(WA!,#L\+V1I=CX-"CQD:78@65A3XF(WA!,#L\ M+V1I=CX-"CQD:78@'1087)T7S4Y.&%D,S@R7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU,1494.B`P<'0[(%1%6%0M24Y$14Y4.B`P M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N)SXQ,"X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D/@T* M/&1I=B!A;&EG;CTS1&QE9G0^/&9O;G0@3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^5&AE#0I#;VUP86YY(')E8V]R9',@:71S('1A>"!P"`\(2TM1490;&%C96AO;&1E M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\U.3AA9#,X,E\W,&4U7S1C-#E?864S95]B,C8Q M.#5E865C868-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3DX860S M.#)?-S!E-5\T8S0Y7V%E,V5?8C(V,3@U96%E8V%F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)TU!4D=)3BU,1494 M.B`P<'0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX- M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXQ,2X\+V9O;G0^ M/"]D:78^#0H\+W1D/@T*/'1D/@T*/&1I=B!A;&EG;CTS1&QE9G0^/&9O;G0@ M3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^3VX-"D1E8V5M8F5R(#$V+"`R,#`Y+"!T:&4@0V]M<&%N M>2!D96-L87)E9"!A(&1I=FED96YD(&EN('1H92!A;6]U;G0@;V8-"B9N8G-P M.R0P+C$P('!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/&1I=CX-"CQD:78^#0H\=&%B;&4@6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)SX-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,BX\ M+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D/@T*/&1I=B!A;&EG;CTS1&QE9G0^ M/&9O;G0@3X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4 M:6UE#(P,4,[2%--4R8C>#(P M,40[*2!A;F0@*&EI*2!496QE<&AO;F4@0F%S960-"D-O;6UU;FEC871I;VX@ M4V5R=FEC97,@*"8C>#(P,4,[5$)#4R8C>#(P,40[*2X\+V9O;G0^/"]D:78^ M#0H\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1J=7-T:69Y/B8C>$$P.SPO9&EV/@T*/&1I=B!S='EL93TS1"=415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE"!A;F0@=&AR964@;6]N=&AS(&5N9&5D#0I*=6YE(#,P+"`R,#$Q(&%N M9"`R,#$P.CPO9F]N=#X\+V1I=CX-"CQD:78@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1C96YT97(^/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@5$585"U$14-/4D%4 M24]..B!U;F1E6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M)SX\8G(@+SX\+V1I=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*2%--4SPO9F]N=#X\+V9O;G0^ M/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4G/@T*5$)#4SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*0V]N M"<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ M(&EN;&EN92<^4VEX($UO;G1H6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,R4@8V]L$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`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`Q,'!T)SXQ-RPS,#`L,30Y/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX- M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX\8G(@+SX\+V1I M=CX-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B!T:6UE"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4G/@T*2%--4SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T* M5$)#4SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*0V]N"<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@;F]W6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^ M#0H\='(@8F=C;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^5&AR M964@36]N=&AS($5N9&5D($IU;F4@,S`L#0HR,#$Q/"]F;VYT/CPO9F]N=#X\ M+V1I=CX-"CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^ M/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`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`Q M,'!T)SXU+#$S.2PQ-S$\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`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`Q,'!T M)SXT,C(L,C@R/"]F;VYT/CPO=&0^#0H\=&0@$$P.SPO M9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SX-"C(P,3`\+V9O;G0^/"]F;VYT/CPO M9&EV/@T*/&1I=CXF(WA!,#L-"CQD:78@86QI9VX],T1L969T/@T*/'1A8FQE M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*2%--4SPO9F]N=#X\+V9O M;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4G/@T*5$)#4SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T* M0V]N"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)T1)4U!, M05DZ(&EN;&EN92<^4VEX($UO;G1H6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,R4@8V]L$$P.SPO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,B!N;W=R87`],T1N M;W=R87`^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N M;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/"]T6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X- M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X- M"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\ M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY);F-O;64-"F)E9F]R92!P6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B8C>$$P.SPO9F]N M=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY4;W1A;`T*87-S971S/"]F;VYT/CPO9&EV/@T*/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS-RPS,#$L.34R/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R M87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA! M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`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`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4G/@T*2%--4SPO9F]N=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*5$)#4SPO9F]N M=#X\+V9O;G0^/"]D:78^#0H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D"<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4G/@T*0V]N"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C M;VQO6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^5&AR964@36]N=&AS M($5N9&5D($IU;F4@,S`L#0HR,#$P/"]F;VYT/CPO9F]N=#X\+V1I=CX-"CPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX- M"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#8R."PS,#D\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX- M"B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);F-O;64-"F)E9F]R92!P M6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SX-"B8C>$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M$$P.SPO9F]N=#X\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS.#4L,3,Y/"]F;VYT/CPO=&0^ M#0H\=&0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/B8C>$$P.SPO M9&EV/@T*/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE"<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/@T*2G5N928C M>$$P.S,P+"8C>$$P.S(P,3$\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X- M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/ M33H@,G!X)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N M;W=R87`^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D$$P.SPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R(&YO=W)A<#TS M1&YO=W)A<#X-"CQD:78@"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(WA!,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@8F=C;VQO6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!415A4+41%0T]2051)3TXZ('5N9&5R;&EN M92<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G/E-I>"!-;VYT M:',@16YD960\+V9O;G0^/"]F;VYT/CPO9&EV/@T*/"]T9#X-"CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXQ+#`W,2PY,3(\+V9O;G0^/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,38L,3(W/"]F;VYT M/CPO=&0^#0H\=&0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"CPO='(^#0H\='(@8F=C;VQO6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/CQF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!415A4+41%0T]2051)3TXZ M('5N9&5R;&EN92<^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4G M/E1H$$P.SPO M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,B4^#0H\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B9N8G-P.R0\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3(E/@T*/&9O;G0@'1087)T7S4Y.&%D,S@R7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY#;VUM:71M96YT6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K)SX\8G(@+SX\+V1I=CX-"CQD:78@2!I2!R96QA=&EN9R!T;R!I=',@ M<')O9'5C=',@86YD('-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM M;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM M/5].97AT4&%R=%\U.3AA9#,X,E\W,&4U7S1C-#E?864S95]B,C8Q.#5E865C &868M+0T* ` end